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ABSTRACT 
Short sleep duration and poor sleep continuity have been related to adverse health outcomes. 
Sleep disturbances are more frequent among older people, who also experience a reduction in 
immune function (immunosenescence). This thesis tested the hypothesis that sleep disruption 
in old age contributes to immunosenescence.  
93 healthy older subjects had their sleep recorded by actigraphy and immunological 
parameters were assessed. The data indicated that sleep continuity and duration in older adults 
does not influence innate immune function but was associated with changes in blood cell 
numbers, in particular an increase in the granulocyte:lymphocyte ratio. Differences in serum 
IL-4 and adiponectin were associated with long sleep duration and poor sleep continuity was 
also associated with raised serum cortisol. However, preliminary data obtained from a small 
pilot study of partial sleep deprivation in young and old adults did not show similar changes 
therefore causality was not confirmed.  
In vitro experiments were performed to evaluate whether adiponectin, whose levels change 
with age, affected neutrophil apoptosis and phagocytosis. Adiponectin extended lifespan of 
neutrophils and inhibited bacterial phagocytosis.  
The findings suggest that sleep dysregulation does not contribute to immunosenescence and in 
vitro studies add weight to the literature showing immunomodulatory roles for adiponectin. 
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1.1 SLEEP 
Sleep is a constitutive behavior of animals indispensable for wellbeing, health and survival. In 
other words, it represents a physiological, cyclical state of rest for both the body and the mind 
during which body movements and consciousness are minimised.  
The average sleep duration experienced by adults has declined over the last decades [1-3], and 
disruptions in sleep parameters have been related to a variety of negative health outcomes, 
both in animals and humans. For instance, rats subjected to total sleep deprivation exhibited 
global deterioration finally resulting in death (maximal survival up to 32 days) [4] and in 
humans epidemiological studies have indicated that both short and long sleep durations are 
significantly associated with increased morbidity and all-cause mortality [5-10]. The general 
belief that the ideal sleep duration is between 7 and 8 hours was confirmed by the majority of 
studies [5-7, 9], however Kripke et al. found that the risk of mortality was lowest for people 
sleeping between 5 and 6.5 hours per night as assessed by actigraphy [11]. 
1.1.1 PHYSIOLOGY OF SLEEP 
During sleep the brain performs a characteristic cycle of electrical activity which can be 
measured by electroencephalography (EEG). On the basis of the differences in the electric 
wave amplitudes and frequencies, two main kinds of sleep have been identified: non-rapid-
eye-movement (NREM) sleep and rapid-eye-movement (REM) sleep. NREM sleep can be 
divided into three progressively deeper stages: N1, N2 and N3. Stages N1 and N2 are 
characterized by low amplitude, high frequency (3-7 Hertz) EEG waves (theta waves), 
whereas stage N3, also named slow wave sleep (SWS) has high amplitude (>75 μV), low 
frequency (<4.5 Hertz) EEG waves (delta waves) [12, 13]. REM sleep consists of low 
amplitude, high frequency EEG activity similar to those of N1 and N2. During REM sleep 
alpha waves (20-60 μV, 6-13 Hertz), typical of wakefulness, may occur [14, 15]. The presence 
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of bursts of rapid eye movement, which give this stage of sleep its name, allows the 
identification of REM sleep (Figure 1.1) [15, 16]. 
These sleep stages differ from each other not only by the frequency and amplitude of EEG 
waves, but are also associated with distinct functions: whilst stage N1 represents the transition 
between wakefulness and sleep, and stage N2 represents the onset of sleep, SWS is thought to 
be the deepest and most revitalizing phase of sleep. In fact, SWS is the stage the most related 
to sleep need; it is accompanied by a gradual decrease in body temperature, breathing 
frequency, blood pressure and heart rate [17], favouring the renewal of body energy [18]. In 
contrast, REM sleep entails absent muscle activity, manifestation of dreams and processing of 
information [15, 16]. 
NREM and REM sleep occur cyclically during the night: healthy individuals usually obtain 4 
to 6 cycles per night with each cycle lasting approximately 90 minutes [19]. Though sleep 
cycles maintain the same length, the individual stages of sleep are subjected to modifications 
during the night: longer periods of SWS are typical of the onset of sleep and they shorten 
progressively in the night to allow longer REM sleep phases, which predominate towards the 
end of the period of sleep [20, 21] (Figure 1.2). 
1.1.2 MEASUREMENT OF SLEEP PARAMETERS 
The gold standard for measuring the physiological body changes that occur during sleep is 
polysomnography, a multi-parameter test which monitors many functions including brain 
electrical activity through EEG, eye movements through electrooculography (EOG), muscle 
activity through electromyography (EMG) and heart rhythm through electrocardiography 
(ECG). Polysomnography is used to diagnose a variety of sleep disorders and conditions, 
including restless leg syndrome, obstructive sleep apnea syndrome (OSAS) and narcolepsy.  
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Figure 1.1 The different stages of sleep as measured by EEG. NREM and REM sleep are 
characterized by the different frequencies and amplitudes of the EEG waves (Figure adapted 
from Bryant et al., 2004 [18]). 
 
 
 
Figure 1.2 Cycles and stages of sleep during the night. Subsequent cycles are featured by a 
progressive shorter SWS phase and longer REM sleep (Figure adapted from Neubauer et al. 
[20]). 
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Despite the wide range of information that it provides, this powerful technique has the 
disadvantage of being invasive and even disruptive to physiological sleep. Because of its 
invasiveness and cost, polysomnography is often substituted with actigraphy, a non-invasive 
and cheap method to study the sleep-wake behaviour and circadian rhythms [22]. The actigraph 
consists of an electrode-free, watch-shaped device which is worn on the wrist of the non-
dominant arm or on the ankle. The parameters that the actigraph can register are:  
- the total sleep time,  
- sleep latency (the time spent awake while in bed before falling asleep),  
- sleep efficiency (the percentage of time spent asleep over the total time spent in bed),  
- wake after onset sleep (WASO, an indicator of disrupted sleep),  
- average sleep and wake bouts (indicators of the physiological fragmentation of sleep) 
- movements performed by the wearer (index of physical activity).  
Usually, the actigraph is continuously worn for at least three consecutive days, allowing the 
achievement of objective measures [23]. Its main limitation is the impossibility to distinguish 
the different stages of sleep. Importantly, actigraphy has been validated against 
polysomnography: actigraphic and polysomnographic measures were recorded in healthy 
individuals [24-26], in insomniacs [27] and OSAS patients, [28] and they were found to correlate 
in all cases. In particular, several studies reported that actigraphy accurately measures sleep 
duration and efficiency [24, 29, 30], while actigraphic WASO and nocturnal waking episodes 
often show a lower correlation when compared to polysomnographic recordings [26, 27, 30]. 
Specifically, the largest discrepancy between actigraphy and polysomnography has been 
found in subjects displaying a high level of WASO [27]. 
The most practical and cost-effective method to assess sleep quantity and continuity in large 
epidemiological studies remains the use of sleep questionnaires, in which subjects are asked 
to provide information about their sleep habits. Several sleep questionnaires and diaries have 
been validated: among them, the Pittsburgh Sleep Quality Index (PSQI) is one of the most 
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common questionnaires used to determine a number of parameters including sleep duration, 
sleep latency, sleep efficiency, subjective sleep quality, daytime dysfunction and use of sleep 
medication [31]. However, self-reported, subjective data provided by questionnaires and sleep 
diaries do not always reproduce objective measures of sleep such as actigraphic recordings [32, 
33]. 
1.1.3 NEUROCHEMICAL REGULATION OF SLEEP  
Sleep depends on two processes, called Process S and Process C. Process S is involved in the 
maintaining of sleep homeostasis and it is related to sleep debt, while Process C, which stands 
for “circadian”, determines the natural rhythmicity of sleep and wakefulness, in which 
maximal sleepiness is experienced towards the evening and is minimal in the morning [34]. A 
wide range of neuropeptides and steroids have been found to have a role in the regulation of 
these two processes. In humans the circadian rhythm of sleep is entrained to a 24 hour period 
and it is finely regulated by a specific region in the brain, called the suprachiasmatic nucleus 
(SCN). The SCN is a bilateral structure situated in the anterior part of the hypothalamus 
which serves as a central circadian oscillator or “body clock” [35, 36]; it does not only control 
the sleep-wake cycle but the organization of the whole organism at cellular and tissue level. 
This is evidenced by the fact that lesions of the SCN in rodents extinguished endocrine and 
behaviour circadian rhythms [37-39], moreover, SCN-specific neurons display their typical 
circadian rhythm in neural firing not only in vivo but also when transplanted in vitro [40].  
To orchestrate the body’s circadian rhythms, the SCN has to synchronise various internal 
biological rhythms with the environment through both internal and external cues. One of the 
most important external cues is light, which is caught and processed by the retinal visual 
system and is transmitted to the SCN where it regulates its function [41]. The internal cues are 
represented by several systemic factors which can influence further the sleep-wake behaviour, 
the duration and the continuity of sleep. 
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1.1.3.1 Melatonin 
The major internal cue maintaining the circadian rhythm of sleep is the hormone melatonin, 
secreted by the pineal gland under the control of the paraventricular nucleus (PVN), which 
itself is controlled by the SCN, and para/sympathetic innervations. Melatonin expression and 
release is suppressed by light and stimulated by dark through the retinal-hypothalamic tract [42, 
43] and its secretion occurs in parallel to the individual’s habitual bedtime and induces evening 
sleepiness [44]. Its endocrine role is to synchronize the circadian rhythms to the peripheral 
organs and tissues: in particular, melatonin can entrain both daily and seasonal rhythms [42, 45]. 
Apart from this function, melatonin has also been suggested to have a somnogenic role, as its 
administration in humans has been found to increase total sleep duration, improving 
efficiency and latency [46, 47]. Melatonin is thought to exert this effect by inhibiting the firing 
of the neurons located in the SCN through a negative feedback process, as demonstrated in 
vitro [48, 49], and possibly through interaction with γ-aminobutyric acid (GABA)-ergic neurons 
[50]. 
1.1.3.2 Regulation of sleep by local neurotransmitters 
Studies have shown that sleep and wakefulness are modulated by multiple neuronal systems 
releasing different neurotransmitters such as orexins, neuropeptide Y (NPY), GABA, galanin 
[51],  adenosine, serotonin, acetylcholine, dopamine and histamine [52, 53]. Cholinergic and 
monoaminergic neurons are believed to maintain wakefulness as their activity is higher during 
wake time and decreases during NREM sleep [53]. Orexins, also called hypocretins, are 
excitatory neuropeptides synthetized by the lateral hypothalamus [54] whose main functions 
are to enhance food intake [54, 55] , stabilize the sleep-wake pattern and maintain wakefulness. 
In fact, dysfunctions in the orexigenic neurotransmission are typical of narcolepsy, a sleep 
disorder characterized by daytime sleepiness, sleep fragmentation, cataplexy and frequent 
REM sleep episodes [56-59].  
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Studies performed in animals and humans indicate that another peptide, NPY, expressed 
mainly by the PVN, the arcuate nucleus and the SCN [60], increases food intake [61] and exerts 
sleep-promoting properties, decreasing sleep latency and REM sleep, increasing stage N2 and 
the total sleep time [62]. NPY exerts those functions by acting as a physiological antagonist of 
corticotropin-releasing hormone (CRH), diminishing corticotropin (ACTH) and cortisol levels 
[62], whose roles in regulating sleep are discussed in detail below (section 1.1.3.3). 
GABA is the major inhibitory neurotransmitter in the mammalian central nervous system. It 
acts by binding to specific transmembrane receptors: GABAA and GABAB receptors, causing 
the hyperpolarization of the target neuron. It is well known that GABA and all the GABA 
receptor agonists induce and maintain the sleep process: benzodiazepines and the other 
GABA receptor agonists reduce sleep latency and fragmentation and promote NREM sleep. 
However, benzodiazepines and other drugs that enhance GABA neurotransmission have been 
also shown to increase high frequency EEG activity during NREM sleep in different species 
[63].   
1.1.3.3 Hypothalamo-pituitary-somatotropic and hypothalamo-pituitary-adrenocortical axes 
In addition to the neural mechanisms described above, other humoral factors, generally 
termed sleep regulatory substances (SRS) [64], can regulate sleep. Among the SRS are 
hormones belonging to the hypothalamo-pituitary-somatotrophic (HPS) and the hypothalamo-
pituitary-adrenocortical (HPA) systems. The molecules at the top of the HPS and HPA axes 
are growth hormone-releasing hormone (GHRH) and CRH respectively. Both of these 
hormones are secreted by many hypothalamic regions, such as the arcuate nucleus and the 
PVN [65, 66], and they act on their receptors expressed by the anterior pituitary gland (or 
adenohypophysis) causing the release of growth hormone (GH) and ACTH. GH induces the 
liver to secrete insulin-like growth factor 1 (IGF-1) [67] and ACTH signals the adrenal gland to 
produce cortisol [65]. Somatostatin is another molecule secreted by the PVN; its function is to 
inhibit the release of GH by the adenohypophysis [68]. Apart from somatostatin, there are no 
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other physiological inhibitors for these hormones, whose production is mainly regulated by 
negative feedback [65, 69] (Figure 1.3). 
 
 
 
 
 
 
 
Figure 1.3 Diagram representing the hormonal cascade characterising the HPS and 
HPA axes. The hormones belonging to the HPS system and HPA systems are respectively 
shown in green and red. The expression of these factors is regulated by reciprocal negative 
feedback. 
 
All these factors are expressed in a pulsatile and circadian manner. Hypothalamic expression 
of GHRH has been shown to be low in the morning, increase in the afternoon and again 
decrease at night in rats [70]. As a consequence the maximal pulses of circulating GH have 
been observed during the first half of the night in humans, in temporal association with SWS, 
progressively decreasing late in the night and in the morning [71, 72]. With regard to the HPA 
axis, CRH mRNA expression has been investigated in the PVN of rats with the maximal level 
observed at midnight while the minimal expression was recorded in the early afternoon [73]. 
The rhythmic variation in the hypothalamic expression of CRH explains the circadian rhythm 
of serum ACTH and cortisol also observed in humans, as these hormones rise in the early 
hours of the morning before awakening and their nadir is reached during the first half of the 
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night [74]. Figure 1.4 shows the fluctuations of cortisol and GH in adults during the night in 
relation with the EEG recordings.  
A physiological sharp increase in cortisol level occurs in the morning, specifically within 30-
45 minutes after awakening. This event is termed cortisol awakening response (CAR) [75, 76] 
and is mainly modulated by the time of awakening, psychological and physical factors [75-77]. 
Moreover, the HPA system is activated in response to stress, during which the release of 
cortisol is enhanced independently of its circadian rhythm [65, 78]. 
 
 
 
 
 
 
 
 
Figure 1.4 Sleep EEG, cortisol and GH secretion in representative young adults. (Figure 
adapted from Steiger A., 2002 [79]). 
 
As mentioned before, sleep is influenced by the HPS and HPA axes. Several lines of evidence 
have demonstrated a bidirectional communication between sleep and these endocrine systems. 
For instance, GHRH can enhance SWS and REM sleep in different animal species after 
intravenous (i.v.) or intracerebroventricular (i.c.v.) administration, even in 
hypophysectomized rats [80-82]. The pro-somnogenic function of GHRH was confirmed in 
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males after i.v. [83-85] and intranasal [86] administration of GHRH, although the effect measured 
was weaker in elderly subjects [87]. However, administration of a GHRH antagonist did not 
affect SWS sleep [88]. With regard to GH, administration of antiserum to GH in rats impaired 
NREM sleep [89] but administration of high dosages of GH [90] or IGF-1 [91] decreased NREM 
sleep as a result of GHRH negative feedback inhibition. In addition, acute or prolonged 
infusion of GH in men was not associated with sleep changes [92].  
Several studies have also investigated the effect of CRH on sleep.  Contrarily to GHRH, CRH 
administration induced a decrease in SWS and NREM sleep in rats and rabbits [80, 93]. The 
same effects were also observed in young men subjected to repeated CRH i.v. injections, 
which caused enhanced cortisol levels and decreased GH surge, reinforcing the idea of a 
reciprocal interaction between HPA and HPS activities [51, 94]. Importantly, when CRH was 
administered during SWS, but not during other sleep stages, the expected increase in ACTH 
and cortisol levels was blunted, supporting the idea that sleep itself can also influence the 
function of the HPA axis [95]. Continuous nocturnal infusion [96] and pulsatile i.v. 
administration of cortisol have been found to increase SWS and decrease REM sleep in both 
young and older adults, with a parallel increase in the levels of GH [97, 98]. Therefore, elevated 
cortisol levels could mediate a negative feedback inhibition of endogenous CRH and reduce 
the CRH:GHRH ratio in favour of the latter [97].  
1.1.3.4 Ghrelin 
Beyond the factors described above, several other hormones are believed to be important for 
the regulation of sleep. Ghrelin is an appetite-promoting peptide [99] initially isolated from the 
stomach [100], and subsequently discovered to be expressed by other tissues such as the 
pituitary gland [101] and the hypothalamus [102], where it can bind the receptor for GH 
secretagogues (GHS-R) [103]. The presence of both ghrelin and GHS-Rs in the hypothalamic-
pituitary system, together with the ability of ghrelin to increase GH release suggests a 
hypophysiotropic role for this peptide [104-106]. A study conducted by Weikel and colleagues 
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showed that ghrelin enhances SWS in humans: hourly administration of ghrelin in healthy 
young males during the night enhanced SWS and decreased REM sleep, increasing also the 
levels of GH, prolactin, ACTH and cortisol [107]. In addition, ghrelin serum concentration 
shows a daily rhythm, its peak occurring at the sleep onset and its levels decreasing during the 
night, as assessed in young males [108]. Intriguingly, physiological short sleep duration has 
been associated with higher morning ghrelin levels [109].  
1.1.4 SLEEP AND HEALTH 
Sleep behaviour deeply impacts upon human health. Epidemiological studies have elucidated 
the higher risk of mortality of long (>8 hours per night) and short (<7 hours per night) 
sleepers [5-9, 11], although the optimal sleep duration has recently been reported to be between 5 
and 6.5 hours per night [11]. Moreover, variation in sleep circadian timing, duration and 
continuity have also been associated with a number of adverse outcomes, including the 
development of insulin resistance [110, 111], hypertension [112, 113], obesity [109, 114], type 2 
diabetes mellitus [115-117], cardiovascular diseases [118, 119], depression [120], cognitive decline 
[121, 122], increased risk of different types of cancer [123-125] and increased risk to common 
infections [126], particularly pneumonia [127] and colds [128] as well as a decreased response to 
vaccination [129]. It is important to note that one of the common features shared by the 
majority of these conditions is a pro-inflammatory state. 
To assess whether inflammation can be influenced by sleep duration, several inflammatory 
markers such as C reactive protein (CRP) and cytokines have been measured in individuals 
after protocols of total/acute sleep deprivation and partial/chronic sleep deprivation. Short 
periods of total sleep deprivation have been associated both with increased [130] and decreased 
levels of CRP [131], while individuals subjected to longer periods of restricted sleep duration 
showed increased [130, 132] or unaltered [133] CRP levels. The effects of sleep deprivation on 
cytokine levels are discussed in section 1.2.7.     
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1.1.4.1 Sleep and obesity 
Several large population studies have identified a U-shaped relationship between sleep 
duration and excessive body weight across all age groups and in several ethnic groups [109, 134, 
135]. Although both short and long sleepers tend to become overweight, obesity appears to be 
mostly linked with short sleep duration [136-138]. Consequently, sleep duration has also been 
found to be associated with increased risk of metabolic syndrome [139-141] and type II diabetes 
[115-117]. On the basis of these findings, a number of groups have tried to elucidate the 
connection between sleep and metabolic functions. First of all, alteration of the circadian 
rhythm itself induces metabolic impairments independently of sleep duration: feeding mice at 
a different circadian time resulted in a gain of weight of the animals [142]; similarly, shift 
workers are characterized by impaired glucose and lipid metabolism [143, 144]. Interestingly, the 
metabolism of glucose varies during at 24 hour period, as glucose concentration is higher in 
the evening compared to the morning in response to the same meal [145]. 
In addition to these studies, physiological sleep duration has also been found to be associated 
with changes in metabolism. Women sleeping less than 5 hours or longer than 8 hours per 
night displayed higher serum triglyceride levels and lower high-density lipoprotein (HDL) 
cholesterol, whereas among males, only longer sleepers showed reduced levels of low-density 
lipoprotein (LDL) [146]. Sleep deprivation protocols have further strengthened the link between 
sleep and metabolism. A single night of total sleep deprivation is sufficient to cause a 
reduction in insulin sensitivity in response to oral glucose administration [147], whereas 
protocols of partial sleep deprivation decreased glucose tolerance [148, 149], and higher total and 
LDL cholesterol levels in post-menopausal women [150]. Interestingly, Nedeltcheva and 
colleagues confirmed that lack of sleep modulates energy intake and expenditure, as partially 
sleep-deprived subjects experienced a reduced amount of fat loss compared to the control 
group in response to the same protocol of caloric restriction [151]. In addition, food intake also 
influences the sleep behaviour, as Michalsen et al. showed that a fasting period of 7 days 
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prompted a decrease in sleep arousals and an increase in the self-reported quality of sleep in 
non-obese individuals [152].  
In light of these results, it could be argued that the sleep-regulating centres in the brain 
directly contribute to the modulation of metabolism. This hypothesis is supported by the fact 
that the neurons in the SCN project to other areas of the hypothalamus communicating with 
orexigenic and anorexigenic neurons, involved in increasing and inhibiting appetite and food 
intake respectively [153]. Additionally, energy expenditure and food intake are known to be 
affected by the hormones of the HPS and HPA axes [154]. Finally, the white adipose tissue 
(WAT) is known to secrete a number of cytokines and other molecules (adipokines) known to 
modulate appetite, energy expenditure and metabolism [155, 156], which might also affect the 
sleep regulatory centres in the brain.  
1.1.4.2 Sleep and leptin  
Leptin is one of the most studied adipokines. Its expression increases after food intake and 
insulin administration [157-159]; like insulin, leptin acts as a satiety signal, decreasing caloric 
intake thus having weight-reducing effects [160, 161]. Despite this anti-appetite function, obese 
people are characterized by high serum levels of leptin: this apparent contradiction can be 
explained by the condition of leptin-resistance which usually develops in parallel with obesity 
[162-164]. 
Many reports have shown that leptin levels are associated with sleep duration, though results 
are often contradictory. For instance Taheri et al. carried out a large population-based 
longitudinal study where a U-shaped relationship between body mass index (BMI) and self-
reported sleep duration was observed [109]. In the same study leptin levels were lower in short 
sleepers and significantly increased in association with longer sleep duration. No differences 
were detected for adiponectin levels whereas morning serum levels of ghrelin negatively 
associated with sleep duration and efficiency [109]. The same positive correlation between 
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leptin levels and sleep duration was found in another epidemiological study by Chaput and 
colleagues [165], but it was not determined in a smaller cohort of adolescents [166]. Furthermore, 
Spiegel et al. analyzed the levels of leptin and ghrelin in a smaller group of healthy male 
volunteers allowed to sleep for 4 hours per night for two consecutive nights and compared 
with a group subjected to extended sleep duration. In this study the authors reported leptin 
levels to be markedly decreased and ghrelin levels increased in the sleep-deprived group [167].  
The data obtained from these studies suggest that short sleep duration increase appetite and 
promote obesity through modulation of leptin levels. However, more recently Hayes et al. 
reported that each hour reduction in physiological sleep duration was associated with 
increased morning level of leptin in a group of healthy adults [168]. In agreement with the latter 
study, it has also been shown that leptin levels significantly raised in sleep-restricted 
participants after 5 nights [169] and a single night of partial sleep deprivation [170]. Similarly, an 
increment in leptin concentration was observed following one night of total sleep loss [171]. 
Despite these contradictions in the literature, leptin may represent an important element 
involved in the regulation of sleep. In fact, serum leptin levels show a clear circadian rhythm, 
increasing in the night and reaching the maximal peak around 3 a.m. in humans [172]. 
Moreover, both ob-ob mice (carrying a loss-of-function mutation in the leptin gene) and db-
db mice (carrying a loss-of-function mutation in the leptin receptor gene) are characterized by 
impaired sleep, displaying an increase in the overall sleep time, in particular in NREM sleep, 
as well as increased sleep fragmentation, with altered EEG waveforms and sleep rhythms [173, 
174].  
Leptin receptor is expressed in the arcuate nucleus of the hypothalamus and in other nuclei, 
including the PVN [175, 176]. Active transcription of leptin mRNA has been demonstrated in the 
hypothalamus, cerebral cortex and pituitary [177, 178]. It is also well established that leptin can 
cross the blood-barrier brain (BBB) likely through a saturable transport system and has been 
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detected in human cerebrospinal fluid, its levels correlating with plasma levels and with BMI 
[179, 180]. Thus, systemic leptin can reach the brain and is believed to regulate neurons of the 
arcuate nucleus by inhibiting the release of products known to be involved in regulation of 
food intake and also sleep, such as NPY [181, 182]. In addition, Luheshi and colleagues found 
that i.c.v. administration of leptin increased the levels of interleukin (IL)-1β in the rat 
hypothalamus, and the effects of leptin on food intake and body temperature were partially 
suppressed by the co-administration of IL-1 receptor antagonist (IL-1RA) and were absent in 
IL-1 receptor-deficient mice [183]. This study highlights a potential mechanism of leptin action 
in the hypothalamus mediated by IL-1β. Such a mechanism could also explain the link 
between leptin and sleep duration, as IL-1β is also a pro-somnogenic cytokine (discussed 
below). 
1.1.4.3 Sleep and adiponectin 
Adiponectin is another very abundant adipokine which is considered a strong anti-diabetic, 
anti-atherogenic and anti-inflammatory molecule which enhances insulin sensitivity and 
decreases glucose production by the liver [184, 185]. Lack of sleep has not always been 
associated with changes in adiponectin serum levels, for instance Taheri and colleagues did 
not observe any difference in adiponectin levels in relation with sleep [109]. Similar 
observations were made in other studies, investigating adiponectin levels in adolescents [166] 
and in police officers working primarily on the day shift and characterized by different sleep 
durations [186]. However, a recent study has investigated adiponectin levels in sleep-deprived 
volunteers allowed to sleep 4 hours for five consecutive nights. In this condition the authors 
found a decline in adiponectin serum levels only in sleep-restricted caucasian women, while 
in African women adiponectin appeared to increase and in males no differences were found 
[187]. In addition, a study conducted on 109 Japanese healthy males showed a positive 
association between self-reported sleep duration and adiponectin serum levels [188]. In 
agreement with the latter, in a group of Saudi teen-aged girls, adiponectin concentration was 
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found to be higher in lean girls compared to obese ones, and increased in proportion to hours 
of sleep [189].  
Although a correlation between physiological sleep duration and adiponectin values has not 
always been found, adiponectin serum concentration is strongly diminished in patients 
suffering from OSAS, as several studies have reported the same result independently of 
obesity and gender and in different ethnic groups [190-192] . OSAS is a sleep condition 
characterized by interrupted breathing during sleep, provoked by obstruction of the upper 
respiratory tract, and a high pro-inflammatory status, as patients are characterized by higher 
levels of tumor necrosis factor (TNF)-α, CRP and IL-6 [193-195]. Therefore, the lower levels of 
adiponectin in OSAS patients could be due to the incremented levels of these factors, which 
have been shown to decrease adiponectin expression in adipocytes [196-199]. 
A few groups reported that adiponectin serum levels show a circadian rhythm, declining in the 
night and increasing during the day with a peak reached in the late morning [200, 201], while 
other studies failed to find any daily variation [202]. A matter of debate is also the presence of 
adiponectin in the brain. Adiponectin is expressed by the pituitary gland but not by the brain 
[203-206], moreover it has been suggested that adiponectin cannot cross the BBB [207, 208]. In 
contrast, other studies have shown that adiponectin is present in human cerebrospinal fluid 
(CSF) at a very low levels (0.1% compared to the serum concentration) and mainly the low 
molecular weight (LMW) isoform [206, 209, 210]. In fact, adiponectin increases in the CSF after 
i.v. administration in mice [206, 211] and it can activate AMP-activated protein kinase (AMPK) 
in the hypothalamus [211]. The action of adiponectin in the central nervous system (CNS) is 
further indicated by the high expression of adiponectin receptors in different hypothalamic 
regions [205, 206]. 
 
 
18 
 
1.2 THE IMMUNE SYSTEM 
The immune system is represented by a heterogeneous group of cells and tissues which are 
responsible for defending the body against infectious agents and aberrant cells recognized as 
“non-self” and therefore potentially harmful for the organism. The immune system can be 
broadly divided into the innate and adaptive immune systems, though in reality they are 
interconnected. The innate immune system is characterized by a rapid, non-specific 
identification of invading elements providing a swift response to avoid the spread of rapidly 
dividing pathogens. The role of adaptive immunity is to amplify and improve the innate 
response by building specificity and memory against a particular agent in order to fight it 
more efficiently on second exposure. Therefore, the adaptive immune response is considered 
“acquired” and is slower but more specific than the innate response. 
The components of innate immunity are represented by:  
- anatomical barriers (epithelial cells, mucus); 
- soluble components: complement system, circulating anti-microbial proteins, 
inflammatory mediators, including chemical factors (histamine, bradykinin, serotonin, 
leukotrienes, and prostaglandins) and cytokines; 
- basophils/mast cells: involved in allergy-related inflammation; 
- neutrophils: specialised in recognition and killing of rapidly divinding bacteria, yeast 
and fungi; 
- eosinophils: deal with parasitic infections; 
- monocytes-macrophages: kill microbes especially intracellular bacteria and also link 
innate and adaptive immunity by presenting antigen to lymphocytes and releasing 
proinflammatory cyotkines; 
- natural killer (NK) cells: recognize and clear tumors and virus-infected cells; 
- dendritic cells: ingest and process antigens and present them to lymphocytes. 
The components of adaptive immunity include: 
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- T lymphocytes, divided into cytotoxic CD8+ T cells, helper CD4+ T cells and the less 
common γδ T cells. Further subpopulations can be distinguished according to the 
phenotype and the cytokines secreted (discussed in section 1.2.5); 
- B lymphocytes which are responsible for the secretion of the five types of antibodies 
IgA, IgD, IgE, IgG, and IgM. 
1.2.1 NEUTROPHILS 
Neutrophils, also called polymorphonuclear cells because of their characteristic multilobed 
nucleus, are the largest immune population (109-1010 cells/litre of blood), which provide the 
first protective response against bacteria and fungi. Neutrophils are post-mitotic, short-lived 
cells that undergo spontaneous apoptosis in the absence of infection. In humans, neutrophil 
half-life was initially estimated to be 7-10 hours in the blood [212, 213], although a more recent 
work by Pillay and colleagues shows that circulating human neutrophils can survive in the 
circulation for up to 5.4 days [214]. Consequently, neutrophil turnover is rapid: approximately 
109 cells per kg of body weight are produced daily by the bone marrow in humans [215]. 
During infection, neutrophils are recruited to the inflamed tissue where they activate their 
anti-microbial functions in order to clear the pathogen. Their survival is also prolonged by the 
presence of cytokines, microbial factors [216] and hypoxia [217-219]. 
1.2.1.1 Neutrophil migration to the site of infection 
When the body is challenged by the entry of a microorganism, neutrophils transmigrate from 
the blood to the infected tissues. Neutrophil transendothelial migration consists of three 
distinct stages: 
1) rolling: once activated, the vascular endothelium increases the surface expression of P- and 
E-selectins [220, 221], allowing the binding of neutrophils through their ligand sialyl-Lewisx [222]. 
The affinity of this carbohydrate-selectin interaction is weak, therefore neutrophils continue to 
move and “roll” on the endothelium. 
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2) tight adhesion: during the “rolling” stage, neutrophils are exposed to pro-inflammatory 
cytokines and chemokines which further modify the expression of neutrophil surface 
receptors. For instance, IL-8 leads to increased expression and conformational activation of 
the integrins Mac-1 (CD11b/CD18) and lymphocyte function-associated antigen (LFA)-1 
(CD11a/CD18) [223, 224]: once rearranged, these integrins can bind to ICAM-1 on endothelial 
cells with high affinity, thereby arresting the “rolling” and promoting the firm adhesion of 
neutrophils to the blood vessel wall [224, 225] . 
3) diapedesis: at this point, neutrophils are ready to transit into the infected tissues. The 
transendothelial migration is mediated by several surface proteins, such as CD31 and 
junctional adhesion molecules (JAMs) [226, 227]. 
Once transmigrated, neutrophils follow the gradient of chemotactic factors including IL-8 
[228], the bacterial product N-formylmethionyl-leucyl-phenylalanine (fMLP) [229] and 
complement factors, such as C5a [230] to reach the site of infection. These chemoattractants 
interact with their respective receptors expressed by neutrophils, causing a morphological 
polarization of the cell along the gradient and the formation of pseudopods and lamellipodia 
[231].  
In addition, in the circulation neutrophils are in a resting state and are not fully committed to 
perform a complete microbicidal activity. In the infected tissues, neutrophils are exposed to 
the gradient of chemokines as well as microbial factors and a range of cytokines produced 
locally. These molecules, for example TNF-α, represent priming agents, as they can boost 
neutrophil anti-microbial function: neutrophil sensitivity to microbial stimuli such as fMLP is 
enhanced and their full killing abilities are achieved [232].  
1.2.1.2 Phagocytosis 
The process of phagocytosis allows neutrophils to recognize, uptake and ingest the invading 
microbes. Pathogens are identified and captured by two different mechanisms:  
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1) pathogens express specific surface molecules, also called pathogen-associated molecular 
patterns (PAMPs), which are directly recognized by specific neutrophil receptors, the pattern 
recognition receptors (PRRs). An example of a PAMP is lipopolysaccharide (LPS) and a 
family of receptors called the Toll-like receptors (TLRs) are the main PRRs. For example 
TLR4 recognizes LPS [233]; 
2) microorganisms are opsonized by serum proteins: complement factors C3b and iC3b and 
antibodies cover their membrane. Neutrophils express receptors for immunoglobulins as well 
as for complement factors, therefore they bind to opsonized pathogens. In particular, 
neutrophils express three classes of the Fcγ receptor: the most relevant ones are FcγRI 
(CD64), FcγRIIa (CD32) and FcγRIIIb (CD16), which recognise the Fc portion of 
immunoglobulins [234]. In addition, neutrophils display the complement receptors CR1 (CD35) 
and CR3, (the dimer CD11b/CD18, alternatively called Mac-1) which bind respectively to the 
complement components C3b and its cleavage product iC3b [235, 236]. After contact, 
neutrophils undergo specific cytoskeletal rearrangements and the microbes are then 
surrounded by extended pseudopods and enclosed into the maturing phagosomes where they 
are killed. From the signalling perspective, neutrophil phagocytosis is accompanied by 
activation of phosphoinositide 3-kinase (PI3K) [237, 238] and the mitogen-activated protein 
kinases (MAPKs) extracellular signal-regulated kinase (ERK) 1/2 and p38 [239, 240]. 
1.2.1.3 Oxygen-independent bactericidal processes 
Neutrophil anti-microbial mechanisms following pathogen uptake are classified as either 
oxygen-dependent or oxygen-independent. Among the oxygen-independent processes are the 
phagosome acidification and the fusion of the phagosome with the cytoplasmic granules to 
form the phagolysosome, where the microbial destruction takes place [241]. The four main 
cytoplasmic granules (azurophilic, specific, gelatinase granules and lysosomes) contain 
antimicrobial proteins such as myeloperoxidase (MPO), elastase, cathepsin G, lysozymes, 
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lactoferrin, acid hydrolases and defensins, creating an environment able to eliminate the 
pathogens [242]. 
1.2.1.4 Oxidative burst 
The oxygen-dependent system by which neutrophils kill microbes includes the generation of 
O2.- and other reactive oxygen species (ROS). O2.- is produced by the enzymatic complex 
nicotinamide adenine dinucleotide phosphate (NADPH) oxidase, consisting of a Rho GTPase 
and five phagocytic oxidases (gp91, p22, p40, p47, p67), which are disassembled in resting 
neutrophils and assembled on plasma and phagosome membranes upon neutrophil stimulation 
[242]. O2.- can be reduced to H2O2 which is converted into HOCl by the enzyme MPO in the 
phagolysosomes [243]. Several different phagolysosome residing enzymes produce other 
radical species having microbicidal properties [242]. 
1.2.1.5 Neutrophil extracellular traps (NETS) 
In 2004 another neutrophil mechanism of defense was discovered: neutrophils can produce 
NETs. NETs consist of extracellular fibers of DNA coated in histones and other proteins 
derived from azurophilic and specific granules, such as elastase, MPO, cathepsin G and 
lactoferrin [244]. Once NETs are released from the cells, which happens in response to a range 
of stimuli (IL-8, LPS, both Gram-positive and Gram-negative bacteria), they contact and kill 
extracellular pathogens [244]. 
1.2.2 NEUTROPHIL APOPTOSIS 
Apoptosis is defined as a programmed, active and ordered form of cell death whose features 
distinguish it from necrosis. Necrotic cells are characterized by loss of membrane integrity 
and cell content, thus they can lead to in vivo inflammation as a result of the leakage of 
cytoplasmic content. On the contrary, apoptotic cells undergo cell shrinkage, membrane 
blebbing and chromatin condensation followed by collapse of the nucleus into apoptotic 
bodies, small vescicles containing parts of the fragmented nucleus which are cleared by local 
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phagocytes [245, 246]. Importantly, the membrane and organelle integrity are maintained during 
the formation of the apoptotic bodies, avoiding the release of cellular content and consequent 
tissue inflammation [245, 246]. The other peculiarity of apoptotic cell death is the activation of a 
group of proteins, the caspases, which are cysteine-containing aspartate-specific proteases 
which mediate the changes within the apoptotic cell ultimately causing its death [247]. 
The process of apoptosis can be initiated either from the intracellular space or from the 
extracellular environment: the internal signals, which are generated in response to stress and 
DNA damage, stimulate the intrinsic, mitochondrial apoptotic pathway whereas the external 
stimuli trigger the death receptor apoptotic pathway. The cellular stressors which directly 
damage the DNA, such as radiations and oxidative stress, induce the internal apoptotic 
pathways [248-251], whereas the extrinsic apoptosis is triggered by extracellular signals such as 
TNF-α, Fas ligand (FasL), and tumor necrosis factor-related apoptosis-inducing ligand 
(TRAIL) which interact with and activate the respective death receptor (DR) [252, 253]. Both of 
these two apoptotic programs converge on activation of caspases [252]. 
As mentioned above, neutrophil lifespan is very short: circulating neutrophils are thought to 
die as a consequence of cytokine deprivation-induced apoptosis, a homeostatic mechanism to 
maintain the appropriate neutrophil number under physiological condition as well as to limit 
uncontrolled inflammatory processes [216, 254]. Ageing neutrophils disappear from the 
circulation and accumulate in organs such as the spleen, the liver and the bone marrow, where 
they have been shown to undergo apoptosis as evidenced by murine studies [255-257]. Apoptotic 
neutrophils are then recognized and phagocytosed by local macrophages and dendritic cells; 
this process is accompanied by macrophage secretion of anti-inflammatory mediators such as 
IL-10 and transforming growth factor (TGF)-β [254, 258]. The prompt removal of dying 
neutrophils represents a process to avoid self-injury, as late apoptotic cells are subjected to 
secondary necrosis releasing the vescicular toxic content in the extracellular space [254] 
causing tissue damage also in sterile and non-inflammatory conditions.  
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In infection, infiltrating neutrophils have an extended lifespan: bacterial products (LPS) [216], 
pro-inflammatory cytokines [216] (such as granulocyte macrophage-colony stimulating factor 
(GM-CSF)) [259] and hypoxia [217-219] contribute to delay the spontaneous apoptotic process, 
thus neutrophils have more time to clear the pathogen. 
Nevertheless, neutrophils are eventually induced to apoptosis once their anti-microbial 
functions are activated: phagocytosis [260, 261], ROS [260, 262, 263] and NETs production [264] 
promote neutrophil death independently of the effective killing of the microorganism. 
Especially in this setting, the removal of apoptotic neutrophils by macrophages is essential to 
resolve the acute inflammation [265]. 
Neutrophil spontaneous apoptosis strongly depends on the balance of the pro- and anti- 
apoptotic proteins belonging to the Bcl-2 family: these cells highly express the two pro-
apoptotic proteins, Bax and Bak [266, 267] as well as the BH3-only members Bad, Bim, Bid, Bik 
[266]. Among the anti-apoptotic proteins, Mcl-1 is highly expressed in fresh neutrophils [266, 268] 
and appears to be the most relevant in dictating neutrophil apoptosis, as Bcl-2 is weakly 
expressed [266, 269] and Bcl-XL expression is controversial [266, 270]. In addition Mcl-1 levels 
positively correlate with neutrophil survival [271, 272] and suppression of endogenous Mcl-1 
expression confirmed the essential role of this protein in delaying neutrophil spontaneous 
apoptotsis [272, 273]. 
PI3K is a family of protein kinases responsible for the production of phosphatidilynositol 3,4 
bisphosphate (PtdIns (3,4)P2) and phosphatidilynositol 3,4,5 triphosphate (PtdIns (3,4,5)P3) 
[274], which in turn induce the binding of  protein kinase B (PKB) and its phosphorylation [275]. 
The activity of these kinases, particularly PI3Kγ, participate in the regulation of neutrophil 
spontaneous apoptosis, as both the levels of PtdIns (3,4,5)P3 and the activation of PKB are 
diminished during neutrophil apoptosis, in parallel with an accumulation of intracellular ROS 
[276]. Anti-apoptotic stimuli such as GM-CSF and LPS have also been shown to exert their 
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effect through activation of PI3K, which acts by enhancing Bad phosphorylation [277, 278] and 
expression [279].  
With regard to the MAPK family, there are contradictory reports relating to their role in 
neutrophil spontaneous apoptosis. Pongracz and colleagues showed that the MEK-1/ERK 1/2 
inhibitor PD98059 and the p38 inhibitor SB202190 do not affect the apoptotic rate, and the 
phosphorylation of ERK 1/2 and p38 do not increase during the apoptotic process, suggesting 
that the modulation of these single pathways is not sufficient to influence spontaneous 
apoptosis [280]. However, some groups have demonstrated that p38 activation accelerates 
neutrophil apoptosis [281] and antagonizes LPS-delayed neutrophil apoptosis [282]. In contrast, 
an anti-apoptotic role for p38 has been proposed in other studies [283, 284]. Despite the fact that 
ERK 1/2 does not have a role in regulating neutrophil spontaneous apoptosis, its activation is 
necessary for the anti-apoptotic role exerted by several stimuli, such as LPS [282, 285] and GM-
CSF [277].  
The pro-inflammatory transcriptional factor nuclear factor kappa-light-chain-enhancer of 
activated B cells (NF-kB) is also involved in prolonging neutrophil lifespan [286]. In resting 
cells, NF-kB is located into the cytoplasm where it forms a complex with inhibitor of kB 
(IkB): once cells are activated by pro-inflammatory stimuli, IkB is degraded and NF-kB can 
translocate into the nucleus and begin the transcription of inflammatory genes [287]. Activation 
of NF-kB by PI3K and MAPK signalling pathways has been shown to mediate the anti-
apoptotic effect exerted by LPS [288], type-1 interferons (IFNs) [289] and hypoxia [217]. 
However, the target genes promoting the anti-apoptotic function of NF-kB in neutrophils are 
still largely unknown. 
Neutrophils express high levels of Fas receptor (CD95) and they are highly susceptible to 
apoptosis when stimulated with activating anti-Fas antibodies [290]. Upon stimulation, CD95 
aggregates and undergoes clustering, [291] triggering the death signal through recruitment of 
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Fas-associated protein with death domain (FADD) and pro-caspase-8, forming the so-called 
death-inducing signaling complex (DISC) [263]. However, neutrophil constitutive apoptosis is 
not affected by the use of antagonist antibodies against CD95 and other death receptors and 
clustering of CD95 has been shown to occur spontaneously, inducing the formation of the 
DISC complex and initiating the extrinsic apoptotic pathway [263]. In particular, accumulation 
of ceramide and generation of ceramide-rich lipid rafts within the membrane is necessary to 
mediate CD95 clustering [291, 292]. In neutrophils, increased levels of intracellular ceramide are 
associated with an increased rate of apoptosis [293], moreover disruption of ceramide-rich lipid 
rafts delays apoptosis [263].  
Ceramides are a family of sphingolipids that are generated through different mechanisms. 
They can be synthetized “de novo”, or through the hydrolysis of sphingomyelin by activation 
of sphingomyelinases or through the “salvage pathway” [293, 294]. Interestingly, ceramide 
production in neutrophils is enhanced by the production of ROS which accumulate during 
spontaneous apoptosis [262, 263]. ROS are already known to trigger neutrophil apoptosis 
following neutrophil activation [262, 295], hence the modulation of ceramide represents a 
mechanism regulating neutrophil apoptosis. 
Another important sphingolipid involved in apoptotic regulation is sphingosine-1-phosphate 
(S1P), a product of ceramide metabolism [294]. In contrast to its precursor, S1P shows distinct 
anti-apoptotic function in different cell types [296, 297] including LPS-treated neutrophils [298]. 
1.2.3 NK CELLS 
NK cells are cytotoxic and cytokine-producing lymphocytes belonging to the innate immune 
system and representing 10-15% of circulating lymphocytes [299]. In addition, they are also 
present in peripheral tissues such as the liver [300], lung [301] and peritoneal cavity [302]. Their 
main function is to recognise and kill tumoral and virus-infected cells. NK cells are identified 
by a range of surface receptors, notably expression of CD56 and CD16 and the absence of 
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CD3 [299]. Two major subsets of NK cells can be identified according to CD56 and CD16 
expression: CD56dim CD16high NK cells represent 90% of all the circulating NK cells and 
show high cytotoxicity using both granule exocytosis and death receptor ligation pathways to 
kill target cells. CD56bright NK cells constitute the remaining 5-10% of the circulating NK cell 
pool and produce cytokines such as IL-10, IL-13, GM-CSF, TNF-α and IFN-γ [303], therefore 
their major role is to boost the function of other immune cells present in the environment [299]. 
NK cell cytotoxicity against target cells is achieved through two different mechanisms, 
granule exocytosis and death receptor-mediated killing. Granule exocytosis is the main 
process by which NK cells kill target cells [304]. NK cells bind to the target cell forming an 
immunological contact allowing NK cells to secrete the cytotoxic content of intracellular 
vesicles thus promoting the apoptosis of the target cell. The effector molecules released by 
activated NK cells are perforin and the granzyme proteases. Perforin is a protein which forms 
a complex on the target membrane and is necessary for the passage of granzymes into the 
cytoplasm. Granzymes are a family of serine proteases that are primarily responsible for 
inducing target cell death through the granule exocytosis pathway [304, 305]. Of the five 
granzymes expressed by human NK cells, granzyme B has been the most studied as is 
indispensable for triggering both caspase-dependent and independent apoptosis [305, 306]. 
NK cells can also kill target cells through engagement of death receptors. Either when 
stimulated with cytokines [307] or activatory ligands [308], NK cells increase the surface 
expression of FasL and TNF-related apoptotic inducing ligand (TRAIL), both ligands of the 
tumour necrosis factor family. Upon ligation with their cognate receptors (Fas and TRAIL-
R1/TRAIL-R2 respectively), they cause the death of target cells through caspase activation 
[304].   
NK cell cytotoxicity is strictly regulated. Starting from the process of NK cell differentiation, 
which takes place in the bone marrow, only NK cells capable of distinguishing self major 
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histocompatibility complex (MHC) class I molecules achieve an efficient killing ability, 
meaning that the binding between self MHC class I molecules and inhibitory receptors on the 
surface of NK cells is necessary for the acquisition of NK cell full effector function [309]. In 
addition, mature circulating NK cells express a wide range of activatory and inhibitory 
receptors, through which they collect signals from the environment. Only when the activatory 
signals overcome the inhibitory signals, NK cells can gain their full cytotoxic ability [310]. 
1.2.4 T and B LYMPHOCYTES 
T lymphocytes are cells responsible for mounting an adaptive, specific immune response 
towards viral, bacterial, parasitic microorganisms and malignant cells. The antigen specificity 
showed by T cells is due to the high variability of the T cell receptor (TCR) expressed on their 
surface, obtained through genetic rearrangement during their thymic development [311]. Once 
they have reached maturation in the thymus, naïve T lymphocytes (characterized by high 
surface expression of C-C chemokine receptor (CCR)7 and CD45 receptor antagonist 
(CD45RA) [312])  leave the thymus and circulate through the blood and lymphoid systems, 
where they can encounter antigen presented on MHC by the antigen-presenting cells 
(macrophages, dendritic cells and B lymphocytes) and are activated through the TCR [313]. 
Upon activation, T cells proliferate and a proportion of them enter the memory pool, which 
accumulates and remains over the individual’s lifespan, assuring a faster, stronger and more 
specific response in successive exposures with the same antigen [313]. Memory T cells are 
divided into subpopulations according to their function and phenotype: central memory (TCM) 
cells, effector memory (TEM) cells [314] and revertant effector memory (TEMRA) cells [315, 316] 
(Table 1.1). 
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MEMORY 
T CELL 
PHENOTYPE FUNCTION 
TCM CCR7+, CD45RA- Proliferation 
Differentiation into TEM cells 
TEM CCR7-, CD45RA- Rapid production of 
effector cytokines 
TEMRA CCR7-, CD45RA+ Terminally differentiated 
Similar function to TEM cells 
 
Table 1.1 List of memory T cell subsets, their phenotypes and function. 
 
The partition between naïve and memory T cells exists for both CD4+ and CD8+ T cells. In 
particular, activated CD8+ T cells, known as cytotoxic T lymphocytes (CTL) display a major 
cytotoxic role whereas CD4+ T cells mainly secrete cytokines to coordinate the response of 
the various immune populations, thus they are named T helper cells. According to the type of 
cytokines released and the receptors for chemokines expressed, CD4+ T helper cells can be 
further distinguished into T helper (Th) 1, Th 2 and Th 17 [313, 314, 317, 318]. Finally, another 
subset of T cells has been identified as suppressor or regulatory T cells (Tregs): these cells are 
involved in maintaining lymphocyte homeostasis and avoiding autoimmune diseases. They 
are phenotypically identified by expression of CD4, CD25 and FOXP3, a transcriptional 
factor essential for their inhibitory role. Their immune suppressive role is achieved by contact 
dependent and independent methods, the latter including secretion of anti-inflammatory 
cytokines such as IL-10 [319].  
B lymphocytes mature in the bone marrow and also circulate in the blood and lymph. Once 
activated by the uptake of antigen and contact with CD4+ T cells [320], they mature towards 
antibody producing cells, termed plasma cells. Like T cells, B cells also are long lived cells 
which provide immune memory. More recently it has been shown that a subset of regulatory 
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B cells (Bregs), identified by expression of CD24 and CD34, also has regulatory function 
secreting IL-10 [321]. 
1.2.5 CYTOKINES 
Cytokines are immunomodulatory molecules, secreted mostly, but not only, by immune cells. 
Generally, they can be divided into three functional categories: hematopoietic growth factors, 
innate immunity modulators and adaptive immunity modulators. A more detailed functional 
classification is shown in table 1.2. Similar to these cytokines there are other soluble factors 
called chemokines with the specific function of inducing cell migration (i.e. IL-8, monocyte 
chemotactic protein (MCP)-1 and macrophage inflammatory protein (MIP)-1α). 
FUNCTIONAL 
CLASS 
PRIMARY 
ROLE OTHER EFFECTS EXAMPLES 
lymphocyte growth 
factors clonal expansion 
Th1/Th2/Th17 
polarization 
IL-2, IL-4, IL-7, IL-17, 
IL-15 
Th1 cytokines ↑ Th1 response clonal expansion of CTL IFN-γ, IL-2, IL-12, IL-18 
Th2 cytokines ↑ Th2 responses ↑ antibody production IL-4, IL-5, IL-18, IL-25, IL-33 
Th17 cytokines ↑ Th17 responses, 
↑ IFNγ autoimmune responses IL-17, IL-23, IFN-γ 
pro-inflammatory 
cytokines 
↑ inflammatory 
mediators 
↑ innate immune 
responses 
IL-1α, IL-1β, TNF-α, IL-12, 
IL-18, IL-23, IL-32, IL-33, 
CD40L 
anti-inflammatory 
cytokines 
↓ inflammatory 
genes 
↓ cytokine-mediated 
lethality 
IL-10, IL-13, TGF-β, IL-22, 
IL-1Ra, IFN-α,β 
colony stimulating 
factors 
hematopoiesis 
 
pro and anti-
inflammatory 
IL-3, IL-7, G-CSF, 
GM-CSF, M-CSF 
type I interferons ↑ class I MHC, anti-viral 
anti-inflammatory, anti-
angiogenic IFN-α, IFN-β 
type II interferons macrophage activation increase in class II MHC IFN-γ 
 
Table 1.2 Functional classification of cytokines (table adapted from Dinarello C.A., 2007 
[322]). 
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1.2.6 SLEEP AND THE IMMUNE SYSTEM 
A large body of literature supports the existence of a bidirectional regulation between sleep 
and immunity, as long term lack of sleep can induce sickness and immune responses influence 
sleep physiology [18]; however the mechanisms at the basis of this interrelation have not been 
fully elucidated.  
The connection between sleep and the immune system is primarily suggested by the fact that 
the number of immune cells shows a daily circadian rhythm. In humans, the number of white 
blood cells (WBC) shows a circadian fluctuation, being higher late in the day and minimal 
early in the morning [323]. The levels of monocytes and neutrophils reach minimal values 
towards the night [324] whereas total T and B cells and both the CD4+ and CD8+ subsets have 
been consistently found to be more abundant during the night [323-326]. The most marked 
rhythm is showed by naïve T cells [326]. On the contrary, NK cells decrease during the night 
[323, 324, 327]. 
Apart from changes in immune cell number, also immune functions display a circadian 
rhythm. In humans, neutrophil phagocytosis is maximal in the dark period [328], whereas NK 
cell cytotoxicity appears to be minimal during the night [329]. In addition, the concentration of 
several cytokines varies during the 24-hour period. In humans, serum levels of IL-1 peak at 
the onset of SWS [330] and other pro-inflammatory cytokines, such as IL-2, IFN-ɣ and IL-6 
reach their maximal level later in the night [331, 332], although contrasting findings have also 
been reported [333]. The in vitro generation of IFN-γ and IL-10 also show a circadian rhythm, 
with the ratio between IFN-γ:IL-10 peaking in the night, implying a shift towards higher 
Th1:Th2 cytokine balance [334, 335]. In light of those data, it has been postulated that the rest 
period represents a pro-inflammatory status [336]. Importantly, cytokines appear to play a role 
in sleep regulation. In general the pro-inflammatory cytokines, especially TNF-α and IL-1β, 
exert a somnogenic effect by encouraging the SWS stage. Anti-inflammatory cytokines, such 
as IL-4 and IL-10, are supposed to inhibit spontaneous sleep [18]. 
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The circadian rhythmicity observed in these various aspects of the immune system is likely to 
be related to circadian hormonal variations. For instance, strong inverse correlations were 
found between the total circulating lymphocytes, as well as the CD4+ and CD8+ subsets, and 
the circadian rhythms of cortisol. The peak of lymphocytes occurs in the night when the level 
of cortisol reaches its nadir [325, 337, 338]. Indeed, cortisol is known to have powerful immune 
suppressive properties, decreasing mitogen-induced lymphocyte proliferation [339], 
antagonizing the actions of IL-1β [340, 341] and suppressing cytokine production by leukocytes 
as well as inhibiting NK cell activity [342, 343]. In particular, naive CD4+ T cells were found to 
be negatively correlated with cortisol rhythms and to upregulate the CXC chemokine receptor 
type 4 (CXCR4) after exposure to cortisol, suggesting that this steroid acts to redirect naive T 
cells to bone marrow [326]. Cortisol circadian pattern was also found to be positively associated 
with the number of circulating neutrophils [325], probably because of its anti-apoptotic role 
exerted specifically on neutrophils [344, 345].  
Catecholamines (epinephrine and norepinephrine) are mainly secreted by the adrenal gland 
and the sympathetic nervous system. Similarly to cortisol, their concentration raises in 
condition of stress [346] and show a distinct circadian rhythm, their nadir being at night [326, 347]. 
These hormones contribute to increase the number of circulating granulocytes and NK cells 
[348] and exert immunomodulatory roles by predominantly suppressing systemic immune 
functions [349]. Interestingly, catecholamines promote the mobilization of effector CD8+ T 
cells to the circulation [326]. 
Melatonin has been discovered to act upon the immune system by increasing monocyte 
activation, production of IL-1, IL-6, TNF-α and oxidative burst [350, 351]. On the contrary, it has 
been shown to inhibit IL-8 release by LPS-stimulated neutrophils [352]. With respect to 
lymphocytes, melatonin enhances peripheral blood mononuclear cells (PBMCs) proliferation 
[353], it promotes the release of the pro- inflammatory cytokines IL-2, IL-6, IFN-γ [354] and it is 
associated with increased Th1 response [355].  
33 
 
Also GH has been demonstrated to have a role in immune regulation. It can increase IFN-γ-
producing CD4+ T cells [356] and stimulate B cell immunoglobulin synthesis [357] and enhance 
hematopoiesis by promoting proliferations of progenitor cells and T lymphopoiesis [358]. 
Ghrelin, which stimulates GH release [103, 106], decreases the production of pro-inflammatory 
cytokines (IL-1β, TNF-α, IL-6) by human T lymphocytes and monocytes. In addition, ghrelin 
also promotes thymopoiesis and T cell development [359, 360].  
It is therefore possible that these hormones represent the main cause of diurnal variations in 
cytokines levels and immune cell numbers.  
1.2.6.1 How cytokines affect sleep 
The first data showing that cytokines could influence sleep architecture come from studies 
conducted on infected animals. Different animal hosts have been challenged with viral, fungal 
and bacterial pathogens or single microbial components and the results systematically indicate 
that such infections increase total sleep and NREM sleep duration [361-366]. Studies in humans 
were also performed. In particular, volunteers injected with evening low doses of LPS 
displayed prolonged and potentiated NREM sleep and decreased REM sleep, as result of 
increased levels of endogenous pro-inflammatory cytokines and their soluble receptors [367-
369], however these results were not reproduced when subjects were administered with higher 
doses of LPS [367] or when LPS was administered in the morning [370]. 
A number of cytokines and chemokines have been studied for their ability to regulate sleep in 
either animals or humans; amongst them only two, TNF-α and IL-1β, have been widely 
investigated to ascertain their role in promoting spontaneous sleep [371-373]. Systemic or central 
injection of either TNF-α or IL-1β has been shown to enhance the duration of NREM sleep, 
especially SWS duration in every species tested so far (rats, mice, rabbits, monkeys, cats and 
sheep) [371, 373, 374]. In confirmation of these findings, blockage of endogenous TNF-α [375, 376] 
and IL-1β [377, 378] decreases NREM sleep duration, and mice lacking TNF- α receptor [379], IL-
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1 type 1 receptor [380] or both [381] spend less time asleep. OSA patients who were subjected to 
treatment with Etanercept, a TNF-α antagonist, experienced a significant decrease of 
sleepiness and increased sleep latency, although no change in other sleep parameters was 
registered [382].  
TNF-α and IL-1β activate NF-κB, which promotes the production of TNF-α and IL-1β in a 
positive-feedback loop, thus resulting in an amplification of their somnogenic effect. The 
involvement of NF-kB in regulating spontaneous sleep has been confirmed by use of its 
inhibitory peptide, which caused reduction of NREM sleep in rats and rabbits [383]. 
Consequently, factors that can inhibit NF-κB activation, such as IL-4 and IL-10, inhibit sleep 
[383-385].  
The processes by which the CNS detects the concentration of systemic cytokines are at least 
three:  
1) cytokines send signals to the brain at the level of the choroid plexus and the 
circumventricular organs: they activate endothelial cells which produce second messengers 
that can enter the brain (humoral pathway); 
2) cytokines can stimulate the primary afferent nerves, such as vagal nerves, which in turn 
transport the information to the brain (neural pathway);  
3) cytokines can also be actively transported into the CNS (cellular pathway) [373, 386, 387]. 
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Figure 1.5 Mechanisms by which peripheral cytokine communicate with the brain. The 
three (humoral, neural and cellular) processes through which cytokines influence the CNS 
(figure adapted from Capuron and Miller, 2011 [387]).  
 
 
Numerous reports have shown that cytokines and their receptors are expressed in loco and 
released in the CNS by neurons and microglia [374, 388, 389]. In addition, hypothalamic neurons 
can also express IL-1 and TNF-α [390, 391]. Notably, Beynon and Coogan found endogenous 
expression of IL-1β and IL-1 Receptor 1 (IL-1R1) in the SCN of both young and old mice, 
observing a different circadian rhythm in the expression of IL-1R1 between young and old 
animals. Although no differences were seen in the circadian rhythm of IL-1β, this cytokine 
was secreted at a lower level in the old mice. IL-1β and IL-1R1 were also expressed in the 
PVN, where they showed a different circadian expression between old and young mice [392]. 
Collectively, these data indicate that TNF-α and IL-1β are involved in physiological sleep 
regulation. IL-6 is another cytokine possibly involved in sleep regulation, as one study 
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conducted on 17 healthy men showed that evening intranasal administration of IL-6 increased 
the duration of SWS sleep in the second half of the night [393], although its injection in rabbits 
did not influence the sleep pattern [394].  
More work is necessary to better elucidate the relationship between the network of cytokines 
and the sleep-regulating brain regions.  
1.2.7 THE EFFECTS OF SLEEP DEPRIVATION ON THE IMMUNE SYSTEM 
In order to understand the impact that sleep has on the immune system, the effects of sleep 
deprivation on immune cell numbers and functions have been examined. However, the 
existing literature varies considerably in its conclusions, probably because of the differences 
in the duration of sleep deprivation used in the different studies. The acute sleep deprivation 
protocols usually consist of periods ranging from a few hours to 126 hours of total sleep 
deprivation. Alternatively, partial sleep deprivation protocols allow sleep for a restricted 
duration, usually few hours per night for multiple nights [395]. The most consistent result 
across all the studies appears to be the rise in neutrophils following both protocols of acute 
and partial sleep deprivation. The majority of studies also report either increased or 
unchanged serum pro-inflammatory cytokines, while data on lymphocyte counts and 
functions are inconsistent. Interestingly, acute and partial sleep deprivation seem to have an 
opposite effect on NK cell cytotoxicity, the former enhancing and the latter inhibiting the 
ability of NK cells to kill target cells (tables 1.3 and 1.4).  
1.2.7.1 Acute sleep deprivation 
The studies conducted on totally sleep-deprived individuals indicated that such a loss of sleep 
caused an increase in the number of WBC in the blood, particularly neutrophils and 
monocytes [323, 396, 397]. Apart from these studies, the literature shows a range of contrasting 
results from studies investigating several aspects of the immune system. Some of these sleep 
deprivation protocols have been performed in combination with additional stressors, such as 
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military activities [398]. Moreover the length of total sleep deprivation, the methodologies 
used, the age and the gender of the participants and the use of a control groups varied among 
the studies. Therefore these differences could explain the inconsistencies found. The data 
obtained from these acute sleep deprivation studies are summarized in table 1.3. 
1.2.7.2 Partial sleep deprivation  
Studies of partial sleep deprivation, which mimic a situation of chronic lack of sleep, are even 
more difficult to interpret because of the vast range in the period of restricted sleep (from one 
single night [399-401] up to 12 nights [133] of reduced sleep time) and because of the presence of 
potential confounders, such as strenuous exercise and decreased caloric intake included in 
some study [402].  Again, differences in the experimental protocols and methodologies used, 
and the age and gender of the participants could also explain the disparity in findings among 
the studies. Gender seems to play an important role, as Irwin and colleagues observed 
dissimilar responses to partial sleep deprivation between males and females [401]. In general 
such protocols cause a decrease in immune function, such as NK cell cytotoxicity. However, 
this condition has often also been associated with increased production of cytokines following 
cell stimulation, as measured in vitro (summarized in table 1.4). Accordingly, Irwin and 
colleagues also found increased activity of the transcriptional factor NF-kB in PBMCs 
obtained from donors subjected to one night of partial sleep deprivation [403]. 
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Table 1.3 Effects of acute sleep deprivation on the immune system. Summary of data from 
studies showing an increase, decrease or no change (=) in immune parameters. 
IMMUNE VARIABLE EFFECT OF ACUTE SLEEP DEPRIVATION 
IMMUNE CELL NUMBER 
↑   WBC [323, 396, 397] 
 
↑ = neutrophils [323, 397, 404] 
 
↑   monocytes [323, 396] 
 
↑ = lymphocytes [323, 396, 397, 404] 
 
↑ = CD19+ B lymphocytes [323, 396, 397] 
 
↑ = CD3+ T lymphocytes [323, 397] 
 
↑↓ CD4+ T lymphocytes [323, 396, 397] 
 
↑ = CD8+ T lymphocytes [323, 396, 397] 
 
↑↓ NK cells [323, 396, 404] 
IMMUNE CELL 
FUNCTION 
↓   neutrophil phagocytosis [398] 
 
↑   neutrophil degranulation [405] 
 
=   neutrophil adherence [406] 
 
↑   NK cell cytotoxicity [329, 396] 
 
↓ = lymphocyte proliferation [396, 406] 
 
↑   whole blood production of IL-1β [323] 
 
↑   whole blood production of TNF-α [323] 
 
=  whole blood production of IL-6 [323] 
SERUM LEVEL OF 
CYTOKINES 
↑ = IL-1β [131, 397] 
 
↑ = TNF-α [397, 407] 
 
↑↓ = IL-6 [131, 407, 408] 
OTHER HUMORAL 
FACTORS 
↑↓= CRP [130, 131, 407] 
 
↑↓= cortisol [407, 409-411] 
 
↑ = Igs, complement factors [397, 412] 
VACCINE RESPONSE ↓= Igs [413, 414] 
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Table 1.4 Effects of partial sleep deprivation on the immune system. Summary of data 
from studies showing an increase, decrease or no change (=) in immune parameters. 
IMMUNE VARIABLE EFFECT OF PARTIAL SLEEP DEPRIVATION 
IMMUNE CELL NUMBER 
↑ = WBC [150, 400, 415] 
 
↑↓  neutrophils [150, 400, 402, 415, 416] 
 
↑ =  monocytes [150, 400, 402, 416] 
 
↑↓= lymphocytes [150, 400, 402] 
 
↑↓  CD19+ B lymphocytes [132, 402] 
 
↑↓= CD3+ T lymphocytes [132, 402] 
 
↑↓= CD4+ T lymphocytes [132, 402, 417] 
 
↑↓= CD8+ T lymphocytes [132, 402, 417] 
 
↓   NK cells [132, 400, 402] 
 
↑   CD8+ T cells producing TNF-α [335] 
IMMUNE CELL FUNCTION 
↑   neutrophil chemotaxis [402] 
 
↓   NK cell cytotoxicity [399, 400] 
 
↓   PBMC production of IL-2 [400] 
 
↓   PBMC production of TNF-α  [132] 
 
↑   PBMC transcription of IL-1β, IL-6 [132] 
 
↑↓  PBMC  proliferation [132, 417] 
 
↑   monocyte production of IL-6, TNF-α [401] 
SERUM LEVEL OF 
CYTOKINES 
↑ = TNF-α [418, 419] 
 
=  IL-1β [402] 
 
↑↓= IL-6 [133, 402, 418-420] 
 
=  IL-8 [416] 
OTHER HUMORAL 
FACTORS 
↑ = CRP [130, 132, 133, 416] 
 
=    dehydroepiandrosterone (DHEA) [421] 
 
↑↓   cortisol [148, 418, 422, 423] 
 
↑   Igs [402] 
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1.3 ADIPONECTIN 
A significant portion of this thesis focused on the effects of the adipokine adiponectin on 
innate immune function, notably neutrophil function and survival. Adiponectin is an abundant 
serum adipokine with levels in serum ranging between 5-10 µg/ml [424-426] , mainly produced 
by the WAT as well as cardiac myocytes [427], muscle cells [428] and PBMCs [429]. This protein 
is characterised by an N-terminal collagen-like region and a C-terminal complement factor 
C1q-like globular domain [430-432].  It circulates as a full-length protein which can oligomerise 
to form trimers (known as LMW adiponectin) and hexamers (medium molecular weight 
(MMW) adiponectin) which can then further oligomerise to form a polymer, the high 
molecular weight (HMW) isoform of adiponectin [424]. Adiponectin also exists as a proteolytic 
cleavage fragment, called globular adiponectin, consisting of the globular C-terminal domain 
which is cleaved by a leukocyte elastase secreted by activated monocytics and neutrophils 
[433]. Trimers and oligomers of adiponectin are the main form present in the circulation [434] 
with the globular fragment reported at very low concentrations only by one group [435]. 
Adiponectin serum levels are diminished in diseases such as type 2 diabetes, cardiovascular 
disease and obesity, while weight loss results in a significant increase in adiponectin 
production [436, 437]. Its concentration is negatively affected by insulin [438], sex hormones [439] 
and pro-inflammatory cytokines, mainly TNF-α [196], while the activation of peroxisome-
proliferator-activated receptor (PPAR)-γ by its ligands thiazolidinediones, which are used in 
the treatment of type 2 diabetes, induces its expression [198]. Although adiponectin is 
decreased in these chronic low grade inflammatory conditions, elevated levels of adiponectin 
are present in chronic autoimmune diseases such as rheumatoid arthritis, systemic lupus 
erythematosus and type 1 diabetes mellitus [440]. Circulating adiponectin levels also differ by 
gender and age, being higher in women [441] and in older adults [442]. 
41 
 
Two adiponectin receptors have been identified, AdipoR1 and AdipoR2: they contain seven 
transmembrane domains but are structurally and functionally distinct from G-protein-coupled 
receptors [443]. Globular adiponectin predominantly activates AdipoR1, whereas AdipoR2 
engages mainly with the full-length variant of adiponectin [444]. In addition, T-cadherin acts as 
a receptor which sequesters MMW and HMW adiponectin but not the trimeric and globular 
isoforms [445, 446]. The expression of AdipoR1 and AdipoR2 is ubiquitous in the majority of 
organs with AdipoR1 expressed at high level in skeletal muscle and AdipoR2 present at high 
level in the liver [444, 447]. With regard to the immune system, Pang and Narendran analyzed 
the surface expression of AdipoR1 and AdipoR2 on human PBMCs by flow cytometry, 
finding that both of these receptors are expressed by approximately 1% of T cells, 93% of 
monocytes, 47% of B cells, and 21% of NK cells [448], mainly the CD56dim subset [449]. T cells 
seem to retain AdipoR1 and AdipoR2 into clathrin-coated vescicles and to upload them at the 
surface upon stimulation [450]. Concerning neutrophils, one study showed that these cells 
express the mRNA for both receptors [429] while another study failed to detect AdipoR2 
mRNA and protein expression in these cells [451]. Intriguingly, both adiponectin receptors 
have been found to be downregulated in monocytes derived from type 1 diabetes patients [452]. 
Through these two receptors adiponectin triggers the activation of AMPK and other signaling 
molecules, such as p38 MAPK, AMPK and PPAR-α and γ [424, 453]. Recently, adaptor protein 
containing PH domain, PTB domain and Leucine zipper motif (APPL)1 has been identified as 
an AdipoR1 and AdipoR2 binding protein. The association between AdipoR1 and APPL1 is 
enhanced by adiponectin and this complex induces the downstream signalling pathways [453]. 
Recently it has been shown that the AdipoR1-APPL1 complex associates with protein 
phosphatase 2A (PP2A), which is activated and in turn inactivates protein kinase C (PKC) ζ, 
allowing liver kinase B (LKB)1 to translocate into the cytosol and activate AMPK [454]. 
AMPK can also be activated by adiponectin in an APPL1-independent and Ca2+-dependent 
pathway involving activation of Ca2+/calmodulin-dependent kinase kinase II [455]. In fact, 
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adiponectin promotes an increase in the intracellular Ca2+ levels through activation of 
phospholipase C (PLC) [456]. Adiponectin has also been shown to activate other signalling 
molecules: for instance it enhances MEK-1/ERK 1/2 signalling in human vascular smooth 
muscle cells, vascular endothelial cells [457], lung epithelial cell lines [458], pancreatic β cells 
[459] and primary human hepatocytes [460]. However, suppression of ERK 1/2 by adiponectin 
has also been demonstrated in smooth muscle cells when stimulated with IGF-1 [461] and IL-6 
[462]. Contradictory results also exist concerning adiponectin-mediated activation of the 
PI3K/PKB pathway: PKB appears to be phosphorylated by adiponectin treatment in 
pancreatic β cells [459], prostate cancer cell lines [463], endothelial cell lines [464] and lung 
epithelial cell line [458], but it leads to suppression of PKB phosphorylation in breast cancer 
cell lines [465] and in human macrophages when transformed to foam cells [466]. Importantly, 
Mao et al. demonstrated that APPL1 mediates adiponectin phosphorylation of p38 and PKB, 
in C2C12 [467] whereas contrasting results have been shown regarding APPL1-mediated 
activation of ERK 1/2 [457, 467]. This is supported by the fact that APPL1 interacts with both 
the two PI3K subunits and PKB [468, 469].  
1.3.1 ADIPONECTIN AND THE IMMUNE SYSTEM 
As discussed above, adiponectin receptors are expressed by immune cells and their surface 
expression is modulated in certain conditions. Therefore a number of studies have 
investigated the effect played by adiponectin in the regulation of immune functions, 
demonstrating an immunomodulatory role for this adipokine.  
1.3.1.1 Adiponectin effects on innate immunity  
Adiponectin has been demonstrated to inhibit the differentiation of myelomonocytic 
progenitors, arresting the formation of colony-forming units-granulocyte-macrophage (CFU-
GM) from human bone marrow mononuclear cells and human hematopoietic CD34+ stem 
cells [470]. In particular, it has been suggested that lymphocyte-secreted adiponectin could play 
a major role in suppressing granulopoiesis [429]. In agreement with these studies, adiponectin 
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influences hematopoietic stem cells (HSCs) by increasing their proliferation and maintaining 
the cells in a functionally immature state through p38 MAPK activation in mice [471]. 
Full-length adiponectin decreases neutrophil ROS production stimulated by phorbol myristate 
acetate (PMA) [472] and fMLP [451]. A recent study has shown that full-length and globular 
adiponectin isoforms differentially modulate phagocyte oxidative burst: the full-length 
isoform has a negative effect whereas globular adiponectin increases the oxidative burst by 
enhancing NADPH oxidase activity through p47phox phosphorylation via p38 MAPK and 
ERK 1/2 activation [451]. Adiponectin can also decrease LPS-induced neutrophil IL-8 
production [473]. 
Adiponectin also negatively regulates monocytes and macrophages by inhibiting IL-8, IL-6, 
TNF-α and IFN-ɣ secretion and increasing the production of the anti-inflammatory IL-10 
following stimulation [474-476]. This anti-inflammatory role of adiponectin on monocytes has 
also been confirmed by Lovren and colleagues, who recently demonstrated that adiponectin 
enhances the anti-inflammatory M2 macrophage phenotype induced by IL-4, these effects 
being mediated by AMPK, PPARα and ɣ activation [477]. In contrast, Cheng et al. reported that 
adiponectin primes unstimulated human macrophages towards a pro-inflammatory M1 
phenotype, enhancing the production of TNF-α and IL-6 [478].  Moreover, another study found 
that HMW, but not LMW adiponectin enhances IL-6 production in primary human monocytes 
[479]. In agreement with the pro-inflammatory role of adiponectin shown in the latter studies, 
adiponectin has also been found to stimulate the release of C-C chemokine ligand (CCL)2 
CCL3 CCL4 and CCL5 in unstimulated human monocytes, and induction in cells obtained 
from overweight subjects is impaired, while the surface abundance of CCR2 and CCR5 
results decreased [480]. 
Similarly, the effect of adiponectin on NK cell cytotoxicity is controversial. Adiponectin was 
shown to increase the ability of NK cells to kill target cells in lean subjects but not in obese 
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subjects [481], whereas Kim et al demonstrated that adiponectin suppressed the IL-2-enhanced 
cytotoxic activity of a human NK cell line, without affecting basal NK cell cytotoxicity but 
suppressing the production of IFN-γ [482]. The latter group extended the finding in vivo by 
using knock out (KO) mice for adiponectin: adiponectin KO mice injected with a lymphoma 
cell line displayed lower tumoral growth, lower number of myeloid-derived suppressor cells, 
increased NK cell population and cytotoxicity. The increased NK cell killing ability was 
explained at least in part by higher expression of the activatory receptor Ly49D on the surface 
of NK cells obtained from adiponectin KO mice [483]. On the contrary Wilk and colleagues 
found that this adipokine does not affect human NK cell cytotoxicity in vitro [449]. 
1.3.1.2 Adiponectin effects on adaptive immunity 
Studies investigating the effect of adiponectin on adaptive immunity have also yielded 
contradictory results. Adiponectin indirectly inhibits B lymphopoiesis by activating 
cyclooxygenase in stromal cells [484]. With regard to adaptive functions, this adipokine has 
been reported to inhibit the generation of antigen-activated CD137+ T lymphocytes by 
inducing apoptosis and decreasing their proliferation. Adiponectin also diminishes the 
secretion of the pro-inflammatory cytokines IFN-ɣ, TNF-α and IL-2 by activated CD137+ T 
lymphocytes [450]. Moreover, co-culturing adiponectin-treated dendritic cells and T cells, 
Tsang and colleagues observed a decrease in T cell proliferation, a reduction of IL-2 
production, and an increase in the percentage of the anti-inflammatory subset of regulatory T 
cells (Tregs) [485]. Palmer and colleagues obtained slightly different results, showing that 
adiponectin caused higher production of IFN-γ, but lower production of IL-6 by human 
PBMCs, particularly by CD4+ and CD8+ T cells, upon stimulation with hepatitis C virus 
(HCV) [486]. In support of a pro-inflammatory function of adiponectin on T cells, more recent 
work demonstrated that the addition of adiponectin to resting CD4+ T cells promoted their 
differentiation into Th1 cells, increasing the expression of the pro-inflammatory cytokines 
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IFN-γ, IL-6 and decreasing the expression of the anti-inflammatory IL-4, typical of Th2 T 
lymphocytes [478]. 
The somehow inconsistent findings regarding adiponectin signalling and the effects exerted 
on innate and adaptive immune cell populations presented in this section are likely to be due 
to the various sources of adiponectin used, commercial or not, containing unspecified mixture 
of the three HMW, MMW and LMW isoforms and often contaminated with LPS [487]. In 
addition, the activation status of the cells treated with adiponectin may have differently 
affected the results [479].  
1.3.1.3 In vivo studies 
In order to examine the effects of adiponectin in the context of inflammatory disorders, 
adiponectin has been administered to different animal models of inflammatory diseases. 
Adiponectin administration prompted beneficial effects in a murine model of experimental 
colitis [488], and it protected against the development of LPS-induced acute lung injury (ALI) 
in mice [489], both the animal models being adiponectin-deficient. Moreover, adiponectin 
treatment resulted in improved hypertension in mice models of metabolic syndrome [490].  
With regard to human studies, the concentration of circulating adiponectin has been 
extensively investigated and it appears to be lower in a number of inflammatory disorders, 
such as metabolic syndrome, type 2 diabetes mellitus, [437], essential hypertension [491] and 
OSAS [190-192]. In subjects affected by these diseases, adiponectin often shows a strong, 
negative association with the inflammatory markers TNF-α, IL-6 and CRP [492-494]. These 
associations are not surprising as TNF-α and IL-6 are suppressors of adiponectin expression 
[196, 197, 495] but also adiponectin could inhibit TNF-α and IL-6 expression, as demonstrated in 
studies cited above [450, 474]. Moreover, a reciprocal negative regulation has been evidenced 
between CRP and adiponectin [199, 496], reinforcing the associations found in vivo.  
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However, adiponectin often exhibits higher serum concentrations in other diseases, 
particularly autoimmune diseases [497], including systemic lupus erythematosus (SLE) [498], 
Behcet’s disease [499], rheumatoid arthritis (RA) [500] and chronic obstructive pulmonary 
disease (COPD) [501] despite their pro-inflammatory status. The causes for its upregulation as 
well as the role played by adiponectin in these disorders are not clear. One hypothesis could 
be that a rise in adiponectin level serves as a compensatory mechanism. A second possibility 
is the emergence of “adiponectin resistance” in which the increase in adiponectin is the result 
of a failure in adiponectin signaling [502]. Nevertheless, adiponectin can act as a pro-
inflammatory adipokine and enhance the inflammatory status rather than contrasting it. Ehling 
and colleagues pointed out a potential pro-inflammatory role of adiponectin in arthritis, as it 
enhanced inflammation and matrix degradation in human synovial fibroblasts by increasing 
IL-6 and matrix metalloproteinase (MMP)1 via p38 activation [503].  
1.4 AGEING 
Ageing is a multifaceted mechanism; it includes all the modifications occurring with time and 
it concerns all the organisms. More specifically, it can be defined as “a continuous process 
that starts at conception and continues until death”, characterized by accumulation of 
physiological changes in the body systems, causing functional decay of organs and tissues and 
ultimately leading to the death of the organism [504]. 
1.4.1 LONGEVITY AND HEALTHY LIFE EXPECTANCY 
Life expectancy has increased since the mid-19th century and the aged population is predicted 
to continue growing over the coming years. However, longer life is not always accompanied 
by good health, on the contrary the susceptibility towards infection [505], cancers [506] chronic 
inflammation  [507] and autoimmune diseases [508, 509] increases during old age. These data 
indicate that life expectancy, without a similar increase in healthy life expectancy, negatively 
impact upon quality of life in old age. For this reason much of the research on ageing now 
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focuses on understanding how to delay the functional decline of the body often through 
improving lifestyle. 
1.4.2 SLEEP CHANGES IN AGEING 
Numerous studies in older adults suggest that sleep disturbances negatively impact upon 
health. In a large epidemiological study, Dew et al. showed that individuals with sleep latency 
(the time taken to fall asleep once in bed) greater than 30 minutes or with sleep efficiency 
lower than 80% had more than a 2 times greater risk of death at follow up [510]. Sleep 
complaints are frequent among older individuals, since more than 50% of the elderly (> 65 
years) reported at least one sleep problem on a regular basis [511]. As shown in figure 1.6, 
ageing is accompanied by sleep alterations, mainly:  
1. Decreased nocturnal sleep duration and efficiency and longer sleep latency. Both stages 1 
and 2 NREM sleep increase but SWS sleep and REM sleep decrease [512-516]; 
2. Increased sleep fragmentation due to increased WASO and number of awakenings [512, 515, 
516]; 
3. Advanced sleep-wake phase (altered circadian rhythm) [517-519] . 
The causes underlying sleep changes in the elderly are many, including: general poor health 
condition [511], chronic pain due to diseases typical of old age (arthritis, depression, 
Alzheimer’s disease), medication, a more sedentary lifestyle, use of stimulants (caffeine, 
smoking) and poor nutrition [520]. However, studies in healthy older adults suggest that the 
homeostatic and circadian mechanisms which regulate sleep are naturally altered during 
ageing. For this reason, sleep disruption occurring in aged subjects has to be considered 
physiological [512, 513]. 
Older adults also experience increased daytime napping compared to young individuals: 
regular napping (4-7 times per week) is reported by 10% of people aged between 55 and 64 
years of age and by 25% of people being between 75-84 years of age [521, 522]. The prevalence 
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of this habit with age could be considered the main consequence of the age-dependent 
disturbances in the sleep pattern during the night and circadian rhythm [521].  
 
                   A 
 
 
 
 
 
 
 
 
 
 
 
 
 
    B 
 
Figure 1.6 Age-related changes in sleep architecture. A. Typical hypnographs of a young 
and an elderly subject (Figure adapted from Neubauer et al., 1999 [20]). B. The decrease in 
SWS and REM sleep over the age (Figure adapted from Van Cauter et al., 2000 [513]).  
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The reasons for these physiological sleep disturbances could be found in the aged-related 
endocrine changes. Nocturnal levels of melatonin drop dramatically from childhood to 
adulthood and continue to decline progressively as a result of the degeneration of the pineal 
gland. This decline in melatonin secretion is thought to be the main cause of sleep disruption 
in older adults and leads to the phase advance of the sleep-wake cycle. In addition, during 
normal ageing, GH production is lower [523, 524] and the HPA axis tends to be hyperactivated, 
thus triggering the rise of circulating CRH, ACTH and cortisol [525-528]. Therefore, the change 
of the ratio between GHRH:CRH in favor of CRH is believed to contribute to sleep 
disturbances during ageing [529, 530].  
There have been few studies investigating the relationship between cortisol and sleep in the 
aged population. Prinz and colleagues showed that 24-hour urinary free cortisol was 
positively associated with earlier habitual rising in the morning and decreased REM sleep in 
the elderly [531, 532], whereas 6 months melatonin administration in elderly women did not 
affect cortisol levels despite a marked improvement in sleep continuity [533].  
The process of adrenopause may also modulate sleep with ageing: the adrenal hormone 
DHEA, a precursor of sex hormones, and its sulfate isoform (DHEAS) decline in the 
circulation with age. Its peak appears to be in the third decade of life; thereafter its level 
decreases progressively to 10-20% of the maximal values by age 70 [534]. Importantly, it is 
considered the main antagonist of cortisol: the higher the ratio between cortisol and DHEAS 
is the greater the catabolic status and frailty are [535]. Moreover, DHEA acts as immune 
enhancing factor which contrasts the immunosuppressive effects of cortisol [536], thus the rise 
in cortisol to DHEAS ratio in old age is believed to contribute to the development of  
immunosenescence (discussed extensively  in the section 1.4.3) [537]. 
With regard to sleep, the role of DHEA has not been extensively investigated: its 
administration led to increased REM sleep in young individuals [538], and its endogenous 
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levels increased after melatonin treatment in elderly women [533], therefore its physiological 
decline seems to contribute to the sleep impairment during ageing. However, its effect on 
sleep pattern could be indirect and mediated by the altered production of other hormones, 
particularly testosterone and estradiol [539]. 
1.4.3 SENESCENCE OF THE IMMUNE SYSTEM 
During the process of ageing there is a functional deterioration of the immune system termed 
immunosenescence. The effects of immunosenescence affect both the innate and the adaptive 
arms of the immune system and the consequences include increased incidence of infectious 
diseases [540, 541], autoimmune diseases [542], malignancies [543, 544], and reduced response to 
vaccination [545, 546]. Another feature of immunosenescence is the development of a subclinical 
pro-inflammatory status, named “inflammaging” which contributes to age-associated frailty, 
morbidity, and mortality [507]. 
1.4.3.1 Ageing of the hematopoietic stem cell compartment 
With ageing the numbers of HSCs increases [547], but they are characterized by accumulated 
DNA damage, suggesting a lower DNA repair efficiency. In addition they have a lower 
mobilization ability, increased intracellular ROS levels [548] and their differentiation potential 
is skewed towards myeloid instead of lymphoid progenitors [547, 548]. Indeed, aged HSCs 
display higher transcription of genes involved in cell cycle regulation and myeloid 
differentiation [547], as well as epigenetic disregulation [549]. In addition to these intrinsic 
mechanisms, ageing of HSCs seems to be driven by cell-extrinsic mechanisms related to the 
marrow niche, such as increased bone formation and adipogenesis, altered extracellular matrix 
components and cytokines [548]. 
1.4.3.2 Innate immunosenescence 
Ageing is not accompanied by a reduction in circulating neutrophil numbers, or the ability to 
produce a neutrophilia in response to infection [550] and constitutive apoptosis is unaltered 
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during ageing, though aged neutrophils are less sensitive to the anti-apoptotic action of pro-
inflammatory factors [551]. The expression of surface molecules, such as the integrin dimers 
LFA-1 (CD11b/CD18) and Mac-1 (CD11a/CD18) does not differ between neutrophils from 
young and old donors [550, 552] suggesting that age does not impair neutrophil ability to adhere 
to the blood vessel and extravasate into the tissues. However, a number of groups have shown 
that several aspects of neutrophil function are reduced with ageing. With regard to 
chemotaxis, the majority of studies have reported impaired migration of neutrophils isolated 
from elderly donors [552, 553]. Ageing does not influence the ability of neutrophils to 
phagocytose non-opsonized pathogens [554], whereas a distinct decrease in the ingestion of 
opsonised yeast and bacteria by neutrophils isolated from aged donors has been observed by a 
number of groups [555-557]. In particular, Butcher et al. attributed this decline to an age-
dependent reduction in the expression of CD16, a low affinity Fc receptor [556]. The effect of 
age on ROS production is more controversial. Whilst some studies have demonstrated a 
decline in superoxide production by aged neutrophils in response to stimulation with fMLP 
and Staphylococcus aureus (S. aureus) [557, 558], others have observed similar levels of ROS 
production in response to Escherichia coli (E. coli) and PMA in cells from young and aged 
donors [559, 560]. 
Neutrophil functional decline is associated with a modification in receptor distribution and 
signalling pathways. Reduced membrane fluidity and formation of lipid rafts are observed in 
aged neutrophils from rodents [561] and could explain the impaired intracellular signalling of 
PI3K, MAPKs and Src homology region 2 domain-containing phosphatase-1 (SHP-1) [562]. 
Moreover, an increase in intracellular levels of Ca2+ has also been detected in aged resting 
neutrophils [557], underlying an inability to further increase Ca2+ concentration in response to 
stimulation [563]. 
Human ageing is accompanied by a decrease in the ability of monocytes to produce IL-6 and 
TNF-α [564] and to mount an effective oxidative burst upon stimulation [565]. However, higher 
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levels of TNF-α and lower levels of TGF-β are secreted by resting monocytes [566], in line 
with the theory of “inflammaging” (discussed in section 1.4.3.4). The number of macrophage 
in the bone marrow is lower in the elderly [567]. In addition, murine and human studies 
revealed that macrophages also display lower ROS production and phagocytosis, reduced 
secretion of IL-6, TNF-α, IL-2 and IL-1β upon LPS stimulation [568-570], possibly caused by 
impaired TLR signaling through p38 MAPK and NF-kB. Also, antigen presentation by 
macrophages is negatively affected by age, in this case because of a decrease in the 
expression of class II MHC molecule [569].  
With regard to the NK cell population, there is a significant increase in NK cell number with 
age [571], specifically the CD56dim subset increases whereas the CD56bright population 
decreases [572, 573] and produces lower amounts of cytokines and chemokines, in particular 
IFN-γ, MIP-1α, regulated on activation normal T cells expressed and secreted (RANTES) and 
IL-8 production in response to IL-2 [574]. Despite the overall increase in their number, NK 
cells from aged subjects exhibit decreased cytotoxicity [575, 576], which is caused by a reduction 
in the secretion and binding of perforin to the target cells [577]. 
Dendritic cells are also negatively affected by age. The expression of class II MHC and the 
co-stimulatory molecules CD86 and CD40 is decreased with age [578] together with the ability 
to uptake antigens [579]. In addition, the phagocytosis of self-antigens and apoptotic cells by 
myeloid dendritic cells also declines with age, increasing the risk of developing autoimmune 
diseases, whereas cytokine production and T cell-induced activation have been variously 
reported to increase and to decrease with ageing [580]. 
1.4.3.3 Adaptive immunosenescence 
The thymus reaches its maximal size in the early years of life and gradually reduces in size 
with age at a rate of 3% per year. This process, termed thymic involution, is accompanied by 
a reduced output of naive T cells, and reduced TCR diversity [581, 582]. As the number of 
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lymphocytes is kept constant the peripheral pool expands and an altered distribution of naïve 
and memory T cells is seen, with a distinct increase in the number of memory and effector T 
cells, particularly the CD8+ cytotoxic subset [583]. Furthermore, persistent subclinical 
infections, specifically Cytomegalovirus (CMV) infection, contribute to increased CD8+ 
memory T cell counts This condition can lead to an increase in the CD8+:CD4+ T cell ratio in 
the oldest old (>85 years) [583-585], which is associated with increased mortality [586-588]. Ageing 
also seems to be accompanied by unbalanced Th1 and Th2 responses, with amplification of 
the Th2 activity [589]. In addition, T cells from older subjects also show a reduction in 
proliferation in response to both non-specific mitogens and to antigens [590], due largely to 
shortening of telomeres. In addition, the highly differentiated T cells lose expression of the 
co-stimulatory molecule CD28 and acquire CD57 [591] and receptors associated with NK cells, 
such as NKG2D [592]. These changes contribute to the increased susceptibility to 
autoimmunity with age. 
The B cell population is also negatively affected by age. The percentage of B lymphocytes 
amongst PBMCs is reduced with age [593] and B cells from old individuals display a reduced B 
Cell Receptor (BCR) repertoire [594]. With regards to B cell responses, the main effect of 
ageing seems to be a decrease in the humoral response [595, 596], despite the fact that an 
increase in serum IgG and IgA occurs in vivo with age [597]. Most importantly, it is well 
established that the response to vaccination is diminished during ageing, with antibody titres 
developed against influenza lower in the elderly compared to young individuals [598]. More 
than a lack in B cell function, this might be the consequence of a lack of T cell help [598] and 
reduced macrophage responses, leading to poor activation of dendritic cells and reduced 
antigen presentation [599].  
1.4.3.4 Inflammaging 
The term “inflammaging” was used for the first time by Franceschi et al, who noted a chronic, 
low grade pro-inflammatory status that develops and persists during human ageing, as a 
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consequence of the higher basal production of pro-inflammatory cytokines (IL-1β, IL-6, IFN-
α, IFN-β, TNF-α) over the anti-inflammatory mediators (IL-10) [600, 601]. Importantly, 
inflammaging is believed to promote frailty and chronic age-associated diseases [507, 602]. 
Sedentary lifestyle, decreased secretion of sex steroids and increased WAT, which is a source 
of pro-inflammatory cytokines, are the main mechanisms underlying the development of 
inflammaging during ageing. However, the existence of an anti-inflammaging process has 
also been postulated and it is mediated by the hyperactivation of the HPA axis during ageing 
[525-527]. In fact, cortisol and the upstream HPA hormones have clear anti-inflammatory effects 
upon immune cell function, including the production of pro-inflammatory cytokines [603-605], 
suggesting that the hyperactive HPA axis counteracts the development of inflammaging. It 
has been suggested that the hyperactivation of the HPA axis can also be considered the result 
of inflammaging, as several cytokines have been shown to increase the HPA function [606, 607]. 
Interestingly, the anti-inflammaging action of the HPA axis and particularly cortisol may also 
explain the apparent paradox of coexisting age-related chronic inflammation and decline of 
immune function. 
1.4.4 ADIPOKINE CHANGES IN AGEING 
As discussed above, clear immune regulatory effects have been demonstrated for the 
adipokines leptin, adiponectin, resistin and visfatin. Therefore, changes in their levels could 
contribute to immunosenescence. In the recent literature, more studies have been performed to 
try and determine whether their serum concentrations differ with age and not just in relation to 
BMI.  
It is well established that leptin serum levels are higher in women than in men [608, 609]; apart 
from gender, leptin levels have been reported to change during ageing, although results are 
contradictory. One study reported that leptin concentration does not differ with age in men, 
while pre-menopausal women display lower serum leptin levels than post-menopausal 
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women [609]. However, another study showed that leptin serum levels significantly decreased 
in females during ageing, while in men there was a non-significant decline in its levels [610]. 
Adiponectin levels tend to increase with age [442, 611, 612], while resistin levels do not appear to 
differ between young and old people [613]. Serum visfatin levels in the context of ageing have 
still to be properly investigated.   
1.5 AIMS OF THE THESIS 
This thesis set out to determine the relationship between changes in sleep duration and 
continuity with ageing and immunosenescence, aiming to uncover also the mechanisms 
underlying any associations found with a particular focus on the role of adipokines.  
The specific objectives were: 
1. To determine the effects of age on sleep duration and continuity in a cohort of healthy 
aged humans; 
2. To determine associations of short and long sleep duration and sleep continuity with a 
range of parameters of innate and adaptive cell phenotype and function; 
3. To determine if there is a relation between sleep duration and continuity and soluble 
factors, notably cytokines and adipokines; 
4. To determine the effect of adipokines, specifically adiponectin, on neutrophil function. 
1.6 HYPOTHESES TO BE TESTED 
Given that ageing is accompanied by negative changes in both sleep and the immune system, 
it was hypothesised that lack of sleep could be associated with a decline in immune function 
in the aged population, thus contributing to the process of immunosenescence. In particular, 
we proposed that sleep dysregulation would: 
- be associated with decreased innate and adaptive immune functions; 
- promote a pro-inflammatory status (inflammaging). 
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We also hypothesised that changes to the serum levels of adrenal hormones and adipokines, 
could mediate changes seen in both sleep and immune functions. In particular, adiponectin is 
a potent anti-inflammatory adipokine whose effect on neutrophils has not been extensively 
investigated. It was therefore decided to study the effect of adiponectin on neutrophil 
apoptosis and phagocytosis, predicting that this adipokine would have promoted neutrophil 
apoptosis and inhibit phagocytosis. 
 
 
 
 
 
 
 
 
 
 
 
57 
 
 
 
 
 
 
 
CHAPTER 2 
 
 METHODS 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
58 
 
2.1 SUBJECTS AND BLOOD COLLECTION 
93 healthy older adults (> 60 years old) were recruited from the Birmingham 1000 Elders 
group to investigate the relationship between physiological sleep and immune functions. An 
additional 10 young (> 35 years old) and 10 elderly (> 60 years old) volunteers were recruited 
for participating in a pilot study exploring the effects of partial sleep deprivation on immune 
functions. For analysis of the role played by the adipokine adiponectin in modulation of 
neutrophil functions the majority of the experiments involved young blood donors aged under 
35 year old and recruited from staff and students at the university. The sleep and ageing study 
was approved by the North Staffordshire local research ethics committee and the studies of 
adiponectin function and the effects of partial sleep deprivation on immunity were approved 
by the University of Birmingham research ethics committee. All participants provided written 
informed consent. Participants were asked to fill in a health screening questionnaire in which 
they provided information about their recent illnesses and infections, chronic diseases and 
medication (see Appendix I). Height and weight measurements were also recorded to 
calculate their BMI, calculated as the mass (kg) divided by the height squared (m2). 
Fasted subjects attended the University Clinical Research Facility (CRF) in the morning (time 
between 9 and 11) and a sample of peripheral blood was collected for measurement of 
immune parameters. 5ml of blood was collected into a vacutainer containing 
ethylenediaminetetraacetic acid (EDTA) tube, in order to perform an immune cell count using 
a Coulter AC  T diff analyser (Beckman Coulter Inc., Brea, CA), and 5 ml of blood was 
collected into an anti-coagulant free vacutainer tube, which was centrifuged at 3000 rpm 
(JOUAN, MR211i) for 5 minutes to obtain the serum sample. 30 ml of blood was drawn in to 
heparin tubes to allow isolation of cells and to perform the functional immune assays.  
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2.2 ACTIGRAPHY 
Actigraphy is a non-invasive method of monitoring human rest/activity cycles. A small 
watch-like actigraph unit (Respironics Inc., Murrysville, PA) was worn on the non-dominant 
wrist by volunteers for 1 week. The actigraph measures gross motor activity, light and dark 
exposure in order to determine the time spent asleep and a number of specific parameters 
evaluating different aspects of the continuity of sleep (Table 2.1). Data were analyzed using 
Respironics Actiware software (Respironics Inc.). An example of an actigraph output is 
shown in Figure 2.1. 
Volunteers were also asked to fill in a 7 day sleep diary, in which they reported self-assessed 
sleep duration plus the episodes of napping during the daytime.  
 
SLEEP PARAMETER DEFINITION 
Time spent asleep Time spent asleep during the night 
Sleep latency The interval of time taken for an individual to fall asleep after going to bed 
Sleep efficiency The percentage of time spent asleep over the time spent in bed 
Wake After Sleep Onset (WASO) The amount of time spent awake after the beginning of sleep 
Average sleep bout (avg sleep bout) The average length of time spent asleep between two awakenings during the night 
 
Table 2.1 Sleep parameters measured by actigraphy. 
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Figure 2.1 An example of actigraph recordings. The individual’s movements and light 
exposure are recorded 24 hours a day for a seven day period. The yellow line represents the 
light intensity; the black bars indicate the strength of movements performed; the red line at the 
bottom suggests the time spent awake whilst the blue area is the period at which the actigraph 
considers the wearer to be asleep. 
 
 
2.3 TISSUE CULTURE 
All cell culture experiments were performed in class 2 type A/B3 biological safety cabinets 
employing sterile equipment and reagents. For cell culture the standard media was RPMI-
1640 supplemented with 2 mM L-glutamine, 100 U/ml penicillin and 100 µg/ml streptomycin 
(GPS) (all purchased from Sigma-Aldrich, Poole, UK) and with 10% heat-inactivated (HI) 
fetal calf serum (FCS; Sera Laboratories International Ltd, Haywards Heath, UK), hereafter 
referred to as complete medium (CM). To prepare HI-FCS, FCS was incubated for 30 minutes 
in a water bath at 56oC. Phosphate buffered saline (PBS) was prepared by dissolving one PBS 
tablet (Sigma-Aldrich) in 200 ml distilled water, and was autoclaved prior to use. Sterile 
pipettes were purchased from Corning Life Sciences (New York, USA), 15 ml and 50 ml 
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polypropylene FalconTM tubes from BD Biosciences, fluorescence-activated cell sorting 
(FACS) tubes were purchased from Becton Dickinson, 96-well round bottomed plates were 
from Sarstedt and flexible 96-well round bottomed plates were from BD Falcon™ (New 
Jersey, USA). 
2.4 PBMCs AND NK CELL ISOLATION, PHENOTYPE AND FUNCTIONAL ASSAYS 
2.4.1 ISOLATION OF PBMCs FROM WHOLE BLOOD 
PBMCs were isolated from peripheral blood by Ficoll density gradient centrifugation. 
Peripheral blood was mixed 1:1 with RPMI-1640 medium supplemented with 1% GPS in 50 
ml FalconTM tubes and overlaid onto 6 ml of Ficoll-HypaqueTM  PLUS (GE Healthcare, Little 
Chalfont,UK) and gradients centrifuged at 1200 rpm for 30 minutes at room temperature (RT) 
with no brake (JOUAN, MR211i). Post centrifugation, mononuclear cells, which reside at the 
interface between the plasma and the Ficoll layer, were harvested, washed with PBS and 
pelleted by centrifugation at 1200 rpm (JOUAN, MR211i) for 10 minutes at RT. After 
washing, cells were re-suspended in 10 ml PBS and counted using a hemocytometer. At least 
1x107 cells were used to isolate NK cells, 1x106 PBMCs were stained for phenotypic analysis 
and the rest were re-suspended in freezing medium consisting of HI-FCS supplemented with 
10% Dimethyl sulfoxide (DMSO) (Sigma-Aldrich) and gradually frozen at a temperature of -
80°C by means of 5100 Cryo 1°C Freezing Container (Nalgene). 
2.4.2 ISOLATION OF NK CELLS FROM PBMCs 
NK cells were isolated from PBMCs by negative selection using MACS® technology (Human 
NK cell isolation kit; Miltenyi Biotec, Bergisch Gladbach, Germany) according to the 
manufacturer’s instructions. Briefly, PBMCs were washed twice in MACS® buffer at 300 x g 
for 10 minutes at 4oC and the subsequent pellet re-suspended in 40 µl of MACS® buffer per 
107 cells. 10 µl of NK cell biotin-antibody cocktail was added and the sample incubated for 15 
minutes at 4oC with occasional mixing. Post incubation, 30 µl of MACS® buffer and 20 µl of 
NK cell microbead cocktail were added and the sample was incubated for 15 minutes at 4oC. 
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Cells were washed in MACS® buffer (2 ml per 107 cells) at 300 x g for 10 minutes at 4oC and 
the pellet re-suspended in 500 µl of MACS® buffer. For magnetic separation, an LS column 
(Miltenyi Biotec) was placed in the magnetic field of a QuadroMACS separator (Miltenyi 
Biotec) and washed with 3 ml of MACS® buffer. The PBMCs were then applied to the 
column, followed by 9 ml of MACS® buffer. The eluted cells represented the purified NK cell 
population. NK cells were centrifuged at 300 x g for 10 minutes at 4oC and re-suspended to a 
final concentration of 1x106 /ml in CM. NK cell purity was assessed by flow cytometry by 
staining with antibodies against CD3 and CD56. NK cell purity was routinely greater than 
95% of the isolated cell population. 
2.4.2.1 NK cell cytotoxicity assay 
The NK cell cytotoxic assay used the MHC class I-deficient erythroleukaemic cell line K562 
as the target cell and a two-colour flow cytometry assay based on the protocol of Godoy-
Ramirez et al. [614]. K562 cells were purchased from the American Type Culture Collection 
(ATCC, Middlesex, UK) (ATCC number CCL-243) and were cultured in CM at 37oC in a 
humidified 5% CO2 atmosphere. Cells were fed and split on the day prior to experimentation. 
The cultures of K562 cells were replaced on a monthly basis. 
For the cytotoxicity assay NK cells were serially diluted in a 96-well round bottomed plate to 
which 100 μl of K562 cells (1x105 /ml) were added in order to give various effector:target cell 
ratios, specifically 10:1, 5:1 and 2.5:1. The plate was then centrifuged at 50 x g for 1 minute 
to increase cell contact before being incubated for 2 hours at 37°C. To account for the 
spontaneous death of K562 cells, 100 μl of these cells were incubated during this period in 
absence of NK cells. Post incubation, cells were pelleted by centrifugation at 250 x g for 5 
minutes and stained with phycoerytrin (PE)-conjugated mouse anti-human CD56 (0.3 μg/ml) 
(clone C5.9) (Dako Ltd, Cambridge, UK) for 10 minutes on ice to identify NK cells. Cells 
were then washed once in PBS and the resulting pellet re-suspended in 100 μl of the cell 
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impermeable DNA binding dye sytox® blue dead cell stain (Invitrogen, Carlsbad, CA), 
diluted 1:8000. The well containing K562 cells alone was stained with sytox® blue to asses 
spontaneous cell death. Cells were rapidly transferred to FACS tubes and analyzed by flow 
cytometry using a CyAnTM ADP flow cytometer. The emission of the two fluorochromes PE 
and Violet-1 (respectively for CD56 and sytox®) was recorded, spectral overlap was 
compensated by running NK cell samples stained separately with each dye.  
Data were analyzed using Summit version 4.3. NK and K562 populations were identified by 
gating on PE and side scatter (Figure 2.2 A). The K562 population, which shows greater side 
scatter, was gated and Violet 1 fluorescence was detected in a separate FACS plot (Figure 2.3 
B). 2000 events were recorded and the percentage of dead K562 was calculated as follows:  
% of sytox® positive cells in test sample - % of sytox® positive cells in spontaneous sample. 
2.4.3 NK AND T CELL PHENOTYPING BY IMMUNOSTAINING 
PBMCs were re-suspended at 2x106/ml in PBS and 50 µl dispensed into a 96-well round 
bottomed plate. For colour compensation, each antibody was added separately to each well, 
but all the antibodies were added together in the test well. The plate was incubated for 15 
minutes in the dark, after which samples were washed in PBS (250 x g for 5 minutes at 4oC), 
re-suspended in PBS and transferred to FACS tubes for flow cytometric analysis on a 
CyAnTM ADP bench top cytometer (Dako). 
The percentage of NK cells within the PBMC population was determined by gating 15,000 
PBMCs and evaluating the number of CD3-CD56+ cells counted. The percentage of T 
lymphocytes within the PBMC population was determined by gating 15,000 PBMCs (Figure 
2.3A) and evaluating the number of CD3+ cells counted (Figure 2.3B). The percentage of 
CD4+ and CD8+ T cells amongst CD3+ T lymphocytes was determined by gating the CD3+ 
T cell population (Figure 2.3C). The percentage of naïve T lymphocytes was evaluated in the 
CD3+CD4+ (Figure 2.3D) and CD3+CD8+ populations, with cells double positive for both 
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CD45RA and CCR7 considered naïve T  (Figure 2.3E). The antibodies used and the final 
concentrations are listed in table 2.2. 
 
           A                                                     B 
              
 
 
 
 
 
 
 
 
Figure 2.2 Flow cytometric analysis of NK cell cytotoxicity. A. Immunostaining of NK 
cells and K562 co-cultures with PE-conjugated mouse anti-human CD56 and sytox®. K562 
can be identified and gated in Region 3 (R3), and NK cells in Region 4 (R4) thus allowing to 
determine the effector:target cell ratio (K562 represent the 9.93% of the mixed population). B. 
Histogram showing the percentage of dead K562, measured as the percentage of sytox® 
positive cells in Region 8 (R8) within 2000 events recorded; the percentage of spontaneous 
K562 death will be subtracted from this value to obtain the percentage of K562 specifically 
killed by NK cells. 
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Figure 2.3 Plots and gating strategy used to measure lymphocyte subsets. A. Forward 
scatter (FS) vs side scatter (SS) plot in which PBMCs are gated in R1. Blue arrows indicate 
the setting of the gates. B. FS vs PE-cyanine 7 (PE-Cy7) (CD3). CD3+ T cells are gated in R9 
C. Violet 1 (CD4) vs PE (CD8) plot from which the percentages of CD4+ and CD8 + T cells 
are measured. D. Violet 1 (CD4) vs PE-Cy7 (CD3) plot; the cells double positive for both 
CD3 and CD4 are gated in R7. E. Fluorescein isothiocyanate (FITC) (CCR7) vs 
allophycocyanin (APC) (CD45RA) plot; the cells double positive for both CCR7 and 
CD45RA represent the naive CD4+T lymphocyte subset. 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
SURFACE MARKER QUANTITY COMPANY 
Anti-human CD3 PE-Cy7 (clone UCHT1) 5 µg/ml eBiosciences 
Anti-human CD4 eFluor® 450 (Violet 1) 
(clone OKT4) 
4 µg/ml eBiosciences 
Anti-human CD8 PE (clone UCHT4) 20 µl/ml Immunotools 
Anti-human CCR7 FITC (clone 150503) 2.5 µg/ml R&D system 
Anti-human CD45RA APC (clone HI100 ) 0.01 µg/ml Biolegend 
Anti-human CD56 PE (clone C5.9) 0.3 µg/ml Dako 
ISOTYPE CONTROLS 
FINAL 
CONCENTRATION COMPANY 
Anti-Mouse IgG1 PE-Cy7 5 µg/ml eBiosciences 
Anti-Mouse IgG2b eFluor® 450 4 µg/ml eBiosciences 
Anti-mouse IgG2a PE 1:50 Dako 
Anti-mouse IgG2a FITC 2.5 µg/ml Dako 
Anti-mouse IgG2b APC 0.01 µg/ml Dako 
Anti-mouse IgG2b PE 0.3 µg/ml Dako 
 
Table 2.2 Antibodies and concentration used to stain T cell subsets and NK cells. 
 
2.5 MEASUREMENT OF NEUTROPHIL FUNCTIONS IN WHOLE BLOOD 
To assess neutrophil ROS production and phagocytosis in whole blood, two commercially 
available kits were used, respectively Phagoburst™ and Phagotest™ (Glycotope-Biotechnology 
GmbH, Heidelberg, Germany). All the reagents were provided by the kits and the experiments 
were performed according to the manufacturer’s instructions. For the sleep studies flow 
cytometric analyses were conducted using a CyanTM ADP flow cytometer (software Summit 
version 4.3), for the experiments regarding adiponectin effects on neutrophil functions flow 
cytometric analyses were conducted using a BD Accuri C flow cytometer (Accuri Cytometers 
Inc, Ann Arbor, MI) (software CFlow Plus 1.0.227.4). 
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2.5.1 OXIDATIVE BURST 
100 μl peripheral blood was incubated either with 20 μl of E. coli or with washing buffer 
(negative control) for 10 minutes at 37°C. Following incubation, 20 μl of the fluorogenic 
substrate dihydrorhodamine (DHR) 123 was added and the blood incubated for a further 10 
minutes at 37°C. After 10 minutes, red cells were lysed and the remaining cells were fixed in 
lysing solution for 20 minutes at RT and immediately washed twice with washing solution by 
centrifugation at 250 x g for 5 minutes. Cells were re-suspended in 200 ul of DNA staining 
solution and incubated for 10 minutes on ice before flow cytometric analysis using a CyAnTM 
ADP flow cytometer. The production of ROS was measured by the mean fluorescence 
intensity (MFI) of FITC positive neutrophils from which the MFI of the negative control was 
subtracted. 
2.5.2 PHAGOCYTOSIS 
100 μl of peripheral blood was incubated with 20 μl of FITC-labelled E. coli for 10 minutes 
either at 37°C or at 0°C (negative control). Following incubation, phagocytosis was stopped 
by addition of ice cold quenching solution and the cells were immediately washed twice with 
washing solution (250 x g for 5 minutes). Following washing, red cells were lysed and the 
remaining cells were fixed in lysing solution for 20 minutes at RT followed by two further 
washing steps. Cells were resuspended in 200 μl of DNA staining solution and incubated for 
10 minutes on ice before flow cytometric analysis. The FS vs SS plot (Figure 2.4A) allows the 
recognition of neutrophils, characterized by greater size and granularity compared to the other 
blood cell populations. Neutrophils were gated and the FITC fluorescence intensity measured 
on a separate histogram (Figure 2.4B). The phagocytic index was used as a measurement of 
the phagocytic capability of the cells and was calculated as the percentage of neutrophils 
which had ingested bacteria (the percentage of FITC positive cells) multiplied by the MFI of 
the FITC positive population. This value was then divided by 100 to give the phagocytic 
index. 
68 
 
         A                                              B                        C 
 
   
Figure 2.4 Plots and gating strategy used to measure neutrophil phagocytosis and 
oxidative burst. A. FS vs SS FACS plot in which neutrophils are distinguished and gated in 
Region 3 (R3). Arrows indicate the setting of the gates. B. Histogram showing the PE 
fluorescence, which indicates the content of DNA among cells gated in R3: the major peak 
gated in R2 represents neutrophil DNA, whereas the minor peak preceding R2 represents the 
DNA from free, non-ingested bacteria. C. Histogram showing the FITC fluorescence among 
the neutrophil population gated in R2: Region 1 (R1) indicates the FITC positive cells. 
 
 
 
2.6 NEUTROPHIL ISOLATION, FUNCTIONAL ASSAYS AND PROTEIN EXPRESSION 
2.6.1 ISOLATION OF NEUTROPHILS FROM WHOLE BLOOD 
Neutrophils were isolated by density centrifugation using Percoll® (Sigma-Aldrich) as 
previously described [615]. Briefly, 2% Dextran 500 (Amersham Bioscience, Uppsala, Sweden) 
made up in 0.9% NaCl (Sigma-Aldrich) solution, was added to peripheral blood at a 1 in 6 
ratio to sediment erythrocytes. The leukocyte layer was removed and overlaid onto a Percoll® 
two step gradient comprising 2.5 ml of 80% Percoll® and 5 ml of 56% Percoll® in a sterile 15 
ml Falcon™ tube. The 80% and 56% Percoll solutions were obtained from a stock 90% 
Percoll® solution which was prepared with 45 ml of Percoll® and 5 ml of 9% NaCl solution. 
From this, further dilutions were made with 0.9% NaCl solution. 
The Percoll® gradient was then centrifuged at 1100 rpm for 20 minutes (JOUAN, MR211i) 
with no brake. After centrifugation, the PBMCs, which equilibrate at the plasma-56% Percoll 
interface, are removed using a sterile, fine tip Pasteur pipette and discarded. The neutrophil 
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enriched layer at the 56%-80% Percoll interface is removed and washed in RPMI-1640 + GPS 
by centrifugation at 1600 rpm (JOUAN, MR211i) for 10 minutes. Neutrophils were then 
counted, re-suspended in the appropriated medium and at the appropriated concentration (1-
5x106/ml). The purity of isolated neutrophils was determined by differential staining using a 
commercial May-Grunwald Giemsa stain (Diff-Quick, Baxter Healthcare, UK) and light 
microscopy, and was routinely greater than 97%.  
2.6.2 MEASUREMENT OF NEUTROPHIL FUNCTION ON ISOLATED CELLS   
Levels of ROS generated by isolated neutrophils were measured using a luminol-based 
chemiluminescent assay [616]. Freshly isolated neutrophils were resuspended at 2x106 cells/ml 
in Hanks Balanced Salt Solution (HBSS) containing Ca2+ and Mg2+ (Sigma-Aldrich). 
Neutrophils were transferred to opaque 96 well plates (Greiner Bio-One GmbH, Stonehouse, 
UK) and luminol was added at a final concentration of 100 μM. Chemiluminescence in 
response to the stimulus fMLP (2.5 μM) (Sigma-Aldrich) was then measured at one minute 
intervals for a period of 30 minutes using a luminometer (Centro LB 960, Berthold 
Technologies, Bad Wildbad, Germany). The area under the curve (AUC) was calculated using 
GraphPad Prism® software version 4 (GraphPad Software Ltd, La Jolla, CA).  
Using reagents provided by the Phagotest™ kit phagocytosis by isolated neutrophils was also 
examined. FITC labeled E. coli were opsonized using 10% autologous plasma in HBSS and 
incubated in 0.5 ml eppendorf tubes at 37°C for 30 minutes. PBS was added to bacteria and 
eppendorf tubes were spun for 1 minute at 13,000 rpm (MSE microfuge). Opsonized E. coli 
were resuspended in RPMI-1640 + GPS at the same initial volume. Isolated neutrophils were 
also resuspended in RPMI-1640 + GPS at 5x106/ml. 50 μl of neutrophils were dispensed into 
a 96-well round bottomed plate and 20 μl of E. coli were added to each well (1:40 ratio 
between neutrophils and bacteria). The suspensions were incubated for 90 minutes (unless 
otherwise specified) at 37°C, after which phagocytosis was stopped by addition of quenching 
solution (100 μl) to extinguish the FITC fluorescence of surface bound bacteria. For every 
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experiment, a suspension of neutrophils and bacteria was incubated at 0oC to act as negative 
control. The samples were transferred to FACS tubes; 10,000 cells were gated and 
fluorescence was analyzed by flow cytometry (BD Accuri C6 flow cytometer) and the 
phagocytic index was determined (as explained in section 2.7.2). Cytospins of the suspensions 
were also obtained and visualized using a LEICA DMI 6000 B microscope x63 objective 
(Leica Microsystems, Wetzlar, Germany). 
The binding of bacteria to the neutrophil membrane was also evaluated. Suspensions were 
incubated at 4oC for 30, 60 and 90 minutes after which quenching solution was not added; 
samples were directly transferred to FACS tubes and analyzed by flow cytometry. 10,000 
neutrophils were gated, FITC negative cells were considered unbound.  
2.6.3 ASSESSMENT OF NEUTROPHIL APOPTOSIS 
2.6.3.1 Membrane exposure of phosphatidylserine  
Apoptotic cells are characterized by exposure of phosphatidylserine on the outer membrane. 
To detect extracellular phosphatidylserine and to distinguish apoptotic cells from late 
apoptotic/necrotic cells, Annexin V/ propidium iodide (PI) staining was used. Neutrophils (1 
x 105) were suspended in 100 µl of Annexin V buffer (10 mM HEPES, pH 7.4; 140 mM 
NaCl; 2.5 mM CaCl2) to which was added 1 µl of AnnexinV-FITC (BD Biosciences, San 
Jose, CA) and cells were incubated in the dark at RT for 10 minutes. After this incubation, PI 
was added (5 µg/ml). Cells were then transferred into FACS tubes and fluorescence was 
analyzed by flow cytometry (BD Accuri C6 Flow Cytometer, Accuri Cytometers Inc.). 10,000 
neutrophils were gated on a FS vs SS plot; neutrophils that were positive for Annexin V but 
negative for PI fluorescence were considered apoptotic [617]. 
2.6.3.2 Caspase 3 activation 
Cleavage and activation of caspases, particularly caspase 3, is a hallmark of apoptotic cell 
death [247], including neutrophil apoptosis. To measure the amount of activated caspase 3 
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neutrophils were fixed in 50 µl of medium A (Fix and Perm® kit, Life technologies, Carlsbad, 
CA) for 20 minutes at RT, then washed in PBS and permeabilized in 50 µl of medium B for 
20 minutes at RT. Neutrophils were washed in PBS and resuspended in 100 µl of PBS, then 
incubated with FITC-conjugated anti-active caspase-3 (clone C92-605; BD Biosciences, San 
Jose, CA) or isotype matched antibody (FITC-conjugated rabbit anti-mouse IgG, Southern 
Biotech) were added in the respective wells (2.5 µg/ml) and cells were incubated for 30 
minutes at RT. Neutrophils were washed in PBS, resuspended in PBS and transferred into 
FACS tubes. 10,000 neutrophils were gated and fluorescence was analyzed by flow cytometry 
(BD Accuri C6 Flow Cytometer, Accuri Cytometers Inc.). 
2.6.3.3 Count of apoptotic nuclei 
Apoptotic neutrophils are characterized by loss of their characteristic multi-lobed nuclei and 
acquisition of single rounded nuclei. Cytospin preparations were differentially stained using a 
commercial May-Grunwald Giemsa stain and apoptotic nuclear morphology was observed by 
light microscopy (Olympus IX71 microscope, Olympus America Inc., Center Valley, PA). 
Apoptotic nuclei were counted amongst 200 cells. Pictures were taken at an original 
magnification of x40. 
2.6.4 ANALYSIS OF SURFACE PROTEIN EXPRESSION AND CERAMIDE 
ACCUMULATION  
Surface expression of receptors and extracellular ceramide accumulation were measured by 
direct or indirect immunofluorescence staining. 100 µl of cells (106/ml) were plated into 96-
well plates and incubated with the primary antibody for 20 minutes at 4°C (the incubation 
time for ceramide detection was 30 minutes). Following incubation, cells were washed in 
PBS. For directly conjugated antibodies, cells were re-suspended in 200 µl PBS, transferred 
into FACS tubes and analyzed by flow cytometry (BD Accuri C6 Flow Cytometer). For 
antibodies requiring staining with a secondary antibody, cells were re-suspended in 100 µl 
PBS and 3 μl of goat serum was added for 5 minutes to prevent non-specific binding. The 
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relevant secondary antibody was added and cells were incubated at 4°C for 20 minutes. 
Samples were washed in PBS (250 x g for 5 minutes), re-suspended in PBS, transferred into 
FACS tubes and analyzed by flow cytometry. Concentration-matched isotype control 
antibodies or relevant secondary antibodies were used as negative controls. The antibodies 
used and their concentrations are listed in Table 2.3. 
 
PRIMARY ANTIBODIES QUANTITY 
Rabbit anti-human AdipoR1 (Phoenix Pharmaceuticals, Inc., 
Burlingame, CA) 
5 µg/ml 
Rabbit anti-human AdipoR2 (Phoenix Pharmaceuticals, Inc.) 5 µg/ml 
Mouse anti-human CD11b (clone 2LPM19c, Dako, Ely, UK) 20 µl 
FITC-conjugated mouse anti-human CD16 (clone DJ130c, Dako) 4 µg/ml 
FITC-conjugated mouse anti-human Mac-1 (clone CBRM1/5, 
eBioscience, San Diego, CA) 
20 µl 
Isotype FITC-conjugated mouse IgG1k (Dako) as the primary 
antibody 
Mouse anti-human ceramide (clone MID 15B4) (Enzo Life Sciences) 10 µg/ml 
Isotype mouse IgM (Dako) as the primary 
antibody 
SECONDARY ANTIBODIES QUANTITY 
FITC-conjugated goat anti-rabbit (Southern Biotech, Birmingham, 
AL)  
2.5 µg/ml 
FITC-conjugated goat anti-mouse (Southern Biotech) 10 µg/ml 
 
Table 2.3 Antibodies and the concentrations used in immunostaining of neutrophils. 
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2.6.5 MEASUREMENT OF F-ACTIN  
Neutrophils were either unstimulated or stimulated with unlabeled, opsonized E. coli for 5 
minutes, after which they were fixed and permeabilized as for caspase 3 staining. To measure 
differences in actin polymerization in response to bacterial stimulation, F-actin was analyzed 
using FITC labelled phalloidin (Sigma-Aldrich), a high affinity probe for F-actin. Neutrophils 
were incubated with phalloidin (1 µg/ml) at 4°C for 30 minutes. After washing in PBS, 
samples were analyzed by flow cytometry and 10,000 neutrophils were measured. Cells 
stained for F-actin were also observed by fluorescence microscopy: cytospins of the 
suspensions were obtained, nuclei were counterstained with DAPI (Life Technologies) and 
fluorescence was visualized using a LEICA DMI 6000 B microscope x63 objective (Leica 
Microsystems, UK). 
2.6.6 ANALYSIS OF PROTEIN EXPRESSION BY WESTERN BLOT 
Neutrophils were spun at 4000 rpm for 4 minutes (MSE microcentrifuge) prior to 
resuspension in lysis buffer (20 mM 3-morpholinopropanesulfonic acid phosphate buffered 
(MOPS), 50 mM NaF, 50 mM β-glycerophosphate , 50 mM Na3VO4, 1% Triton X-100, 1 
mM dithiothreitol (DTT), 1 mM AEBSF and 1% proteases and phosphatase inhibitor 
cocktails, all purchased from Sigma-Aldrich). Lysis of neutrophils was performed on ice for 
30 minutes with occasional vortexing. Lysates were centrifuged at 13,000 rpm for 1 minute 
(MSE microcentrifuge), supernatants collected and combined with an equal volume of 2X 
sodium dodecyl sulfate (SDS) sample buffer (125 mM HCl pH 6.8, 5% glycerol, 2% SDS, 
1% β-mercaptoethanol, 0.003% bromophenol blue) and boiled for 10 minutes.  
Samples were loaded onto a 10% SDS- polyacrylamide gel together with a pre-stained protein 
standard marker (Bio-Rad, Hercules, CA). Gels were run for 2 hours at 130 V and then 
transferred onto methanol-activated 0.45 micron polyvinylidene difluoride (PVDF) membrane 
(Scientific Laboratory Supplies Ltd, Hessle, UK) in a wet blotter and proteins transferred at 
0.5 A for 1.5 hours. After proteins were transferred, the membrane was placed on an orbital 
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shaker and non-specific protein binding was blocked using either 5% bovine serum albumin 
(BSA) (Sigma-Aldrich) for the phosphospecific antibodies, or 5% non-fat milk in Tris Buffer 
Saline Tween20 (TBST) (20 mM Tris HCl pH 7,5, 150 mM NaCl, 0.1% Tween20, Sigma-
Aldrich) for one hour at RT. Membranes were then incubated with the primary antibody 
(listed in table 2.4) overnight at 4°C, then washed for 3x10 minutes in TBST and incubated 
with the appropriate secondary antibody (Horseradish-peroxidase (HRP)-linked  anti-rabbit or 
anti-mouse IgG; GE Healthcare, Uppsala, Sweden) for 1 hour at RT and then washed again 
3x10 minutes in TBST. The membrane was immersed in enhanced chemiluminesence (ECL) 
solution (GeneFlow, Lichfield, UK) for 3 minutes, to visualise proteins either by 
autoradiography against X-ray film (GE Healthcare) or in a BioRad chemi-doc technology 
(BioRad).  
To confirm that proteins were equally loaded, membranes were subjected to mild stripping by 
incubating in stripping buffer (200 mM glycine, 0,1% SDS, 1% Tween 20) for 2x 10 minutes, 
followed by 2x10 minute washes in PBS and 2x5 minutes washes in TBST, with all the 
incubations performed at RT. Membranes were then blocked again in either 5% BSA or 5% 
non-fat milk in TBST for one hour and then probed again overnight at 4°C with the 
appropriate antibody. 
Densitometric analyses were performed using National Institute of Health ImageJ software 
package (http://rsbweb.nih.gov/ij/). 
 
 
 
 
 
75 
 
ANTIBODY DILUTION 
P-AMPK (Thr172) (Cell Signaling Technology) 1:1000 
AMPK (Cell Signaling Technology) 1:1000 
P-PKB (Ser473) (Cell Signaling Technology) 1:1000 
PKB (Cell Signaling Technology) 1:1000 
P-ERK 1/2 (Thr202/Tyr204) (Cell Signaling Technology) 1:1000 
ERK 1/2 (Cell Signaling Technology) 1:1000 
P-p38 (Thr180/Tyr182) (Cell Signaling Technology) 1:1000 
p38 (Santa Cruz Biotechnology, Santa Cruz, CA) 1:500 
Mcl-1 (clone S-19) (Santa Cruz Biotechnology) 1:500 
β-actin (Sigma-Aldrich) 1:5000 
 
Table 2.4 Antibodies and the dilutions used for Western blots. 
 
2.7 MEASUREMENT OF SERUM FACTORS 
2.7.1 MEASUREMENT OF CORTISOL AND DHEAS SERUM LEVELS 
Serum concentrations of the adrenal hormones cortisol and DHEAS were assessed by 
enzyme-linked immunosorbent assay (ELISA) using commercial kits purchased from IBL 
International (Hamburg, Germany) and the assays were performed according to 
manufacturer’s instruction. Briefly, the standard curve and the quality controls supplied by the 
kits, and the serum samples (20 µl for cortisol ELISA and 25 µl for DHEAS ELISA) were 
dispensed into the plate provided by the kit, whose wells are already coated with anti-cortisol 
or anti-DHEAS antibodies. 200 µl of enzyme conjugate solution were added to each well and 
the plate was incubated for one hour at RT. After washing the wells, 100 µl of 3,3′,5,5′-
tetramethylbenzidine (TMB) solution provided by the kit was dispensed into each well and 
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the plate was incubated for 15 minutes at RT in the dark. To stop the colorimetric reaction, 
100 µl of stop solution supplied by the kit was added and the plate was was read using a 
microplate reader (EL808, BioTek®, Potton, UK) at 450 nm. 
2.7.2 MEASUREMENT OF SERUM ADIPOKINE LEVELS 
Serum concentrations of leptin and adiponectin were measured by ELISA. Leptin and 
adiponectin ELISA kits were purchased from R&D Systems (Minneapolis, MN) and the 
assays were performed according to manufacturer’s instructions. Briefly, 96 well-plates 
(NUNCTM, eBiosciences, San Diego, CA) were coated with the relevant capture antibody over 
night at RT. ELISA plates were then washed three times with washing solution (0.05% Tween 
20 in PBS) using an automated microplate washer (ASYS, Atlantis). Plates were then blocked 
for 1 hour at RT using 300 μl of reagent diluent. Following three washes, 100 μl of diluted 
samples and standards were placed into the appropriate wells and incubated for 2 hours at RT. 
Plates were then washed three times before incubation with biotinylated detection antibody 
for 1 hour at RT. Following three more washes, streptavidin conjugated with horseradish 
peroxidase (HRP) and the chromogen substrate TMB (Sigma-Aldrich) were added in 
sequence. After 10 minutes, the colorimetric reaction was stopped by addition of 50µl H2SO4. 
The plate was read using a microplate reader (EL808, BioTek®) at 450 nm and corrected by 
subtracting the reading at 550 nm. 
2.7.3 MEASUREMENT OF SERUM CYTOKINE LEVELS  
Serum levels of the cytokines: GM-CSF, IL-1β, IL-2, IL-4, IL-5, IL-6, IL-8, IL-10, IFN-γ, 
TNF-α were detected using multiplex technology and a Human Cytokine 10-Plex Panel 
(Luminex® assay, Invitrogen, Carlsbad, CA). The kit provides polystyrene beads which are 
internally dyed with red and infrared fluorophores of different intensities, allowing 
differentiation of one bead from another. Beads of defined spectral properties are conjugated 
to cytokine-specific capture antibodies. Briefly, the wells of a microplate were coated with 
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mixed beads for 30 minutes. Following coating, the wells were washed and the standards or 
test samples were added and incubated for 2 hours at RT. After washing, cytokine-specific 
biotinylated detector antibodies were added and incubated for one hour allowing them to bind 
to the appropriate immobilized cytokines. After washing to remove the excess biotinylated 
antibody, PE-streptavidin was added and incubated for 30 minutes to allow the formation of a 
four-member solid phase sandwich. The excess PE-streptavidin was washed and the beads 
were analyzed using a Luminex detection system (Luminex 100, Bio-Rad). By monitoring the 
spectral properties of the beads and the amount of associated PE fluorescence, the 
concentration of cytokines was determined.  
2.8 STATISTICAL ANALYSES 
In the sleep studies data were analyzed using IBM SPSS statistics version 20 (New York, 
NY). To check if data followed a normal distribution, the Kolmogorov-Smirnov test was 
used. Non-normally distributed data were either log (ln) or square root (sqrt) transformed to 
confer a normal distribution. To identify potential confounder variables (for example age, 
BMI), bivariate correlations or t-test as appropriate were performed between social 
demographics and anthropometric variables and each of the sleep, immune and hormone 
variables. Significant confounding variables were then entered at Block 1 in linear regressions 
with the predicting variable added at Block 2 in the model. Change in R square (ΔR2) is 
reported as a measure of the effect size. When independent samples were split into more than 
two categories (i.e. sleep variables split into tertiles), Univariate General Linear Model with 
least significant difference (LSD) post hoc tests was used; analyses were controlled for 
significant confounding variables. Groups of matched samples were analyzed by Repeated 
Measures General Linear Model with the Greenhouse–Geisser correction. Analyses were run 
both unadjusted and adjusted for gender and BMI. Results were reported as mean ± standard 
deviation (SD) in tables and graphed as mean value ± standard error mean (SEM) using either 
SPSS or SigmaPlot 12.0.  
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Power analysis was conducted using G*Power version 3.1.9.2 (Dusseldorf, Germany). 
For analysis of in vitro results data were analyzed using GraphPad Prism® software, version 4. 
Two-tailed paired and unpaired Student’s t-test were used to compare respectively two groups 
of paired and independent samples.  Repeated measures ANOVA was used to analyze more 
than two groups of matched samples, followed by Tukey’s multiple comparison test.  
A p value of less than 0.05 was accepted as significant in all analyses. 
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CHAPTER 3 
 
THE EFFECTS OF SLEEP ON THE 
IMMUNE SYSTEM 
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3.1 INTRODUCTION 
Sleep is a physiological behaviour, essential for maintaining human health and wellness. As 
shown by several epidemiological studies, sleep duration influences the risk of morbidity, 
with the strongest association being between short sleep duration and obesity-related diseases 
[115, 118, 139-141]. In addition the risk of mortality increases with both very short and very long 
sleep [5-11] and in subjects reporting poor sleep continuity [510, 618]. As sleep duration and 
continuity decline with age [512-519, 619, 620], it is possible that this contributes to some of the 
detrimental effects of ageing upon the body’s major systems and to age-related pathology.  
To understand how sleep can influence tissue functions, particularly of the immune and 
endocrine systems, studies of sleep deprivation have been performed on small groups of 
individuals. The data achieved from these experimental protocols confirm the link between 
sleep behaviour and risk of metabolic diseases, as glucose tolerance, insulin response and 
cholesterol levels were altered following the period of partial sleep deprivation [148, 150]. Levels 
of adipokines were also found to be altered after a period of partial sleep deprivation, 
although contradictory results have been reported especially regarding the change in serum 
leptin levels [167-169]. In addition, other works investigated the response of the immune system 
to acute and partial sleep deprivation, focusing on changes in cell numbers, function and level 
of inflammatory markers. Again, discrepant outcomes are present in the literature, probably 
due to different protocols of sleep deprivation used, however the majority of studies support 
the hypothesis that forced loss of sleep tends to lower immune functions [398-400] and increase 
inflammation [131, 323, 418].  
Old age is physiologically accompanied by changes in sleep architecture, including a 
reduction in total sleep duration, an increase in sleep latency and fragmentation and a phase-
advance in the sleep-wake cycle [20, 512-514, 517-519, 619]. Ageing is also accompanied by 
remodelling of the immune system, immunosenescence, and an increase in systemic 
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inflammation, inflammaging, contributing to the higher frequency of infections [540], and a 
range of age-related diseases including cancer [621], autoimmune diseases [508] and chronic 
inflammatory disease. What is currently poorly understood is whether there is a link between 
age-related changes to sleep duration and continuity, immunosenescence and inflammaging. 
3.1.1 HYPOTHESIS AND AIMS 
The main hypothesis tested in this chapter is that a physiological lack of sleep occurring 
during ageing contributes to the development of immunosenescence. In addition, it is 
proposed that changes in sleep will be associated with and mediated by age-related changes in 
soluble factors, such as cytokines, adipokines and adrenal hormones.  
These hypotheses were addressed in the following aims: 
- To determine sleep duration and architecture in a cohort of healthy older subjects; 
- To determine if immunosenescence and/or inflammaging was more frequent in aged 
individuals with short sleep duration and/or impaired sleep continuity; 
- To determine associations between serum cytokine, endocrine hormone and adipokine 
levels and sleep parameters; 
- To determine causality by testing if 3 days of partial sleep deprivation can induce 
features of immunosenescence or increase inflammaging in young subjects or 
exacerbate these in older subjects. 
3.2 METHODS 
The methods used for the various functional assays are described in chapter 2. 100 healthy 
elderly adults (>60 years old) were initially recruited from the Birmingham 1000 Elders group 
and gave written informed consent to participate in the study. Because of issues in blood 
taking and breaking of the actigraphs, the final cohort recruited from whom blood and sleep 
measurements were obtained consisted of 93 healthy older adults. The study was approved by 
the South Staffs Local Research Ethics Committee. For sleep measurements, an actigraph was 
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worn by volunteers for one week following blood sampling and participants kept a sleep diary 
in the same week. 
Additionally 10 healthy young (<35 years old) and 10 elderly volunteers (>60 years old) were 
recruited to participate in a partial sleep deprivation study consisting of sleeping for four 
hours during three consecutive nights from 1 a.m. to 5 a.m.  
The exclusion criteria for participation in both studies were: diagnosis of sleep disorders (and 
thus use of sleep medication), use of any medication known to modify immune function (such 
as steroids) and diabetes (both type 1 and 2). For the partial sleep deprivation study 
participants showing a baseline sleep duration of 4 hours or less were also excluded. 
Fasted volunteers came to the University CRF between 9 a.m. and 11 a.m. the morning before 
the study began, again after 3 nights of partial sleep deprivation and again after a single day of 
sleep recovery; on each of these occasions they gave a blood sample. Volunteers wore an 
actigraph for the week before beginning the partial sleep deprivation to estimate their baseline 
sleep duration and they continued wearing it for the duration of the experimental protocol to 
ascertain adherence to the protocol and during the following day of sleep recovery to evaluate 
the amount of sleep recovery. All participants gave written consent. 
Blood was collected to assess immune cell function as described in chapter 2. 
3.3 RESULTS 
3.3.1 SUBJECT DEMOGRAPHICS 
The 93 healthy older adults (mean age: 75.06 ± 6.75; 42 men; mean BMI: 26.2 ± 4.42, 92 
Caucasians, 1 Asian) recruited considered themselves to be generally healthy, were not taking 
any sleep medication, had not travelled to a different time zone in the month preceding the 
actigraphic measurement, had not been diagnosed with a sleep disorder or a mental illness and 
had not worked shifts in the year preceding the study, as reported in the healthy screening 
questionnaire. However, over 60 of the group (64%) declared they were taking a regular 
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medication, most frequently anti-hypertensive drugs (40%) or statins to lower cholesterol 
levels (28%).  
3.3.1.1 Sleep characteristics 
The actigraph recorded nocturnal sleep duration, efficiency, latency, WASO and average 
sleep bout for one week and the average values across the seven nights were used for the 
analyses. The sleep diary contained information about sleep duration and the time spent 
napping. Table 3.1 shows the objective and subjective sleep characteristics of the cohort.  
Within the cohort age and BMI did not correlate with any of the sleep parameters, whereas 
sleep latency (t(91)= -2.055, p=0.043) and average sleep bout (t(91)= -2.512, p=0.014) were 
longer in females. As there were differences between genders as well as a different number of 
men and women participating in the study, all the statistical analyses performed were adjusted 
for gender and if necessary additional covariates. Sleep parameters were also analysed with 
regard to the use of statins and anti-hypertensive drugs but there was no effect of the use of 
these medications (data not shown). 
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SLEEP PARAMETER MEAN (± SD) (n) 
Time spent asleep (minutes per night) (actigraphy) 417 (± 55) (93) 
Sleep efficiency (% per night) (actigraphy) 85.64 (± 5.03) (93) 
Sleep latency (minutes per night) (actigraphy) 20.47 (± 8.04) (93) 
WASO (minutes per night) (actigraphy) 46.34 (± 21.01) (93) 
Avg sleep bout (minutes per night) (actigraphy) 23.13 (± 10.80) (93) 
Time spent asleep (hours per night) (sleep diary) 6.38 (± 1.09) (88) 
Napping (minutes per week) (sleep diary) 67.42 (± 101.17) (88) 
 
Table 3.1 Sleep characteristics of the volunteers recruited obtained by actigraphy and 
sleep diary. 
 
Actigraphic sleep duration was compared to subjective sleep duration reported in the sleep 
diary and a strong correlation was found between the two measures of sleep duration 
(R2=0.464, β=0.680, p<0.001). The time spent napping per week reported in the sleep 
questionnaire was also negatively associated with both subjective (R2=0.185, β= -0.430, 
p<0.001) and objective (R2=0.153, β= -0.391, p<0.001) time spent asleep per night, 
potentially representing a compensatory mechanism for nocturnal short sleep duration. 
Several correlations were discovered also amongst sleep variables measured by actigraphy 
(Table 3.2). In particular, sleep duration positively correlated with sleep efficiency and 
average sleep bout. 
Data from sleep diaries were analysed against immune and hormonal variables but they did 
not offer significant results (data not shown), thus in this thesis they are not further considered 
and only analyses conducted on actigraphic sleep recordings are presented.   
Groups of tertiles were created for each actigraphic sleep variable (Table 3.3). Tertile groups 
were preferred to groups of hours of sleep as they retain an equal number of volunteers. Such 
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tertiles have been used for following analyses complementing the information obtained from 
the linear regression analyses. 
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Table 3.2 Bivariate correlations between sleep variables. β coefficient and p values are reported; p values of statistically significant 
associations are highlighted in red. 
  
 
 
 
 
 
Time spent asleep 
β              p 
Efficiency (ln) 
β              p 
Latency (sqrt) 
β              p 
WASO (ln) 
β              p 
Avg sleep bout (ln) 
β              p 
Time spent asleep  0.393      <0.001 0.285         0.112    -0.097          0.353 0.345        0.001 
Efficiency (ln) 0.393       <0.001  -0.253         0.014 -0.736       <0.001 0.641      <0.001 
Latency (sqrt) 0.285        0.112 -0.253       0.014  0.284         0.112 -0.086        0.413 
WASO (ln) -0.097       0.353 -0.736     <0.001 0.284         0.112  -0.718      <0.001 
Avg sleep bout 
(ln) 0.345        0.001 0.641     <0.001 -0.086         0.413 -0.718      <0.001  
87 
 
 
1ST TERTILE 
(min-max) 
2ND TERTILE 
(min-max) 
3RD TERTILE 
(min-max) 
Time spent asleep 
(minutes) 
296 – 395 396 – 448 449 – 580 
Efficiency (%) 71.64 – 85.15 85.16 – 88.20 88.24 – 93.71 
Latency 
(minutes) 
10.00 – 16.17 16.42 – 22.51 23.52 – 43.26 
WASO (minutes) 14.34 – 36.34 37.00 – 51.00 51.08 – 148.52 
Avg sleep bout 
(minutes) 
8.57 – 17.38 17.51 – 25.13 25.16 – 68.55 
 
Table 3.3 Sleep variables divided into groups of tertiles (n=31 each). The minimum and 
the maximum values of every sleep variables are reported for each tertile. 
 
3.3.2 RELATIONSHIP BETWEEN SLEEP AND IMMUNE PARAMETERS 
3.3.2.1 Sleep influences the number of circulating immune cells 
The circulating pool of total WBC, granulocytes, monocytes and lymphocytes were assessed 
using a coulter cell counter, whereas the NK cell population (CD56+ CD3-) was measured by 
immunostaining and flow cytometry. The granulocyte to lymphocyte ratio (G:L) was also 
calculated as this parameter is considered a marker of inflammation [622, 623] and predicts 
mortality in several conditions [624-626]. All the participants had WBC and granulocyte counts 
in the normal range (data not shown), excluding the presence of infectious diseases. 
Linear regressions were performed for cell counts with the sleep parameters (time spent 
asleep, efficiency, latency, WASO and average sleep bout) adjusting for gender only (Table 
3.4). Both sleep duration and sleep efficiency were negatively correlated with the number of 
WBC, granulocytes, monocytes and the G:L ratio. WASO and average sleep bout, two 
complementary indicators for sleep fragmentation, were also associated with the G:L ratio in 
a positive and negative manner respectively. Average sleep bout also negatively correlated 
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with the number of monocytes. Latency did not show any significant relationship with any of 
the immune cell populations. Additionally, immune cells were compared amongst tertiles of 
sleep parameters. The results obtained from a Univariate General Linear Model (controlled 
for gender) reproduced the significant changes observed with the linear regressions (data not 
shown). Although sleep duration did not predict the number of lymphocytes according to the 
linear regression performed before, the analysis of tertiles revealed that the group of long 
sleepers was characterised by a significant decrease in the number of lymphocytes 
(F(2,68)=3.988, p=0.023, η2=0.105) (Figure 3.1). These results indicate an influence of sleep 
on the distribution of the circulating immune cell populations in the elderly. 
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Table 3.4 Linear regressions performed between sleep parameters and blood cell counts. ΔR2, β coefficient and p value are reported. The p 
values of statistically significant regressions are highlighted in red.
PREDICTOR WBC 
ΔR2           β          p 
Granulocytes (ln) 
ΔR2           β          p 
Monocytes (sqrt) 
ΔR2           β          p 
Lymphocytes (sqrt) 
ΔR2           β          p 
G:L (sqrt) 
ΔR2           β          p 
NK cell number 
ΔR2           β          p 
Time spent asleep 0.122    -0.350   0.002 0.124    -0.352   0.002 0.070    -0.265   0.022 0.010    -0.102   0.387 0.070    -0.265   0.022 0.012     0.110   0.307 
Efficiency (ln) 0.101    -0.317   0.006 0.106   -0.326    0.005 0.115   -0.339    0.003 0.006     0.078    0.508 0.137   -0.371    0.001 0.014   -0.047    0.666 
Latency (sqrt) 0.015    0.129    0.294 0.002    0.047    0.701 0.018    0.138    0.257 0.033    0.187    0.124 0.010   -0.103    0.395 0.011   -0.107    0.327 
WASO (ln) 0.016    0.128    0.283 0.018    0.136    0.250 0.023   0.153   0.1949 0.036   -0.190   0.107 0.083    0.289     0.012 0.007    0.084     0.438 
Avg sleep bout (ln) 0.012   -0.111    0.365 0.017   -0.113    0.273 0.057   -0.246    0.040 0.039    0.203   0.093 0.080   -0.291   0.014 0.002   -0.050    0.654 
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Figure 3.1 Lymphocyte cell count amongst tertiles of sleep duration. The cohort was 
divided into tertiles of short (n=23), middle (n=26) or long (n=25) sleep duration and 
lymphocyte count determined and expressed as the square root (sqrt) of the value. Blood cell 
counts were not obtained from the whole cohort, only from 74 individuals. Data are mean ± 
SEM. 
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The use of anti-hypertensive drugs was associated with increased numbers of WBC (t(68)= -
2.374, p=0.020), granulocytes (t(68)= -3.364, p=0.001) and the G:L ratio (t(68)= -2.306, 
p=0.024), whereas the use of statins was associated with increased numbers of WBC (t(68)= -
2.085, p=0.041) and granulocytes (t(68)= -2.958, p=0.004). Therefore, the regressions were 
repeated with further adjustment for the use of these medications. After controlling for these 
variables, the significant associations between WBC, granulocytes and G:L ratio with sleep 
duration and efficiency persisted, and G:L ratio remained significantly associated with both 
WASO and average sleep bout (data not shown). 
3.3.2.2 Sleep affects neutrophil ROS production  
Neutrophil phagocytosis and ROS production were assessed in whole blood and NK cell 
cytotoxicity was measured by challenging isolated NK cells with the erythroleukaemic target 
cell line K562.  
Gender and BMI were not associated with changes in neutrophil function and NK cell 
cytotoxicity, whereas age significantly correlated with neutrophil ROS production (R2=0.073, 
β= -0.283, p=0.010) and NK cell cytotoxicity (R2=0.091, β=0.271, p=0.020). Innate immune 
functions were not affected by the use of both anti-hypertensive drugs and statins, as assessed 
by parametric t-test (data not shown). Linear regressions were performed between sleep 
parameters and innate immune cell functions. Analyses for neutrophil ROS production and 
NK cell cytotoxicity were adjusted for age and gender, whereas the phagocytic index was 
controlled just for gender. No significant associations were found between sleep parameters 
and immune functions, suggesting that altered sleep does not accelerate the development of 
innate immunosenescence (Table 3.5).  
Neutrophil and NK cell functions were also analysed amongst tertiles of sleep variables. The 
results showed significant differences in neutrophil ROS production amongst the tertiles of 
average sleep bout, with highest function in the middle tertile (F(2,76)=3.232, p=0.045, 
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η2=0.078) and thus lower ROS production mainly showed by the tertile of short average sleep 
bout. Moreover, the middle tertile of sleep duration was characterised by a trend towards 
higher neutrophil phagocytic ability than long or short sleepers although the differences did 
not reach statistical significance (F(2,78)=2.124, p=0.126, η2=0.052) (Figure 3.2). No 
significant differences were observed with other sleep parameters. NK cell data were still not 
significantly altered by sleep if tertiles of sleep parameters were used for analysis (data not 
shown).  
These innate immune functions were not affected by use of medications (data not shown), 
therefore analyses were not further adjusted. 
 
 
Table 3.5 Linear regressions performed between sleep parameters and innate immune 
functions. ΔR2, β coefficient and p value are shown. 
 
PREDICTOR 
Neutrophil 
phagocytosis 
  ΔR2              β          p 
Neutrophil ROS 
production (ln) 
  ΔR2             β          p 
NK cell cytotoxicity 
(sqrt) 
  ΔR2             β          p 
Time spent asleep 0.002     -0.040    0.722 0.004     0.065     0.550 0.021     -0.144    0.212 
Efficiency (ln) 0.002      0.039    0.726 0.004      0.085     0.556 0.000    -0.015     0.897 
Latency (sqrt) 0.002     -0.040    0.724 0.000      0.063     0.884 0.016     0.131     0.274 
WASO (ln) 0.001     -0.023    0.836 0.006     -0.082    0.452 0.001     0.033     0.780 
Avg sleep bout (ln) 0.012      0.112     0.332 0.038      0.208    0.064 0.005    -0.070     0.559 
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        A                                                                      B 
 
Figure 3.2 Neutrophil functions amongst tertiles of sleep parameters. The cohort was 
divided into tertiles of short (n=27), middle (n=26) or long (n=30) average sleep bout for 
analysis of neutrophil ROS production (A) and short (n=26), middle (n=30) and long (n=28) 
sleep duration for analysis of neutrophil phagocytosis (B). Data are mean ± SEM. 
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3.3.2.3 The distribution of T cell subsets is affected by sleep 
The number of circulating naïve T lymphocytes is negatively affected by age, whereas 
memory T cells increase [582, 583, 585]. In parallel, the ratio between CD8+ and CD4+ T 
lymphocytes is often found to be increased with advanced age, possibly as a consequence of 
subclinical infections [584]. To explore whether sleep could enhance immunosenescence of T 
cell subsets, PBMCs were stained with antibodies against specific markers and T cells 
subpopulations were identified.  
In our cohort of volunteers females had significantly higher percentages of CD4+ naïve T 
cells (t(88)=,-2.163 p=0.033), CD8+ naïve T cells (t(88)=-1.028, p=0.034) as well as CD4+ 
and CD8+ naïve:memory T cell ratios (t(88)=-2.042, p=0.044) (t(88)=-2.076, p=0.041). Age 
correlated with the percentages of CD4+ T cells (R2=0.048, β=0.219, p=0.038), CD8+ T cells 
(R2=0.086, β=-0.294, p=0.005) and the CD4+:CD8+ T cell ratio (R2=0.050, β=0.224, 
p=0.034), whereas BMI had no effect on the distribution of these subpopulations. T cell 
subsets were not affected by the use of either anti-hypertensive drugs or statins (data not 
shown). 
Linear regressions were performed between sleep parameters and T cell subsets adjusting for 
gender only (CD4+ naïve T cells, CD8+ naïve T cells, CD4+ and CD8+ naïve:memory T cell 
ratios) or both age and gender (CD4+ T cells, CD8+ T cells, CD4+:CD8+ T cell ratio). 
Results are shown in table 3.6. There were significant negative associations between both 
CD4+ T cells and the CD4+:CD8+ T cell ratio with sleep efficiency and positive correlations 
between both CD4+ T cells and the CD4+:CD8+ T cell ratio with WASO. Surprisingly, it was 
found that naïve CD4+ and CD8+ T cells as well as CD4+ naïve:memory T cell ratio were 
negatively associated with sleep duration, indicating that long sleep duration is associated 
with a decrease in the pool of naïve T cells. Analysis of tertiles of sleep variables reproduced 
the results obtained from the linear regressions (data not shown).  
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Table 3.6 Linear regressions performed between sleep parameters and T cell subsets. ΔR2, β coefficient and p value are reported. The p 
values of statistically significant regressions are highlighted in red. 
PREDICTOR CD3+ T cells                      
ΔR2               β         p 
CD4+ T cells                    
ΔR2               β         p 
CD8+ T cells (sqrt)                 
ΔR2               β         p 
CD4+:CD8+ T cells (sqrt)     
ΔR2               β          p 
Time spent asleep 0.004      -0.062     0.561       0.028     -0.169      0.104        0.005     -0.068     0.508        0.006     -0.079      0.450 
Efficiency (ln) 0.005       0.068     0.528       0.086     -0.293      0.004        0.018     -0.133     0.197        0.048     -0.203      0.033 
Latency (ln) 0.028       0.172     0.113       0.000     -0.006      0.953        0.001     -0.026     0.807        0.000      0.005      0.959 
WASO (ln) 0.013      -0.116     0.280       0.050      0.227      0.031        0.001      0.034     0.747        0.044      0.215      0.040 
Avg sleep bout (ln) 0.023       0.157     0.152       0.014     -0.123     0.258        0.000      0.021     0.843        0.009     -0.098      0.364 
PREDICTOR 
CD4+ naive T cells 
ΔR2               β         p 
CD8+ naïve T cells (sqrt) 
        ΔR2               β          p 
CD4+ naïve:memory T cells 
(sqrt)                                     
ΔR2               β          p 
CD8+ naïve:memory T cells 
(sqrt)                                     
ΔR2               β          p 
Time spent asleep       0.055      -0.236      0.023      0.050      -0.224     0.031       0.055      -0.235      0.023       0.028      -0.168     0.108 
Efficiency (ln)       0.017      -0.129      0.215      0.025      -0.159     0.128       0.025      -0.157      0.132       0.011      -0.103     0.325 
Latency (sqrt)       0.000      -0.010      0.928      0.016      -0.131     0.220       0.000       0.013      0.906       0.022      -0.152     0.155 
WASO (ln)       0.028      -0.169      0.108      0.005      -0.073     0.486       0.027      -0.166      0.114       0.009      -0.097     0.359 
Avg sleep bout (ln)       0.014       0.123       0.252      0.000      -0.016     0.879       0.011       0.108      0.315       0.000       0.009     0.934 
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3.3.2.4 Sleep is associated with changes in the levels of some cytokines 
Ageing is accompanied by a chronic low grade inflammatory status, termed inflammaging, 
resulting from the increased concentration of pro-inflammatory cytokines [600]. 10 cytokines 
(IL-1 β, IL-2, IL-4, IL-5, IL6, IL-8, IL-10, GM-CSF, IFN-γ, TNF-α,) were measured by 
Luminex® technology in the serum of elderly volunteers. The concentration of some of these 
cytokines was often too low to be detected, therefore the concentration ascribed was 0 pg/ml. 
In addition, some values were very high and exceeded the healthy value [627, 628] thus these 
data were excluded from the analysis.  
With regard to age, gender and BMI, only GM-CSF was positively correlated with BMI 
(R2=0.065, β=0.256, p=0.037). Cytokines did not associate with age and did not differ 
between genders (data not shown). Linear regressions were thus adjusted for gender and 
analysis for GM-CSF was adjusted for gender and BMI. IL-10 and IL-6 were negatively 
associated with sleep duration and latency respectively, whereas IL-8 negatively correlated 
with both sleep duration and latency (Table 3.7).  
With regard to the use of medications, IL-4 was significantly upregulated in subjects using 
anti-hypertensive drugs (t(70)=-2.540, p=0.013) and IL-8 was lower in subjects taking statins 
(t(84)=2.656, p=0.010). After adjustments for these medications, IL-8 lost its association with 
sleep duration (ΔR2=0.020, β=-0.142, p=0.187) but still correlated with sleep latency 
(ΔR2=0.082, β=-0.297, p=0.006). Analysis of tertiles of sleep parameters did not reveal any 
additional significant differences. IL-6 showed a trend towards being reduced in long sleepers 
but this did not reach significance (F(2,85)=1.381, p=0.257, η2=0.031) (Figure 3.3A) and IL-4 
was significantly different amongst tertiles of sleep duration (F(2,60)=3.704, p=0.030, 
η2=0.110) (Figure 3.3B).  
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In summary, these data indicate that sleep duration and latency affects the inflammatory status 
in elderly volunteers, although the effect was limited to just a few cytokines notably IL-4 after 
adjustment for the use of medications.  
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Table 3.7 Linear regressions performed between sleep parameters and cytokines. ΔR2, β coefficient and p value are reported. The p values 
of statistically significant regressions are highlighted in red. 
PREDICTOR 
 IL-1β (sqrt) 
ΔR2        β         p 
IL-2 (sqrt) 
ΔR2       β          p 
IL-4 (sqrt) 
ΔR2       β          p 
IL-5 (sqrt) 
 ΔR2        β          p 
 IL-6 (sqrt) 
ΔR2       β         p 
Time spent asleep 0.000     0.013   0.982 0.008    0.092    0.415 0.022    0.148    0.202 0.009    0.094    0.399 0.024    -0.154   0.145 
Efficiency (ln) 0.011     0.106   0.367 0.000    0.010    0.929 0.022    0.147    0.204  0.009    0.094    0.400 0.008     0.084   0.426 
Latency (sqrt) 0.002     0.042   0.728 0.002   -0.043    0.714 0.003    0.053    0.653 0.001   -0.036    0.755 0.066   -0.263   0.014 
WASO (ln) 0.003    -0.056   0.636 0.002   -0.048   0.674 0.000   0.003    0.979 0.000   -0.016    0.884 0.000   -0.007   0.950 
Avg sleep bout (ln) 0.024     0.163   0.182 0.004    0.069    0.559 0.024    0.161    0.176 0.001   -0.033    0.777 0.002    0.044   0.690 
PREDICTOR 
IL-8 (sqrt) 
ΔR2        β         p 
IL-10 (sqrt) 
ΔR2       β          p 
GM-CSF (sqrt) 
ΔR2       β          p 
IFN-γ (sqrt) 
 ΔR2       β          p 
TNF-α (sqrt) 
ΔR2      β         p 
Time spent asleep 0.053    -0.231   0.027 0.043   -0.209    0.050  0.007   -0.083   0.505 0.015   -0.124    0.269 0.005    0.070    0.546             
Efficiency (ln) 0.022     0.149   0.157 0.001    0.028    0.793 0.005     0.072   0.562 0.003    0.058    0.604 0.003    0.051    0.661 
Latency (sqrt) 0.103    -0.326   0.002 0.026   -0.163    0.132  0.016    0.130   0.294 0.002   -0.040    0.728 0.002    0.040    0.737 
WASO (ln) 0.015    -0.122   0.249 0.001    0.030    0.784  0.030    -0.179   0.151 0.017   -0.131    0.245 0.005   -0.071   0.543 
Avg sleep bout (ln) 0.003     0.053   0.630  0.006  -0.079    0.472 0.013    0.124    0.349 0.001    0.025    0.833 0.027    0.169    0.155 
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Figure 3.3 Serum concentrations of IL-6 and IL-4 amongst tertiles of sleep duration.  
The cohort was divided into tertiles of sleep duration: short sleep n=30, middle sleep n=30, 
long sleep n=31 for IL-6 (A); short sleep n=24, middle sleep n=25, long sleep n=23 for IL-4 
(B). Cytokine levels were converted to the square root value (sqrt) and data are mean ± SEM. 
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3.3.3 SLEEP, BMI, ADIPOKINES AND ADRENAL HORMONES 
3.3.3.1 Serum concentration of adiponectin is affected by sleep 
BMI has been shown to have a U-shaped relationship with sleep duration in young adults and 
elderly subjects [109, 134, 135]. Leptin, the main adipokine which promotes satiety, positively 
correlates with sleep duration [109] although few studies on sleep-deprived subjects showed 
opposite results in the variation of levels of leptin [169, 171]. In the majority of studies 
adiponectin did not associate with sleep pattern [109, 166], though some groups reported this 
adipokine to be positively associated with sleep duration [188, 189]. 
As previous studies reported a U-shaped relationship between sleep duration and BMI, this 
relationship was assessed firstly by splitting sleep duration into tertiles and evaluating the 
differences amongst groups. Age (R2=0.000, β=-0.009, p=0.933) and gender (t(85)=0.811, 
p=0.420) did not associate with BMI. No significant differences for BMI were observed 
amongst the three groups of sleep duration (F(2,81)=1.613, p=0.206, η2=0.038). Analyses 
adjusted for gender only revealed that there were no significant differences also amongst 
tertiles of the other sleep variables (efficiency: F(2,81)=0.113, p=0.893, η2=0.003; latency: 
F(2,81)=2.355, p=0.101, η2=0.055; WASO: F(2,81)=0.290, p=0.749, η2=0.007; average sleep 
bout: F(2,81)=2.488, p=0.089, η2=0.088). Linear regressions did not show any significant 
result either (sleep duration: ΔR2=0.002, β=-0.046, p=0.676; efficiency: ΔR2=0.007, β=-
0.087, p=0.428; latency: ΔR2=0.008, β=0.093, p=0.399; WASO: ΔR2=0.000, β=0.000, 
p=0.998; average sleep bout: ΔR2=0.001, β=0.037, p=0.743). 
BMI was significantly higher in subjects taking statins (t(81)= -2.374, p=0.020) but not anti-
hypertensive drugs (t(81)=-1.086, p=0.281). Therefore, the Univariate General Linear Model 
analyses were repeated controlling for use of statins, and in this case BMI was significantly 
different amongst tertiles of sleep duration (F(2,71)=6.042, p=0.004, η2=0.145), with lower 
BMI values displayed by the tertile of middle sleep duration (Figure 3.4). 
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Figure 3.4 Differences in the BMI amongst tertiles of sleep duration. The cohort was 
divided into tertiles of short (n=28), middle (n=30) or long (n=25) sleep duration and related 
to BMI expressed as the log value. BMI data were obtained from 83 individuals. Data are 
mean ± SEM. 
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Serum concentrations of leptin were strongly affected by gender (t(91)= -3.491, p=0.001) and 
BMI (R2=0.385, β=0.621, p<0.001), but not age (R2=0.000, β= -0.018, p=0.865), whereas 
adiponectin levels were higher in females (t(91)= -2.965, p=0.004) and positively correlated 
with age (R2=0.106, β=0.325, p=0.001) but were not associated with BMI (R2=0.018, β= -
0.133, p=0.219). Again, both linear regressions and Univariate General Linear Models were 
used to analyse these adipokines with regard to sleep parameters. Analyses for leptin were 
controlled for gender and BMI whereas analyses for adiponectin were controlled for gender 
and age. Linear regressions did not reveal any significant correlation (Table 3.8), whereas 
adiponectin concentration was significantly different amongst tertiles of sleep duration and 
WASO (Figure 3.5). Long sleepers had higher levels of adiponectin than middle (p=0.021) or 
short sleepers (p=0.017) (F(2,86)=3.810, p=0.026, η2=0.081) and levels of adiponectin were 
lower in those with long WASO (p=0.019) and short WASO (p<0.001) than those within the 
middle tertile of WASO (F(2,86)=7.012, p=0.002, η2=0.140) (Figure 3.5). 
Adiponectin levels were not affected by use of either anti-hypertensive drugs (t(86)=1.078, 
p=0.284) or statins (t(86)=1.551, p=0.125), whereas concentrations of leptin were 
significantly higher in subjects using statins (t(86)= -2.504, p=0.017) but not anti-
hypertensive drugs (t(86)= -1.061, p=0.293). Therefore, linear regressions and Univariate 
General Linear Model analyses were repeated for levels of leptin with adjustment for use of 
statins, but no other significant results were found (data not shown). 
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Table 3.8 Linear regressions performed between sleep parameters and the adipokines 
leptin and adiponectin. ΔR2, β coefficient and p value are shown.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
PREDICTOR 
Leptin (sqrt) 
    ΔR2           β             p 
Adiponectin 
   ΔR2          β              p 
Time spent asleep 0.001       -0.025      0.733 0.030        0.174       0.065 
Efficiency (ln) 0.006      -0.079      0.290 0.017        0.131       0.165 
Latency (sqrt) 0.016       0.128      0.089 0.009       -0.099       0.307 
WASO (ln) 0.003       0.051      0.499 0.000        0.005       0.961 
Avg sleep bout (ln) 0.009      -0.098      0.205 0.001        0.027       0.783 
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       A                                                                        B 
Figure 3.5 Serum concentration of adiponectin amongst tertiles of sleep duration and 
WASO. The cohort was divided into tertiles of short (n=31), middle (n=31) and long (n=31) 
sleep duration (A) and WASO (B) and serum adiponectin was determined. Data are mean ± 
SEM. 
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3.3.3.2 Cortisol, but not DHEAS, associates with parameters of sleep fragmentation 
The secretion of cortisol from the adrenal gland shows a diurnal rhythm dependent on the 
release of ACTH which in turn is regulated by the hypothalamic, anti somnogenic factor CRH 
[51, 65, 74]. Cortisol concentration increases in response to stress [65] and its levels are slightly 
increased with age [525, 526, 528] contributing to frailty [535] and immunosenescence [537]. On the 
contrary, DHEA and its sulphate ester decrease with age [534]. A high ratio between cortisol 
and DHEAS (C:D) is considered an indicator of frailty [535]. Moreover these two hormones 
have opposite immunomodulatory roles, cortisol is a potent immune suppressor whereas 
DHEAS exerts immune enhancing functions [536].  
In our volunteers, total secretion of cortisol was measured at one single time point in the 
morning. Cortisol, DHEAS and the C:D ratio were all analysed both with linear regressions 
and amongst tertiles of sleep variables. Cortisol was associated with age (R2=0.188, β=0.434, 
p<0.001), but did not correlate with BMI (R2=0.015, β= -0.121, p=0.278) or differ between 
genders (t(84)=1.270, p=0.208). DHEAS did not significantly correlate with BMI (R2=0.004, 
β= -0.018, p=0.551), age (R2=0.039, β= -0.198, p=0.061) but it was significantly elevated in 
males (t(88)=2.505, p=0.014); the C:D ratio did not differ between genders (t(82)= -1.895, 
p=0.062) and did not associate with either age (R2=0.011, β=0.104, p=0.345) and BMI 
(R2=0.002, β= -0.041, p=0.720). Thus, analyses were adjusted either for both gender and age 
or gender only. Linear regressions revealed a positive association between cortisol and 
WASO and a negative association with average sleep bout. In contrast, DHEAS was not 
influenced by sleep parameters (Table 3.9). Analysis of tertiles of sleep parameters did not 
reveal any further significant differences (data not shown). 
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Table 3.9 Linear regressions performed between sleep parameters, cortisol, DHEAS and 
C:D. ΔR2, β coefficient and p values are shown. The p values of statistically significant 
regressions are highlighted in red. 
 
With regard to use of medications, levels of cortisol were significantly higher in subjects 
using anti-hypertensive drugs (t(79)=-2.033, p=0.045), but not DHEAS levels (t(83)=0.805, 
p=0.423) and C:D ratio (t(75)= -1.998, p=0.052). Use of statins also did not affect the 
concentration of these hormones (cortisol: t(79)= -0.515, p=0.608, DHEAS: t(83)=0.019, 
p=0.985, C:D: t(75)= -0.809, p=0.421). Therefore, cortisol analyses were repeated with 
adjustment for use of anti-hypertensive drugs.  
The linear regression between cortisol and WASO lost significance (ΔR2=0.033, β=0.188, 
p=0.075) whereas the association between cortisol and average sleep bout was confirmed 
after adjustment (ΔR2= 0.069, β= -0.277, p=0.009). 
3.3.4 THE EFFECT OF PARTIAL SLEEP DEPRIVATION ON IMMUNE FUNCTIONS 
Associations had been found between sleep duration or average sleep bout and specific 
immune parameters, such as the G:C ratio, neutrophil ROS production and levels of cytokines 
and adipokines. It was thus necessary to try and determine causality and thus a partial sleep 
deprivation study was carried out to determine direct effects of shortened sleep duration and 
PREDICTOR 
Cortisol (ln) 
   ΔR2          β           p 
DHEAS (ln) 
   ΔR2         β           p 
C:D (sqrt) 
    ΔR2         β            p 
Time spent asleep 0.007     -0.084     0.443 0.010     0.102      0.325 0.019     -0.147     0.180 
Efficiency (ln) 0.002      -0.040     0.712 0.000     -0.008     0.937 0.001     -0.034     0.757 
Latency (sqrt) 0.004       0.061      0.583 0.000     -0.016     0.880 0.000      0.012     0.916 
WASO (ln) 0.042       0.210      0.035 0.001     -0.034     0.744 0.012      0.108     0.328 
Avg sleep bout (ln) 0.073      -0.280      0.005 0.009     -0.096     0.368 0.018     -0.137     0.221 
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whether there were any age-related differences in effects seen. 10 healthy young individuals 
(mean age: 27.4 ± 2.4, 5 males, mean BMI: 22.37 ± 2.05, 9 Caucasians, 1 Asian) and 10 
healthy older individuals (mean age: 74.2 ± 6.1, 7 males, mean BMI: 24.93 ± 3.46, 9 
Caucasians, 1 Asian) were recruited to participate in the protocol of partial sleep deprivation. 
In the health screening questionnaire all the participants reported themselves as generally 
healthy, were not taking any sleep medication, had not travelled to a different time zone in the 
month preceding the study and had not worked shifts in the year preceding the study. None of 
the young volunteers recruited reported taking medications, whereas 6 elderly participants 
declared the regular use of medication, namely statins (n=3) and anti-hypertensive drugs 
(n=4).  A schematic representation of the partial sleep deprivation protocol is shown in figure 
3.6. 
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Figure 3.6 Schematic representation of the partial sleep deprivation protocol. 
Participants filled in the health screening questionnaire and were given the actigraph which 
was worn for the following two weeks. During the first week (screening phase) the baseline 
sleep characteristics were measured. After the screening phase, volunteers donated a sample 
of blood on three occasions: before and after the three nights of partial sleep deprivation 
(experimental phase), and after a single night of sleep recovery (recovery phase).  
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3.3.4.1 Sleep characteristics  
The baseline sleep duration and the other parameters measured in the first screening week by 
actigraphy were averaged across the seven nights and are shown in table 3.10. No significant 
differences were found in the baseline sleep parameters between young and elderly. The 
volunteers affirmed that they did not nap during the three days of experimental protocol and 
no significant napping periods were recorded by actigraphy. Actigraphy also confirmed that 
all the participants followed the partial sleep deprivation protocol and their level of sleep 
during the recovery day was determined (Table 3.10). Sleep latency and WASO were 
significantly decreased during the partial sleep deprivation nights compared to baseline nights 
(data not shown). There was no difference in the sleep recovery period between the young and 
elderly subjects. 
 
SLEEP PARAMETER (n=10) YOUNG           mean (± SD) 
ELDERLY     
mean (± SD) P value 
Baseline time spent asleep            
(minutes per night) 406 (± 46) 375 (± 62) 0.227 
Sleep efficiency (% per night) 84.05 (± 7.71) 83.83 (± 4.73) 0.938 
Sleep latency (minutes per night) 20.01 (± 10.01) 20.59 (± 9.03) 0.826 
WASO (minutes per night) 57.38 (± 27.93) 51.20 (± 17.76) 0.554 
Avg sleep bout (minutes per night) 17.29 (± 7.61) 18.59 (± 9.51) 0.747 
Partial sleep deprivation              
(minutes per night) 221 (± 15) 217 (± 25) 0.722 
Sleep recovery (minutes per night) 450 (± 66) 400 (± 82) 0.175 
 
Table 3.10 Sleep parameters recorded by actigraphy before, during and after the partial 
sleep deprivation protocol. 
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3.3.4.2 Partial sleep deprivation does not alter the number of circulating immune cells 
Several studies reported that protocols of both acute and partial sleep deprivation induce an 
increase in WBC count, especially neutrophils [150, 397, 402, 416]. In addition, NK cells have been 
reported to decrease in sleep deprived subjects [132, 400]. Here the volunteers subjected to the 
protocol of partial sleep deprivation, both young and elderly, did not display significant 
changes in the number of immune cells in the circulation as analysed by Repeated Measures 
General Linear Model (both unadjusted analyses and adjusted for gender and BMI). Only in 
the young individuals there was a trend towards changes in the number of NK cells in 
unadjusted analyses (Table 3.11 and figure 3.7).  
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Table 3.11 The effect of partial sleep deprivation and recovery on immune cell numbers in the groups of young and elderly volunteers. F, 
p and η2 are shown for unadjusted analyses and adjusted for gender and BMI. WBC, granulocytes, monocytes and lymphocytes are measured as 
number of cells x109/L, NK cells are measured as % of PBMCs.    
 
 
 
 
YOUNG 
unadjusted                         adjusted 
   F              p             η2            F              p              η2 
ELDERLY 
unadjusted                         adjusted 
   F              p             η2            F              p               η2 
WBC 1.252        0.313       0.152        0.644        0.513         0.114 0.433        0.547       0.046        0.003        0.965         0.000 
Granulocytes 0.524        0.544       0.070        0.936        0.405         0.158 0.446        0.530       0.047        0.017        0.904         0.002 
Monocytes 1.793        0.213 0.204        0.041        0.928         0.008 1.820        0.206       0.168        0.661        0.478         0.086 
Lymphocytes 2.109        0.188       0.232        0.110        0.760         0.022 1.375        0.278       0.133        1.044        0.367         0.130 
G:L 0.827        0.450       0.106        0.051        0.940         0.010 1.157        0.325       0.114        0.025        0.934         0.004 
NK cells 3.469        0.059       0.278        1.281        0.306         0.155 0.342       0.678        0.037        0.534         0.549        0.071 
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Figure 3.7 The effect of partial sleep deprivation and recovery on the percentage of NK 
cells. The percentage of NK cells in the PBMC fraction was measured at baseline, after 3 days 
of partial sleep deprivation and one day after the study in young (n=10) and old (n=10) 
subjects. Data are mean ± SEM. Two tailed paired T test analyses revealed no statistical 
differences in NK cell percentage between baseline and partial sleep deprivation in both age 
groups (young: t(9)=2.074, p=0.068, elderly: t(9)=-0.635, p=0.541). A significant increase in 
NK cell percentage between partial sleep deprivation and sleep recovery was found in the 
young group (young: t(9): -2.700, p=0.024, elderly: t(9)=-0.068, p=0.947).  
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3.3.4.3 Partial sleep deprivation increases neutrophil ROS production in the young 
Few studies have looked at the effect of partial sleep deprivation on innate immune cell 
functions. In this study and in unadjusted analyses the young group showed an increase in 
neutrophil ROS production after the partial sleep deprivation (p=0.012), which was returned 
to baseline after the sleep recovery period. The elderly volunteers also showed a trend towards 
higher neutrophil ROS production after partial sleep deprivation and recovery, although the 
differences did not reach statistical significance (Table 3.12). Neutrophil phagocytosis was 
unchanged in both the groups. NK cell cytotoxicity was not significantly affected by the 
partial sleep deprivation in the young group, whilst it appeared to be persistently reduced after 
both partial sleep deprivation and recovery in the elderly (unadjusted analyses), although the 
changes did not reach significance (Table 3.12 and figure 3.8). 
3.3.4.4 Partial sleep deprivation affects T cell subset distribution in young but not in elderly 
individuals 
The effect of partial sleep deprivation on T cell subpopulations is poorly fully understood, 
with the literature reporting this either to be unchanged or increased after sleep disruption [132, 
402, 417]. In this study the young volunteers displayed a significant decrease in CD4+ and CD8+ 
naïve T cell subsets after the day of sleep recovery compared to the value directly after the 
partial sleep deprivation (unadjusted results). However, the same change was not seen in 
elderly individuals (Table 3.13, figure 3.9). 
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Table 3.12 The effect of partial sleep deprivation and recovery on innate immune functions. F, p and η2 are reported for unadjusted analyses 
and adjusted for gender and BMI. Neutrophil ROS production is reported as MFI, neutrophil phagocytosis is calculated as phagocytic index and 
NK cell cytotoxicity is measured as the percentage of K562 killed by NK cells.  
                                                                              
YOUNG                                                         
unadjusted                          adjusted 
    F              p             η2            F              p              η2   
                                                                         
ELDERLY                                                     
unadjusted                          adjusted 
   F              p             η2            F              p             η2   
Neutrophil ROS 
production 6.615        0.012       0.424        1.620        0.240        0.188 3.690        0.066       0.291        0.369        0.624        0.050 
Neutrophil 
phagocytosis 1.641        0.229       0.154        0.316        0.661        0.043 1.102        0.351       0.109        1.205        0.324        0.147 
NK cell 
cytotoxicity 1.641        0.229       0.154        0.316        0.661        0.043 3.332        0.065       0.994        0.316        0.392        0.124 
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Figure 3.8 The effect of partial sleep deprivation and recovery on innate immune 
functions. Neutrophil ROS production in response to FITC labelled E coli (expressed as 
MFI), neutrophil phagocytosis of E coli expressed as phagocytic index, and NK cell 
cytotoxicity expressed as % lysis of target cells in young (n=10) and elderly (n=10) subjects 
at baseline, after 3 days of partial sleep deprivation and one day of recovery. Data are mean ± 
SEM. Two tailed paired T test analyses confirmed a significant increase in neutrophil ROS 
production between baseline and partial sleep deprivation in the young, but not in the elderly 
group (young: t(9)=-3.067, p=0.013, elderly: t(9)=-1.533, p=0.160). No significant differences 
were observed between partial sleep deprivation and sleep recovery (two tailed paired T test, 
young: t(9)=1.781, p=0.109, elderly: t(9)=-0.806, p=0.441). A lack of significant differences 
was also observed for NK cell cytotoxicity (between baseline and partial sleep deprivation: 
young: t(9)=1.323, p=0.218, elderly: t(9)=1.945, p=0.084) (between partial sleep deprivation 
and sleep recovery, young: t(9)=-1.985, p=0.078, elderly: t(9)=0.892, p=0.396). 
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Table 3.13 The effect of partial sleep deprivation and recovery on the distribution of T cell subsets. F, p and η2 are shown for unadjusted 
analyses and adjusted for gender and BMI. The T cell subpopulations values are percentage of PBMCs. 
 
 
                                                                             
YOUNG                                                         
unadjusted                         adjusted 
    F             p             η2             F              p             η2 
                                                                         
ELDERLY                                                    
unadjusted                         adjusted 
     F            p             η2             F              p             η2 
CD3+ T cells 2.245       0.160       0.200         0.921       0.388        0.116 1.457       0.262       0.139         0.382       0.644        0.052 
CD4+ T cells 4.746       0.043       0.345         0.148       0.761        0.021 1.558       0.244       0.148         0.736       0.432        0.095 
CD8+ T cells 1.375       0.278        0.133         1.045       0.372       0.130 3.289       0.094       0.268         2.548       0.152        0.267 
CD4+:CD8+ T cells 2.790       0.103        0.237         1.026       0.375       0.128 2.462       0.130       0.215         0.658       0.486        0.086 
CD4+ naive T cells 0.504       0.606        0.053         0.974       0.401       0.122 0.940       0.396       0.095         3.900       0.073        0.358 
CD8+ naive T cells 7.395       0.006        0.451         0.185       0.812       0.026 2.860       0.088       0.241         2.384       0.135        0.254 
CD4+ naïve:memory  
T cells 0.206       0.742        0.022         4.003       0.051       0.364 2.245       0.160       0.200         0.921       0.388        0.116 
CD8+ naïve:memory  
T cells 2.977       0.092        0.249         0.650       0.498       0.085 1.433       0.265       0.137         4.087       0.057        0.369 
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Figure 3.9 The effect of partial sleep deprivation and recovery on CD4+ and CD8+ naïve 
T cells. Percentages of CD4+ and naïve CD8+ T cells were determined in young and elderly 
subjects at baseline, after 3 days of partial sleep deprivation and one after sleep recovery. Data 
are expressed as % of CD3 T cells and are mean ± SEM (n=10). Two tailed paired T test 
revealed no significant differences in the percentage of CD4+ T cells between baseline and 
partial sleep deprivation in both the young and the elderly groups (young: t(9)=-1.879, 
p=0.093, elderly: t(9)=-1.890, p=0.091). A significant decrease was observed between 
baseline and sleep recovery just in the young (young: t(9)=3.709, p=0.005, elderly: t(9)=-
0.976, p=0.354). No significant differences were observed for the percentage of naïve CD8+ 
T cells between baseline and partial sleep deprivation in both groups (young: t(9)=-1.619, 
p=0.140, elderly: t(9)=-2.059, p=0.070), while the young showed a significant decrease of this 
T cell subset after the night of sleep recovery (young: t(9)=3.513, p=0.007, elderly: 
t(9)=0.690, p=0.507).  
118 
 
3.3.4.5 Partial sleep deprivation does not affect serum cytokines 
Protocols of acute and partial sleep deprivation have often been shown to cause a rise in 
circulating levels of pro-inflammatory cytokines, however again the results are often 
discrepant [133, 402, 416, 418]. Here no significant changes in the levels of any cytokines were 
observed in either of the groups, with both adjusted and unadjusted analyses (Table 3.14). 
Analysing the results in more detail, it was noticed that the pro-inflammatory cytokines IL-6 
and IL-8 were transiently raised in young individuals after the partial sleep deprivation period, 
but such a transient increase did not happen in the elderly (Figure 3.10) In addition, the anti-
inflammatory cytokine IL-4 was increased in the volunteers after the sleep recovery period 
(Figure 3.10). 
3.3.5 THE EFFECT OF PARTIAL SLEEP DEPRIVATION ON ADIPOKINES AND 
ADRENAL HORMONES 
3.3.5.1 Partial sleep deprivation does not affect levels of leptin and adiponectin 
Serum concentrations of adipokines, especially leptin, have been found to be altered by sleep 
deprivation protocols [167, 169-171, 187]. Thus, leptin and adiponectin were measured but no 
significant effect was seen of partial sleep deprivation on either adiponectin or leptin levels 
(Table 3.15 and figure 3.11). 
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Table 3.14 The effect of partial sleep deprivation and recovery on serum concentration of cytokines. F, p and η2 are shown for unadjusted 
analyses and adjusted for gender and BMI. Concentrations of all cytokines are in pg/ml. 
 
                                                                             
YOUNG                                                         
unadjusted                         adjusted 
    F             p             η2             F              p             η2 
                                                                                   
ELDERLY                                                
unadjusted                         adjusted 
    F             p             η2             F              p             η2 
IL-1β (sqrt) 0.365       0.643        0.039         0.756       0.464        0.097 1.642       0.226       0.170         0.099       0.895        0.016 
IL-2 (sqrt) 0.503       0.602        0.053         0.760       0.469        0.098 0.517       0.563       0.061         0.158       0.786        0.026 
IL-4 0.770       0.414        0.079         0.099       0.773        0.014 0.776       0.405       0.088        2.364       0.174        0.283 
IL-5 (sqrt) 0.289       0.648        0.031         0.185       0.732        0.026 0.919       0.386       0.103         0.372       0.620        0.058 
IL-6 (sqrt) 1.321      0.291        0.128         1.101       0.351        0.136 0.328       0.681       0.039         0.063       0.902        0.010 
IL-8 0.548       0.562        0.057         1.599       0.244       0.186 0.195       0.754       0.027         0.315       0.689        0.059 
IL-10 (sqrt) 0.634       0.500        0.073         0.735       0.462       0.109 0.060       0.888       0.008         0.002       0.989        0.000 
 GM-CSF (sqrt) 0.032       0.968        0.004         0.369       0.693       0.050 0.180       0.780       0.025         0.177       0.703        0.034 
 IFN-γ (sqrt) 0.676       0.502        0.070         0.428       0.627       0.058  0.125       0.810       0.015         0.914       0.394        0.132 
TNF-α (sqrt) 0.459       0.353        0.049        0.594       0.477       0.078 0.692        0.434       0.080         0.299       0.611        0.048 
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Figure 3.10 The effect of partial sleep deprivation and recovery on serum IL-4, IL-6, IL-
8 and TNF-α levels. Serum IL-4, IL-6, IL-8 and TNF-α were determined by multiplex in 
young and elderly subjects at baseline, after 3 days of partial sleep deprivation and one after 
sleep recovery. Data are mean ± SEM (n=10). Two tailed paired T test revealed no significant 
differences between baseline and partial sleep deprivation and between partial sleep 
deprivation and sleep recovery (data not shown).   
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Table 3.15 The effect of partial sleep deprivation and recovery on serum concentration of leptin and adiponectin. F, p and η2 are shown 
for unadjusted analyses and adjusted for gender and BMI. Concentrations of leptin and adiponectin are ng/ml and µg/ml respectively. 
                                                                              
YOUNG                                                           
unadjusted                          adjusted 
    F              p             η2            F              p             η2   
                                                                         
ELDERLY                                                     
unadjusted                          adjusted 
   F              p             η2             F              p             η2   
Leptin 1.133        0.344       0.112        0.112        0.864        0.016 1.023        0.369        0.102        0.143        0.829        0.020 
Adiponectin  1.101        0.342       0.109        3.955        0.060        0.361 0.865        0.416       0.088        0.256        0.729       0.035 
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Figure 3.11 The effect of partial sleep deprivation and recovery on adiponectin and 
leptin. Serum levels of adiponectin and leptin were determined by ELISA in young and 
elderly subjects at baseline, after 3 days of partial sleep deprivation and one after sleep 
recovery. Data are mean ± SEM (n=10). Two tailed paired T test revealed no significant 
differences between baseline and partial sleep deprivation and between partial sleep 
deprivation and sleep recovery (data not shown).   
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3.3.5.2 Sleep recovery decreases the levels of cortisol 
Studies of partial sleep deprivation have reported that cortisol is usually decreased in the 
morning following the experimental protocol [170, 418, 422], whereas in the evening of the same 
day it appears elevated, suggesting a decreased functionality of the negative-feedback 
mechanism driven by this hormone [148, 423]. In this study both young and elderly volunteers 
showed a trend towards lower morning cortisol level after partial sleep deprivation though this 
did not reach significance (Table 3.16 and figure 3.12). When young and elderly data were 
analysed together as one single group, the unadjusted analysis became significant for reduced 
cortisol (unadjusted analysis: F=3.805, p=0.038, η2=0.167; analysis adjusted for age, gender 
and BMI: F=0.620, p=0.533, η2=0.037). Serum DHEAS and the C:D ratio were not 
significantly affected by the partial sleep deprivation protocol (Table 3.16). 
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Table 3.16 The effect of partial sleep deprivation and recovery on serum concentration of cortisol, DHEAS and the ratio C:D. F, p and η2 
are shown for unadjusted analyses and adjusted for gender and BMI. Concentrations of cortisol and DHEAS are measured as ng/ml.
                                                                             
YOUNG                                                         
unadjusted                          adjusted 
    F              p             η2            F              p              η2   
                                                                         
ELDERLY                                                     
unadjusted                          adjusted 
   F              p             η2            F              p              η2   
Cortisol  3.192        0.073       0.262        0.192        0.807        0.027 1.593        0.237        0.150        1.791        0.219        0.204 
DHEAS   0.003        0.988       0.000        0.332        0.662        0.045  0.097       0.827        0.011        3.237        0.101        0.316 
C:D  0.919        0.363       0.093        3.413        0.107        0.328  0.853       0.383        0.087        0.371        0.571        0.050 
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Figure 3.12 The effect of partial sleep deprivation and recovery on serum cortisol. Serum 
cortisol was determined by ELISA in young and elderly subjects at baseline, after 3 days of 
partial sleep deprivation and one after sleep recovery. Data are mean ± SEM (n=10). Two 
tailed paired T test analyses revealed a significant drop in cortisol level between baseline and 
partial sleep deprivation in the elderly but not in the young group (young: t(9)=0.714, 
p=0.493, elderly: t(9)=2.303, p=0.047). No significant difference between the partial sleep 
deprivation and sleep recovery was observed (young: (t)=1.536, p=0.159, elderly: (t)=-0.290, 
p=0.779). Interestingly, there was a significant decrease in cortisol level between baseline and 
sleep recovery in the young group (young: (t)=3.070, p=0.013, elderly: (t)=1.376, p=0.202). 
Similarly, when the whole group was considered, the significant decrease in cortisol between 
baseline and sleep recovery was reproduced (t(19)=3.122, p=0.006). 
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3.4 DISCUSSION 
3.4.1 SLEEP AND THE IMMUNE SYSTEM 
Ageing is characterised by a physiological decline in the quantity and continuity of sleep, with 
a reduction in total time spent asleep, specifically SWS and REM sleep duration, an increment 
in fragmentation and an advance in the sleep-wake cycle [512-514, 516-519, 619, 620]. During ageing 
the immune system also undergoes physiological changes, namely a general impairment in 
immune functions (immunosenescence) which affects both innate and adaptive arms of 
immunity [559, 582], and a chronic, persistent increase in the levels of inflammatory cytokines 
(inflammaging) [507]. To understand whether sleep disruption could negatively impact upon 
the immune system in old age, several immune variables were evaluated in relation to sleep 
duration and continuity in a cohort of healthy elderly subjects, as well as in subjects 
undergoing a session of partial sleep deprivation. Despite significant associations observed in 
a few immune and endocrine parameters, our elderly volunteers did not show major changes 
in relation to both physiological and forced sleep disruption. Therefore, sleep dysregulation 
does not appear to be linked in any major way to immunosenescence.  
With regard to the cohort of elderly participants recruited, the age range was sufficiently 
broad (from 62 to 93 years old) and average age sufficiently old (40% of the participants were 
between 70 and 80) for the study of immunosenescence, as the decline of immune functions is 
observed as early as the age of 60 [629]. However, the sleep parameters displayed by the cohort 
recruited were very uniform. In particular, the sleep duration observed within the middle 
tertile ranged from 6.36 to 7.27 hours per night and the majority of the participants (n=35) had 
an average nocturnal sleep duration between 6.30 and 7.30 hours. Only two volunteers had an 
average sleep duration slightly below five hours (minimum: 4.56 hours per night) and 
amongst the long sleepers, only two participants slept more than 8.30 hours and just one 
displayed more than 9 hours of sleep duration. With such a narrow variability it is more 
difficult to find significant associations by use of linear regressions as well as to detect 
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significant differences when tertiles of sleep duration are analysed. The variables showing the 
highest variability were the parameters of sleep fragmentation WASO and average sleep bout. 
The average sleep duration showed by our participants is in line with other studies [515, 516, 630, 
631] but when the baseline sleep parameters were compared between the 10 older and 10 
younger volunteers before undergoing the session of partial sleep deprivation, no significant 
differences in any of the sleep parameters considered were found. This suggests that both 
sleep duration and continuity were not disturbed by the ageing process in the older adults 
recruited. The overall preserved continuity of sleep presented by this cohort could explain the 
lack of association between sleep and immunosenescence. 
3.4.1.1 Sleep and immune cell numbers 
In this study physiological sleep duration and efficiency were found to be negatively 
associated with the number of WBC, granulocytes, monocytes and the G:L ratio. Two 
parameters of sleep fragmentation, WASO and average sleep bout, were also associated with 
the G:L ratio. Moreover, the group of long sleepers had significantly lower numbers of 
lymphocytes. This is the first study finding such a relationship between blood cell counts and 
physiological sleep, one other study reported that individuals having the habit of going to 
sleep earlier had lower numbers of granulocytes and higher numbers of lymphocytes 
compared to individuals habitually going to sleep later, but no associations were found 
between cell counts and sleep duration [632]. 
Elevated counts of circulating WBC, granulocytes and a raised G:L ratio are distinct 
characteristics of a pro-inflammatory status [622-624]. These biomarkers are also associated with 
development of chronic inflammatory conditions such as cardiovascular and metabolic 
diseases [622, 633-635] and with increased risk of mortality [624, 625, 636]. Therefore, from the data 
obtained it could be proposed that short sleep duration and poor sleep continuity may 
contribute to inflammaging. However, in our elderly cohort none of the pro-inflammatory 
128 
 
cytokines was raised in the short sleepers, or associated with sleep duration in adjusted 
analyses. The level of the anti-inflammatory cytokine IL-4 was significantly lower in short 
sleepers compared to long sleepers when analyses were adjusted for use of anti-hypertensive 
medications, whereas IL-6 was not raised in short sleepers but also showed a trend towards 
lower values only in long sleepers. However, the level of the anti-inflammatory cytokine IL-
10 also negatively correlated with the time spent asleep and it is possible that this cytokine 
contributes to the trend towards lower IL-6 in the long sleepers. From these data it cannot be 
inferred that the pro-inflammatory status is more pronounced in short sleepers and more likely 
that longer sleep is anti-inflammatory.  
In parallel we determined that long sleepers have lower numbers of all the immune cell types 
considered, which could contribute to the higher risk of mortality observed in long sleepers [5-
11]. These associations between sleep and immune cell counts could be caused by changes in 
the hematopoietic process, specifically with regard to myeloid and lymphoid differentiation. 
The hematopoietic compartment in bone marrow is known to be affected by ageing, with a 
characteristic skewing towards myelopoiesis [547, 548]. How sleep duration could affect such 
changes has not been investigated here, but corticosteroids are known to modulate 
hematopoiesis [637], though the single and modest association between cortisol and average 
sleep bout would not support this hypothesis.  
The majority of studies of partial sleep deprivation reported that short sleep duration induces 
an increase in WBC, especially neutrophils [150, 402, 415, 416], except for one study by Irwin et al., 
which showed the percentage, but not the number of granulocytes to be decreased following a 
single night of partial sleep deprivation [400]. Here sleep-deprived participants did not show 
any significant changes in the number of circulating immune cells in both young and elderly 
volunteers subjected to 3 nights of partial sleep deprivation. This could be due to both the 
small number of volunteers recruited and the individual response towards this stressful 
condition. Indeed for many of the parameters tested data approached but did not reach 
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significance suggesting that the study was inadequately powered. This study was in fact very 
much a pilot study and before any firm conclusions can be made the study needs to increase 
its sample size, with a power calculation made using the variance figures established in this 
study. In fact, the post-hoc power analyses conducted showed a low power value of less than 
0.4. Further analysis indicated a required sample size of 34 individuals in total in order to 
achieve a medium effect size of 0.5 using t test with power at 0.80 and alpha at 0.05.  
3.4.1.2 Sleep and innate immune functions 
As sleep influences the risk of morbidity and mortality, this study aimed to determine whether 
poor sleep quantity and continuity could affect innate immune functions therefore 
contributing to immunosenescence. Neutrophil functions (ROS production and phagocytosis) 
and NK cell cytotoxicity were assessed. No changes have been found apart from lower 
neutrophil ROS production in subjects with shorter average sleep bout. Intriguingly, the tertile 
of middle sleep duration showed a trend towards higher neutrophil phagocytosis compared to 
both short and long sleepers, potentially indicating a healthier condition of this group, 
although differences were not statistically significant. The overall results indicate that 
physiological sleep does not have a substantial influence on neutrophil and NK cell functions 
therefore it does not contribute significantly to innate immunosenescence in the elderly.  
Few studies have looked at the effect of sleep deprivation on neutrophil functions. One study 
found that acute sleep deprivation decreased neutrophil phagocytosis [406] while another study 
showed that individuals subjected to continuous exercise and partial sleep deprivation showed 
an increment in neutrophil chemotaxis [402]. Here the protocol of partial sleep deprivation did 
not induce substantial changes in the immune functions considered. The unadjusted analyses 
suggested that neutrophil ROS production was significantly increased after the partial sleep 
deprivation and it decreased after the day of sleep recovery in the young group, whilst in the 
elderly the increase in this function was not significant. These data could be interpreted as a 
consequence of the process of immunosenescence, resulting in neutrophil ROS production in 
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the elderly which is refractory to the increase induced in the young after exposure to a 
stressor. 
NK cell cytotoxicity appears to vary according to the protocol of sleep deprivation used: it 
increases in individuals subjected to acute sleep deprivation [329, 396] whereas it decreases after 
a protocol of partial sleep deprivation [399, 400]. NK cell cytotoxicity was not affected by sleep 
continuity or duration in the healthy elderly but showed a strong trend towards a decrease 
after the partial sleep deprivation and interestingly there was no recovery after one night of 
normal sleep. In particular this result may indicate that NK cell function is susceptible to 
partial sleep deprivation in the elderly and is less flexible and cannot recover as quickly. 
Again the data did not quite reach significance but an increased sample size could confirm 
this potentially important finding.  
3.4.1.3 Sleep and T lymphocytes 
Adaptive immunosenescence is characterized by a reduction in the thymic output of naïve T 
cells [581, 582]. Moreover, a decrease in the ratio between helper CD4+ and cytotoxic CD8+ T 
cells is often reported in old age, possibly due to persistent subclinical viral infections [583, 584]. 
Importantly, a low CD4:CD8 ratio is associated with higher risk of mortality [586, 587]. In this 
study the percentage of CD4+ cells and the CD4+:CD8+ T cell ratio negatively correlated 
with sleep efficiency and was positively associated with WASO. In addition, both CD4+ and 
CD8+ naïve T cells and the naïve:memory CD4+ T cell ratio significantly decreased with 
increased time spent alseep. These results were unexpected as inadequate sleep continuity 
(poor sleep efficiency and high sleep WASO) was associated with an increased circulating 
pool of CD4+T cells and the CD4+:CD8+ T cell ratio. In addition, short sleep duration was 
associated with increased numbers of circulating naïve CD4+ and CD8+ T cells, as well as a 
higher CD4+ naïve:memory T cell ratio. Therefore, with regard to adaptive immunity a 
physiological lack of sleep seems to be beneficial and would not contribute to the 
development of immunosenescence.  
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However, in the elderly partially deprived of sleep no such changes were observed, though the 
adaptive system of elderly individuals might be less sensitive to temporary changes in sleep 
duration. In the literature few studies have reported that partial sleep deprivation caused an 
increase in the percentage of both CD4+ and CD8+ T cells [417], although other studies did not 
show any changes [132]. The differences in the protocols administered, the age and gender of 
the volunteers recruited might all contribute to the discrepancies between our study and the 
literature. 
3.4.1.4 Sleep and cytokines  
Cytokines are inflammatory mediators whose role in regulating sleep has been recently 
determined. In general, pro-inflammatory cytokines (mainly TNF-α and IL-1β) are believed to 
enhance sleepiness, increase sleep time and specifically SWS duration [371-373]. Importantly, 
elderly individuals are characterised by a persistent, low grade pro-inflammatory status 
(inflammaging), with a raised level of pro-inflammatory cytokines and a decrease in anti-
inflammatory cytokines [600, 601]. In this study the level of the pro-inflammatory cytokine IL-8 
was negatively associated with sleep duration, though this disappeared when analysis was 
adjusted for use of statins. Importantly, we found that long sleepers were characterised by 
higher levels of the anti-inflammatory cytokine IL-4 after adjustment for medications. As 
discussed above, the remaining cytokines showed no association with sleep duration and a 
case cannot be made for altered sleep contributing to inflammaging in this cohort of elderly 
subjects. In the literature a few epidemiological studies conducted on elderly adults (>50 
years old) showed contrasting results: in a longitudinal study, Ferrie et al. found that sleep 
duration between 7 and 8 hours was associated with lower levels of IL-6 and CRP compared 
to <5 or >9 hours of sleep [638], whereas Dowd and colleagues reported that individuals 
sleeping over 8 hours per night had increased concentration of IL-6 [639]. These analyses were 
based on self-reported sleep duration. Interestingly, in a younger cohort of individuals long 
self-reported sleep duration was associated with increased levels of CRP and IL-6, however in 
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the same individuals polysomnographic short sleep duration significantly correlated with 
higher levels of TNF-α with no associations with IL-6 and CRP [640]. These inconsistent 
findings are roughly in line with the lack of association with cytokines revealed by our 
analyses. They also strengthen the importance and novelty of the few associations found here, 
as there are no studies evaluating levels of inflammatory markers with physiological sleep 
measured by actigraphy in the elderly. Intriguingly, serum levels of both IL-8 and IL-6 
negatively correlated with sleep latency. This could mean that long sleep latency decreases 
inflammation, however this is more likely to indicate that these cytokines promote sleepiness 
therefore they reduce the onset latency of sleep. In the literature there are data to support a 
pro-somnogenic role of both IL-6 [393] and IL-8 [641] as their administration enhanced 
NREM/SWS duration in humans (IL-6) and rabbits (IL-8). However, IL-6 has also been 
shown to negatively correlate with SWS and sleep efficiency in humans [642-644] and no data 
are available regarding the relationship between these cytokines and sleep latency. Thus, the 
interpretation of these results is premature and more studies are needed to clarify the role of 
these cytokines on the regulation of sleep.  
Studies of partial sleep deprivation have reported conflicting results regarding the levels of 
cytokines [133, 402, 416, 418, 419]. Due to the low number of participants and the inter-individual 
variability in response to partial sleep deprivation, no significant differences were seen in the 
levels of any of the 10 cytokines measured, including TNF-α which has a well documented 
effect on sleep. Nevertheless, young individuals were characterised by a trend towards 
increased IL-6 and IL-8 after partial sleep deprivation, whereas these cytokines remained 
unchanged in the elderly. This might also explain the transient increase in neutrophil ROS 
production in sleep-deprived young subjects, as both IL-6 and IL-8 prime neutrophils for 
enhanced oxidative burst [645, 646]. 
 
133 
 
3.4.2 SLEEP, METABOLISM AND ADRENAL HORMONES 
3.4.2.1 Relationship between sleep, BMI and adipokines 
A U-shaped relationship between BMI and sleep duration has been reported in both the 
general [109] and the elderly population [134, 135]. In the cohort of elderly subjects studied here 
there were no significant differences in the BMI amongst tertiles of sleep duration, however 
after controlling for use of statins, BMI was significantly lower in the middle tertile of sleep 
duration, in agreement with the previous studies [109, 134, 135].  
Levels of leptin, which correlated with BMI and also varied with the use of statins, did not 
change in relation to any of the sleep parameters considered, contrary to epidemiological 
studies showing lower levels of leptin in self-reported short sleepers [109, 165]. With regard to 
the anti-inflammatory adipokine adiponectin, its concentration was significantly higher in 
long sleepers. This finding is in agreement with Kotani et al., who found a positive 
association between adiponectin levels and self-reported sleep duration in men [188], but such 
an association was not observed in the large cohort investigated by Taheri and colleagues [109]. 
Interestingly serum adiponectin concentration has been reported to be negatively associated 
with levels of several pro-inflammatory cytokines in vivo (such as TNF-α and IL-6) in obese 
people as well as in subjects suffering from other inflammatory diseases [190, 196, 494]. In 
addition, IL-6 and TNF-α are known to inhibit adiponectin expression by adipocytes [196-198]. 
Therefore, the higher levels of adiponectin found in long sleepers are in line with the finding 
of a trend towards a lower IL-6 level in long sleepers.  
Leptin serum concentration has been reported both to be decreased [167]and increased in 
partially sleep deprived individuals [169]. With regard to adiponectin, a single study showed 
that a protocol of partial sleep deprivation caused a decrease in adiponectin concentration in 
Caucasian but not African women [187]. In this study, despite the different levels of 
adiponectin in elderly long sleepers, partial sleep deprivation did not cause any change in its 
concentration in both young and elderly groups. Similarly, leptin levels were not affected by 
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the experimental protocol. This might suggest that a longer period of partial sleep deprivation 
is required in order to alter the levels of adiponectin or leptin. 
3.4.2.2 Relationship between sleep, cortisol and DHEAS 
Cortisol is released in a pulsatile and diurnal manner by the adrenal gland [65, 74]. In particular 
cortisol level shows a transitory, elevated peak early in the morning after awakening [74-76]. Its 
concentration also increases in response to stress [65] and it is believed to contribute to frailty 
and immunosenescence in the elderly, processes which are antagonised by the other adrenal 
steroid DHEAS which acts as an immune enhancer [536]. 
It is well established that the hormones belonging to the HPA axis regulate physiological 
sleep [51] with a marked anti-somnogenic role for CRH [51, 94] which induces peripheral 
production of cortisol through ACTH secretion [65]. However disturbed sleep could represent 
itself a source of stress which might influence the production of cortisol, or the altered HPA 
axis which occurs with age leading to a raised C:D ratio [647] could contribute to altered sleep. 
In this study cortisol did not associate with the time spent asleep. Similarly, a lack of 
association between awakening salivary cortisol levels and actigraphic sleep duration was 
previously reported in middle-aged subjects [648]. This could suggest either that the age-related 
changes in HPA axis activation are not sufficient to affect sleep duration, or that 
physiologically short or long sleep duration is not a sufficiently stressful condition to raise the 
levels of this stress hormone. However, higher WASO and shorter average sleep bout were 
associated with increased levels of cortisol, although only a significant correlation between       
cortisol and average sleep bout persisted after correction for use of anti-hypertensive drugs. 
These data could imply that highly fragmented sleep represents a condition of stress able to 
enhance cortisol levels, or that the increased HPA axis in older adults results in sleep 
fragmentation.  
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The protocol of partial sleep deprivation induced only minimal changes in the levels of 
cortisol in both young and elderly individuals, which did not reach significance until the two 
data sets were combined. However, cortisol levels decreased progressively after the partial 
sleep deprivation and recovery of sleep rather than increased. These results were not 
completely unexpected, as morning levels of cortisol have been reported to be decreased both 
in serum [422] and saliva [170] following sessions of partial sleep deprivation. As the blood was 
taken at the same time in the morning (between 9 a.m. and 11 a.m.) and the volunteers woke 
up earlier after the partial sleep deprivation (5 a.m.) compared to the baseline day, the 
decrease in cortisol levels following the partial sleep deprivation could be the consequence of 
the different time between awakening and blood taking, cortisol levels being dependent on the 
time of awakening [75, 77]. In fact, previous works showed that cortisol level peaked earlier 
after partial sleep deprivation protocols, but the value was lower compared to the baseline 
value [418, 420]. This decrease in cortisol level could be considered a beneficial effect for 
immune functions; however we did not measure the concentration of this hormone at other 
times during the day. Other groups reported cortisol levels to be significantly elevated in the 
evening following the partial sleep deprivation period [148, 423], suggesting a dysregulation of 
the HPA system and its circadian rhythm. 
Moreover, cortisol levels decreased further in response to sleep recovery in the volunteers. 
This result is in agreement with Pejovic et al. [420] who found a reduction in the 24-hour 
profile of cortisol after sleep recovery compared to baseline, but not with the study by Wu et 
al. in which morning cortisol concentration returned to baseline following a day of sleep 
recovery [422].  
3.5 LIMITATIONS OF THE STUDIES 
To investigate the relationship between sleep behaviour and the immune system in old age, a 
cohort of 93 individuals was recruited. The major limitations characterising this study are 
136 
 
related to the small number of volunteers taking part, compared to other epidemiological 
studies, and the amount of occasional missing data, such as information missing for BMI, use 
of medications, blood cell counts and results from immunological and hormonal assays (i.e. 
neutrophil and NK cell functions, concentration of hormones and cytokines). Because of the 
lack of these data, the analyses could not be fully controlled for the whole cohort. In addition, 
the analyses performed were not controlled for the existence of multicolinearity between sleep 
variables, which may have further affected the results.  
With regard to the protocol of partial sleep deprivation, the major limitation was represented 
by the low number of volunteers recruited in both groups. Importantly, participants were not 
kept in the same controlled standard conditions (i.e.: in hospital) during the partial sleep 
deprivation session, as they were allowed to conduct their every-day life as normal. This 
means that they were free to eat what they preferred, they could perform more or less physical 
activity according to their needs, and all these variables could have influenced the outcomes 
of this study. Moreover, some of the elderly volunteers reported to use anti-hypertensive 
drugs and/or statins: statistical analyses were not adjusted for use of medications due to the 
small sample size and the pilot nature of the study. 
Finally, in both studies it would have been useful to measure the chronotype of the subjects 
(i.e. diurnal or nocturnal preference) and the daily intake of caffeine, as these variables might 
have influenced the results.  In addition, measuring the level of other circulating factors, such 
as GH, ghrelin and catecholamines, could have helped to give a better interpretation of the 
results, as these hormones have effects on the regulation of sleep, response to stress and 
influence immune functions. 
3.6 CONCLUSIONS 
In summary, it can be concluded that physiological sleep duration and continuity exert an 
influence on the immune system though this is not major. There were associations with the 
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distribution of circulating immune populations, the G:L ratio and T cell subsets, as well as 
inflammatory status (main effect seen for IL-4 levels), though this was most marked for the 
anti-inflammatory adipokine adiponectin rather than classical cytokines. There were no major 
effects on innate immune functions, other than neutrophil ROS production. Sleep 
fragmentation was associated with activation of HPA axis as determined by increased cortisol 
levels. Therefore, physiological sleep does not appear to significantly contribute to 
immunosenescence but it could contribute to promote inflammaging. The data obtained from 
the partial sleep deprivation study were not conclusive due to small sample size and thus 
causality for any of these parameters has not been established. 
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CHAPTER 4 
 
 THE EFFECT OF ADIPONECTIN 
ON NEUTROPHIL APOPTOSIS 
AND PHAGOCYTOSIS 
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4.1 INTRODUCTION 
Neutrophils are the most abundant immune cell in the blood, representing the first line of 
defence against microbial pathogens. Thanks to their chemotactic ability, these cells move 
towards the site of infection where they contribute to the removal and the killing of pathogens 
through the processes of phagocytosis, degranulation, the production of ROS and the 
generation of NETs [242, 244]. As reported for other immune cells, neutrophils are negatively 
affected by ageing, with impairments described in many of their defensive strategies such as: 
phagocytosis [556], chemotaxis and ROS production [551, 557, 558]. 
Neutrophils are post mitotic cells characterized by a very short lifespan, undergoing 
constitutive apoptosis approximately 5 days after leaving the bone marrow [214]. However, 
their lifespan is increased at sites of infection by a range of factors including the bacterial 
product LPS [216], pro-inflammatory cytokines [259] and hypoxia [217]. The tight regulation of 
apoptosis and the prompt removal of apoptotic neutrophils are central to the resolution of the 
inflammatory response and prevention of tissue damage and chronic inflammation [258]. In 
contrast neutrophil apoptosis does not seem to be altered during ageing [551]. 
Adiponectin is the most abundant adipokine present in the blood, its serum concentration is 
between 5 and 10 µg/ml [426]. The full-length isoform has aroused increasing interest because 
of its insulin-sensitising [649], anti-atherosclerotic [650] and anti-inflammatory properties [424]. In 
particular adiponectin prevents LPS-induced ALI in mice [489], protects against LPS-induced 
liver injury in obese mice models [651] and inhibits neutrophil oxidative burst in vitro [451]. 
However, some groups have reported pro-inflammatory functions of adiponectin on dendritic 
cells [652] and macrophages [478]. Adiponectin appears to exert many of these actions through 
activation of AMPK, with phosphorylation of AMPK shown to increase following treatment 
with adiponectin in several cell types including phagocytes [451]. 
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As adiponectin has immune regulatory effects changes in its levels with age could contribute 
to immunosenescence, including reduced neutrophil function. As described in chapter 1, 
adiponectin levels have been reported to increase with age [442, 611, 612]. 
4.1.1 HYPOTHESIS AND AIMS 
Contradictory results exist in relation to the effect that adiponectin has on apoptosis [450, 653-
657]. Importantly, an association between low serum adiponectin concentration and high levels 
of apoptotic markers in the blood was recently reported [473]. The effect of adiponectin on 
neutrophil phagocytosis and apoptosis has not been investigated, though any modulatory 
effect could contribute to a pro- or anti-inflammatory role for this adipokine. Thus, the aim of 
this chapter was to assess whether neutrophil apoptosis or phagocytosis are influenced in vitro 
by adiponectin and to define the mechanism through which adiponectin acts. Since 
adiponectin is mainly considered an anti-inflammatory adipokine and has already been 
demonstrated to inhibit the oxidative burst in neutrophils, it was hypothesized that it would 
decrease neutrophil phagocytosis and increase their constitutive apoptosis. 
4.2 METHODS 
The methods used for the various assays, assessment of neutrophil apoptosis and analysis of 
adiponectin effects on signalling pathways are described in chapter 2. The other protocol 
details specific to studies in this chapter are described here. 
4.2.1 SUBJECTS 
Heparinized and anticoagulant-free peripheral blood was obtained from healthy young (< 35 
years old) and elderly (> 60 years old) human donors and all volunteers gave written informed 
consent prior to their participation. Neutrophils were isolated as previously described 
(Chapter 2) and the effects of adiponectin on their function and survival determined. 
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4.2.2 NEUTROPHIL TREATMENTS 
To exclude unwanted effects from contamination of adiponectin with LPS, cells were treated 
with Polymyxin B (10 μg/ml) (Millipore, Billerica, MA) 30 minutes before addition of 
adiponectin (Enzo Life Sciences, Farmingdale, NY) at the physiological concentration of 10 
μg/ml [425, 426], unless otherwise specified. 
To study phagocytosis, neutrophils were re-suspended in RPMI-1640 + GPS in the absence of 
serum to exclude possible interference by adiponectin in the serum. As the study of neutrophil 
apoptosis requires longer incubation times, for these experiments neutrophils were re-
suspended in CM. Serum-free medium was also used for comparison (Corning® SF Medium, 
Cellgro®, Mediatech Inc., Manassas, VA). 
Pharmacological protein kinase inhibitors and activators were employed to determine the 
signalling pathways triggered by adiponectin and their role in adiponectin mediated regulation 
of phagocytosis and apoptosis. Specific inhibitors were added to neutrophil culture 30 
minutes before the addition of adiponectin. The equivalent volume of diluent (water or 
DMSO) was added to control wells. In table 4.1 the drugs and the respective concentrations 
used are listed. 
COMPOUND FINAL CONCENTRATION 
 AICAR (Enzo Life Sciences) 1 mM 
Compound C (Sigma-Aldrich) 10 µM 
LY294002 (Millipore) 10 µM 
PD98059 (Cell Signaling Technology, Beverly, MA) 10 µM 
SB202190 (Sigma-Aldrich) 10 µM 
Cycloheximide (Sigma-Aldrich) 5 µM 
 
Table 4.1 List of compounds and concentrations used to inhibit or activate specific 
pathways. 
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4.3 RESULTS 
4.3.1 ELDERLY SUBJECTS SHOW HIGHER SERUM LEVEL OF ADIPONECTIN 
Serum adiponectin levels have been reported to increase with age [611, 612, 658]. To confirm this 
finding we compared the concentration of this adipokine in serum samples obtained from 
young and elderly volunteers. In agreement with the literature, the results show a marked 
increase of adiponectin serum levels in elderly subjects compared to the young (p<0.001) 
(Figure 4.1).  
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Figure 4.1 Elderly subjects display high serum levels of adiponectin. Concentration of 
adiponectin was assessed by ELISA in serum samples obtained from young (n=57) and 
elderly (n=98) individuals. Data are expressed as mean ± SEM. *** indicates p<0.001. 
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4.3.2 NEUTROPHIL SURFACE EXPRESSION OF ADIPONECTIN RECEPTORS 
The expression of AdipoR1 and AdipoR2 by neutrophils is still a matter of debate. One study 
found a high expression of both AdipoR1 and AdipoR2 mRNA in neutrophils [429], whereas 
another study failed to detect AdipoR2 at both the protein and mRNA level [451].  Therefore, 
the protein expression of AdipoR1 and AdipoR2 was measured on neutrophil membranes by 
indirect immunostaining and flow cytometry (Figure 4.2). The two receptors were found to be 
highly expressed both in young and elderly subjects and modest but significant differences 
were found in the percentage of neutrophils expressing AdipoR2 with age (84.1% ± 2.5 for 
young vs 93.6% ± 1.1 for elderly, p=0.003) and between young males and females (78.7% 
±2.9 for young males versus 89.4 ± 2.3 for young females, p=0.020) (Table 4.2).  
4.3.3 ADIPONECTIN DELAYS NEUTROPHIL APOPTOSIS 
Recently it has been demonstrated that adiponectin plays a significant role as a hematopoietic 
factor, not only in the maintenance of the pool of hematopoietic stem cells but also in the 
inhibition of myelopoiesis and granulopoiesis [429, 470]. As the impact of adiponectin on the 
lifespan of mature neutrophils is unexplored, it was determined whether it could modulate 
neutrophil apoptosis. In the following experiments adiponectin was added to cultures of 
neutrophils obtained from young donors, as the rate of spontaneous apoptosis is unaffected by 
ageing [551]. 
The results (Figure 4.3A and B) show that addition of adiponectin at physiological 
concentrations (1 and 10 μg/ml) decreased neutrophil apoptosis in a dose dependent manner, 
after both 6 and 20 hours incubation. The apoptotic cells were taken as those that were 
Annexin V positive and PI negative (Figure 4.3C). The most effective concentration of 10 
µg/ml adiponectin was used in the remaining experiments.  
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Figure 4.2 Neutrophils express adiponectin receptors. Isolated neutrophils were 
immunostained for the adiponectin receptors Adipo R1 and Adipo R2. Representative FACS 
plots are shown. 
 
 
 
 
 
 
 
Table 4.2 Gender and age difference in the percentage of neutrophils expressing 
AdipoR1 and AdipoR2 on the surface. The percentage of neutrophils expressing AdipoR1 
and AdipoR2 is shown for the young and the elderly donors, and for the gender categories in 
each age group (n=10 in each age group, n=5 in each gender category). * indicates p<0.05 and 
** indicates p<0.01. 
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To exclude any interference of the FCS present in the medium in which neutrophils were 
cultured, apoptosis was also evaluated in neutrophils cultured in serum-free media. 
Adiponectin decreased the number of apoptotic cells after 20 hours of incubation (p=0.005) 
(Figure 4.3D).  
Activation of caspase 3 is essential for induction of apoptotic cell death [247]. To assess 
whether adiponectin inhibited the cleavage of caspase 3, neutrophils were stained with an 
antibody against its cleaved active form. As shown in figure 4.4A adiponectin significantly 
decreased the percentage of cells expressing active caspase 3 after 20 hours of incubation 
(p=0.027). To further confirm the anti-apoptotic effect of adiponectin, the morphology of 
nuclei was examined after 20 hours of culture. As shown in figure 4.4B and C, there was a 
higher number of neutrophils displaying mono-lobed nuclei (indicated with arrows) in the 
control sample compared to adiponectin-treated cells, the majority of which still had the 
multi-lobed nuclear morphology of healthy neutrophils (p<0.001) (Figure 4.4B and C).  
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Figure 4.3 Adiponectin inhibits neutrophil spontaneous apoptosis assessed by Annexin 
V/PI staining. Human neutrophils were treated with adiponectin at the concentrations shown 
and the percentage of apoptotic cells was evaluated at (A) 6 hours and (B) 20 hours 
incubation (n ≥ 6 experiments). C. Representative FACS plots showing the decrease in the 
percentage of Annexin V positive cells induced by adiponectin (10 μg/ml) after 20 hours 
incubation. D. Apoptosis was also assessed on neutrophils incubated in serum-free media with 
and without of adiponectin after 20 hours incubation (10 μg/ml). Data are expressed as mean 
± SEM. * indicates p<0.05, ** p<0.01. 
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Figure 4.4 Adiponectin inhibits neutrophil spontaneous apoptosis as assessed by 
caspase-3 cleavage and nuclear morphology. A. The presence of active caspase 3 was 
measured by immunostaining after 20 hours of incubation with and without 10 μg/ml of 
adiponectin (n=5). B. Nuclear morphology was examined  and apoptotic nuclei were counted 
(n=5 experiments). C. Representative pictures are shown: arrows indicate late apoptotic 
neutrophils. Data are expressed as mean ± SEM. * indicates p<0.05, ** p<0.01. 
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4.3.4 ADIPONECTIN INHIBITS LOSS OF MCL-1 EXPRESSION 
The anti-apoptotic protein Mcl-1 is known to be the main regulator of apoptosis in neutrophils 
[273] and a number of anti-apoptotic agents contribute to increase its expression by inhibiting 
its turnover [268, 659]. Thus, Mcl-1 protein levels were assessed in adiponectin-treated 
neutrophils and compared with controls. As shown in Figure 4.5A and B, adiponectin 
maintained the expression of Mcl-1 in neutrophils after 6 and 20 hours of incubation.  
To understand whether adiponectin increased Mcl-1 levels by enhancing its stability, 
neutrophils were pre-treated with cycloheximide (5 µg/ml), an inhibitor of protein synthesis, 
and Mcl-1 levels were evaluated after 6 hours of incubation. As previously shown [659], 
cycloheximide on its own decreased Mcl-1 protein expression, however addition of 
adiponectin in cycloheximide-treated cells induced a significant increase in Mcl-1 levels 
(p=0.027) (Figure 4.5C).  
In summary, these findings show that adiponectin exerts an anti-apoptotic effect on 
neutrophils, by decreasing caspase 3 activation and Mcl-1 rate of turnover.  
4.3.5 ADIPONECTIN ACTIVATES AMPK, PKB, ERK 1/2 AND p38 MAPKs 
Adiponectin has been reported to activate AMPK and p38 MAPK in monocytes and other cell 
types [451, 478]. Therefore the phosphorylation of these and other kinases involved in regulating 
neutrophil apoptosis, the PI3K substrate PKB and ERK 1/2 [278, 282, 660], was examined in 
response to adiponectin treatment.  
Adiponectin triggered a transient activation of AMPK for up to 15 minutes and 
phosphorylation of PKB, ERK 1/2 and p38 MAP kinases which persisted for up to 30 minutes 
as revealed by time course experiments (Figure 4.6).   
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Figure 4.5 Adiponectin upregulates Mcl-1 levels by increasing its stability. A. 
Representative Western blots and densitometric analyses showing Mcl-1 protein expression in 
freshly isolated, untreated and adiponectin-treated neutrophils after 6 hours and (B) 20 hours 
of incubation. C. Representative Western blots and densitometric analysis showing the effect 
of cycloheximide (5 µg/ml) on Mcl-1 upregulation mediated by adiponectin. Densitometric 
analyses are expressed as the ratio of Mcl-1 to β-actin (n≥3). Data are expressed as mean ± 
SEM. * indicates p<0.05, ** p<0.01, *** p<0.001. 
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Figure 4.6 Adiponectin triggers phosphorylation of AMPK, PKB, ERK 1/2 and p38 
MAPKs. Representative Western blots and densitometric analyses showing time courses for 
AMPK, PKB, ERK 1/2 and p38 phosphorylation mediated by adiponectin. Densitometric 
analyses are expressed as the ratio of phosphorylated to unphosphorylated forms of the 
proteins (n=4). Data are expressed as mean ± SEM. * indicates p<0.05, ** p<0.01. 
 
 
152 
 
4.3.6 ADIPONECTIN EXERTS ITS ANTI-APOPTOTIC EFFECT VIA AMPK AND PKB  
As it was found that adiponectin activated multiple intracellular pathways, it was necessary to 
determine whether they all contributed to adiponectin’s anti-apoptotic effect. Thus, 
neutrophils were treated with specific pharmacological inhibitors against AMPK (Compound 
C), PI3K (LY294002), MEK1/ERK 1/2 (PD98059) and p38 (SB202190) for 30 minutes prior 
to the addition of adiponectin and apoptosis was measured by Annexin V/ PI staining after 20 
hours incubation. The results show that the anti-apoptotic action of adiponectin was 
significantly reduced by pharmacological inhibition of AMPK, PKB and ERK 1/2, but not 
p38 MAPK (Figure 4.7).  
Phosphorylation of AMPK appeared to decline before the maximal phosphorylation of PKB, 
ERK 1/2 and p38, therefore the next question posed was whether AMPK was responsible for 
the activation of the other kinases. To address this question, neutrophils were pre-treated with 
the AMPK inhibitor compound C for 30 minutes prior to addition of adiponectin for a further 
30 minutes. After these incubations, proteins were extracted for assessment of the 
phosphorylation of PKB, ERK 1/2 and p38 MAPK. As revealed in Figure 4.8, compound C 
itself triggered the phosphorylation of PKB, ERK 1/2 and p38, although only the 
phosphorylation of p38 reached statistical significance. Compound C also blocked the 
phosphorylation of PKB mediated by adiponectin, with no significant effect on ERK 1/2 or 
p38 MAP kinases, indicating that activation of AMPK could contribute to adiponectin-
mediated phosphorylation of PKB (Figure 4.8A). To test this hypothesis, neutrophils were 
incubated with the pharmacological activator of AMPK, AICAR (1 mM) for 30 minutes, but 
AICAR failed to increase the phosphorylation of PKB, as well as the other kinases ERK 1/2 
and p38 (Figure 4.8B). From these results it was concluded that activation of AMPK is not 
involved in adiponectin-mediated phosphorylation of PKB, ERK 1/2 and p38.  
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Figure 4.7 AMPK, PKB and ERK 1/2 mediate the anti-apoptotic role of adiponectin. 
Neutrophils were incubated with compound C (AMPK inhibitor) (10 µM), LY294002 (PI3K 
inhibitor) (10 µM), PD98059 (MEK-1/ERK 1/2 inhibitor) (10 µM), or SB202190 (p38 
inhibitor) (10 µM) for 30 minutes prior to treatment with adiponectin (10 μg/ml). Apoptosis 
was measured by Annexin-V / PI staining after 20 hours of incubation (n=7). Data are mean ± 
SEM. * indicates p<0.05, ** p<0.01, *** p<0.001. 
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Figure 4.8 Adiponectin does not appear to activate PKB, ERK 1/2 and p38 via AMPK. 
Representative Western blots and densitometric analyses showing (A) phosphorylation of 
PKB, ERK 1/2 and p38 in response to adiponectin (10 µg/ml) in the absence or presence of 
compound C (10 µM) (n=6) and (B) effect of AICAR (1 mM) on PKB, ERK 1/2 and p38 
phosphorylation (n≥3). Densitometric analyses are expressed as the ratio of the 
phosphorylated to unphosphorylated forms of the proteins. Data are expressed as mean ± 
SEM. * indicates p<0.05, ** p<0.01, *** p<0.001. 
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4.3.7 ACTIVATION OF AMPK INHIBITS NEUTROPHIL APOPTOSIS 
AMPK is activated by a low intracellular ATP:AMP ratio [661] and its activation is associated 
with increased apoptosis in cancer cells [662]. However, activation of AMPK also results in 
increased survival in post mitotic cells, such as neurons subjected to a transient starvation [663]. 
To understand the role of AMPK in the context of neutrophil apoptosis, cells were treated 
with AICAR and compound C, activators and inhibitors of AMPK respectively, and apoptosis 
assessed. AICAR reduced the percentage of apoptotic neutrophils as measured by Annexin V 
staining (p=0.002) and caspase 3 activation (p=0.006) after 20 hours incubation (Figure 4.9A 
and B). Compound C slightly increased neutrophil apoptosis as measured by Annexin V 
staining, although this difference did not reach statistical significance after 20 hours of 
incubation (p=0.092) (Figure 4.7). However, compound C significantly increased activation 
of caspase 3 at the same time point (p=0.016) (Figure 4.9C). Compound C on its own did not 
affect the levels of Mcl-1 but it decreased Mcl-1 expression in adiponectin-treated cells after 6 
hours incubation (Figure 4.10A). In line with these data, Mcl-1 levels were unchanged after 
20 hours of treatment with AICAR (Figure 4.10B). AICAR and compound C efficacy in 
modulating AMPK activation were evaluated and confirmed by western blot (Figure 4.10C). 
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Figure 4.9 AMPK regulates neutrophil apoptosis. Neutrophils were incubated with the 
AMPK activator AICAR (1 mM) or inhibitor compound C (10 µM). Apoptosis was measured 
by (A) Annexin V staining and (B and C) caspase 3 activation after 20 hours incubation 
(n=7). Data are expressed as mean ± SEM. * indicates p<0.05, ** p<0.01.  
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Figure 4.10 AMPK modulates neutrophil apoptosis without affecting Mcl-1 levels. 
Representative Western blots and densitometric analysis showing the effect of (A) compound 
C and adiponectin on Mcl-1 levels after 6 hours treatment and (B) the effect of AICAR on 
Mcl-1 after 20 hours treatment. Densitometric analyses are expressed as the ratio of Mcl-1 to 
β-actin (n=6). Data are expressed as mean ± SEM. * indicates p<0.05, ** p<0.01. C. 
Representative Western blot showing the efficacy of AICAR (1 mM) and compound C (10 
µM) in modulating the phosphorylation of AMPK in neutrophils. Neutrophils were incubated 
with these compounds for 30 minutes after which proteins were extracted and analysed by 
Western blotting.  
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4.3.8 ADIPONECTIN AND AMPK REGULATE THE ACCUMULATION OF CERAMIDE 
IN NEUTROPHIL MEMBRANES 
Ceramide is a pro-apototic sphingolipid physiologically generated by cells including 
neutrophils. During the neutrophil lifespan ceramide accumulates in the membrane forming 
ceramide-rich lipid rafts; these promote death receptor clustering and ultimately induce cell 
death [263, 293], AICAR [664], compound C [665] and adiponectin itself [666] have been shown to 
modulate the generation of ceramide, thus the accumulation of ceramide on neutrophil 
membranes was assessed after 20 hours treatment with these compounds. In addition, the 
level of ceramide was also evaluated after treatment with inhibitors of PI3K, ERK 1/2 and 
p38 MAPKs (Figure 4.11). AICAR and compound C respectively decreased and increased 
accumulation of ceramide on neutrophil membranes, suggesting a potential mechanism 
through which modulation of AMPK regulates neutrophil apoptosis. Adiponectin also 
significantly reduced the content of ceramide, although the decrease was less pronounced than 
AICAR treatment (Figure 4.11). PI3K, ERK 1/2 and p38 inhibition did not alter ceramide 
accumulation. Therefore, amongst the signalling pathways activated by adiponectin, only 
AMPK appears to be involved in adiponectin-mediated decrease of ceramide. 
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Figure 4.11 Adiponectin and pharmacological modulators of AMPK activity regulate 
the accumulation of ceramide in neutrophil membrane. Neutrophils were incubated for 20 
hours with adiponectin (10 µg/ml), AICAR (1 mM), compound C (10 µM), PD98059 (10 
µM), SB202190 (10 µM) and LY294002 (10 µM) (n ≥ 4) and the surface level of ceramide 
was determined. Data are expressed as mean percentage relative to control ± SEM. * indicates 
p<0.05. B. Representative FACS plots showing the modulation of ceramide content in 
neutrophil membranes by adiponectin, AICAR and compound C. 
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4.3.9 EFFECT OF ADIPONECTIN ON NEUTROPHIL FUNCTION IN WHOLE BLOOD 
Both neutrophil phagocytosis and superoxide generation have been shown to be reduced with 
age [556, 557], though for superoxide generation the literature is conflicting and suggest that the 
decline is seen mainly in response to gram positive bacteria [557]. To examine whether 
adiponectin could influence neutrophil phagocytosis and oxidative burst and to determine 
whether this differed with age, 100 µl of whole blood was pre-treated with Polymyxin B for 
30 minutes and then incubated with 10 µg/ml of adiponectin for one hour. After this 
incubation the neutrophil functional assays were performed. Data were normalized to the 
percentage increase above the control untreated value. 
Adiponectin did not significantly affect neutrophil oxidative burst in whole blood from young 
or elderly subjects (Figure 4.12A), but it did significantly decrease the phagocytic index and 
the percentage of phagocytic cells in both the young (p=0.023 and p=0.019) and elderly group 
(p=0.006 and p=0.031) (Figure 4.12B and C).  
4.3.10 ADIPONECTIN DECREASES ROS PRODUCTION FROM ISOLATED 
NEUTROPHILS 
Full length adiponectin is known to be a powerful inhibitor of ROS production on isolated 
neutrophils [451, 472]. Although adiponectin did not alter neutrophil oxidative burst in whole 
blood,  a significant decrease in fMLP-stimulated ROS production was observed in isolated 
neutrophils  pre-incubated with adiponectin (10 µg/ml) (Figure 4.13).  
 
 
 
 
161 
 
                                  A 
 
 
 
 
 
                                B 
 
 
 
 
  
                                C 
          
 
 
 
 
 
 
Figure 4.12 Adiponectin decreases neutrophil phagocytosis but not oxidative burst in 
whole blood. (A) Neutrophil ROS production, or (B) phagocytic index measured in untreated 
(control) and  adiponectin treated cells from young or old donors (n=10), expressed as 
percentage of control. Data are mean ± SEM. (C) Percentage of phagocytic cells both in 
young and old volunteers (n=10). Horizontal bar shows the mean values. * indicates p<0.05 
and ** indicates p<0.001.  
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Figure 4.13 Adiponectin inhibits ROS production by isolated neutrophils. A. Isolated 
neutrophils were stimulated with fMLP, the luminescence was recorded for 30 minutes and 
the values plotted. Representative plots obtained from untreated and adiponectin-treated 
neutrophils stimulated with fMLP are shown. B. ROS production expressed as AUC 
calculated from the plots (n=5). Data are mean ± SEM. * indicates p<0.05 and ** indicates 
p<0.001. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
163 
 
4.3.11 MEASUREMENT OF PHAGOCYTOSIS USING ISOLATED NEUTROPHILS 
Neutrophil phagocytosis was measured in the whole blood using the commercial kit for flow 
cytometry Phagotest™. The same reagents provided by the kit were employed to optimize a 
protocol for studying the phagocytosis of isolated neutrophils in absence of serum. 
Neutrophils isolated from three different donors were incubated with a fixed amount of 
bacteria (20 µl of volume, 40:1 ratio between E. coli and neutrophils) and a time course was 
performed to measure the phagocytosis after 1, 2, 3, and 4 hours. Both the phagocytic index 
and the percentage of phagocytic neutrophils are shown in Figure 4.14A and B. From these 
experiments a high variability was seen in the phagocytic index. In general, the percentage of 
phagocytic cells reached a plateau after 2 hours, whereas the phagocytic index was more 
variable with a more pronounced increase between 1 and 2 hours. Hence, an incubation time 
of 1.5 hours was chosen to assess the differences in neutrophil phagocytosis induced by 
adiponectin on isolated neutrophils. 
To assess whether adiponectin can directly modulate neutrophil phagocytosis, isolated 
neutrophils suspended in serum-free media were pre-treated with adiponectin for one hour 
and then challenged with opsonized E. coli (40:1 ratio between E. coli to neutrophils). As 
shown in figure 4.15A, adiponectin decreased phagocytosis of isolated neutrophils in a dose-
dependent manner. Intriguingly, the reduction in the phagocytic index induced by adiponectin 
on isolated neutrophils was greater than that observed in whole blood, possibly because of the 
presence of endogenous adiponectin in the blood.  
The inhibitory effect of adiponectin was also time-dependent. During the time course shown 
in figure 4.15B, the maximal reduction of phagocytosis was observed after 90 minutes of 
incubation with the bacteria. Different bacteria to neutrophil ratios (5:1, 20:1 and 40:1) 
(Figure 4.15C) and microscopic evaluation (data not shown) have been tested and the 
decrease was reproducible.  
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Figure 4.14 Time course of neutrophil phagocytosis with plasma-opsonized E. Coli. Time 
course of the phagocytic index (A) and the percentage of phagocytosing cells (B) measured at 
1, 2, 3 and 4 hours after the addition of bacteria, in three different samples.  
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Figure 4.15 Adiponectin inhibits phagocytosis by isolated neutrophils. A. Isolated human 
neutrophils (n=6) were treated with adiponectin at different concentrations (0.1, 1 and 10 
μg/ml) for one hour prior to addition of opsonized FITC labelled E. coli; after 90 minutes the 
phagocytic index was assessed by flow cytometry. B. Time course of neutrophil phagocytosis 
(30, 60, 90 minutes) with and without addition of adiponectin (10 μg/ml) (n=6). C. Neutrophil 
phagocytosis measured at different bacteria to neutrophil ratios with and without addition of 
adiponectin (n=6). Data are expressed as mean ± SEM. * indicates p<0.05, ** indicates 
p<0.01.  
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4.3.12 EFFECT OF ADIPONECTIN ON EXPRESSION OF PHAGOCYTIC RECEPTORS 
Phagocytosis of opsonized pathogens is initiated and promoted by a range of receptors 
expressed on neutrophils. To evaluate whether adiponectin could reduce the phagocytosis of 
E. coli through regulation of phagocytic receptors, surface expression of CD16, CD11b and 
TLR4 on unstimulated neutrophils was assessed after one hour treatment with adiponectin. 
CD11b, CD16 and TLR4 expression was unaffected by treatment with adiponectin (Figure 
4.16A, B and C).  
The dimer CD11b/CD18, also known as complement receptor 3 (CR3), or Mac-1, is a 
receptor involved in phagocytosis of iC3b-opsonized pathogens. It is activated by 
conformational change when neutrophils are stimulated with pro-inflammatory agents [667]. 
Mac-1 activation was assessed in neutrophils pre-incubated with adiponectin and stimulated 
with opsonized unlabelled E. coli for 90 minutes using an antibody against the activation 
epitope. As shown by Figure 4.17A and B, Mac-1 activation (expressed as MFI) and the 
percentage of cells expressing active Mac-1 in response to E. coli stimulation were 
significantly decreased when adiponectin was added to the culture. As the conformational 
change that Mac-1 undergoes during its activation increases its affinity towards ligands [667], 
whether the binding of bacteria to neutrophils was also affected by adiponectin was 
determined. The binding of FITC labelled E. coli to the neutrophil membrane was measured 
at 4oC after pre-incubation with adiponectin at different time points (30, 60 and 90 minutes). 
A significant increase in the percentage of unbound neutrophils (FITC negative cells) was 
found in samples treated with adiponectin (Figure 4.17C).  
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Figure 4.16 Adiponectin treatment does not alter neutrophil surface expression of the 
phagocytic receptors CD11b, CD16 and TLR4. Isolated neutrophils treated with 
adiponectin for 1 hour were immunostained for expression of (A) CD11b, (B) CD16 and (C) 
TLR4. Data are expressed as mean ± SEM (n=5). 
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Figure 4.17 Adiponectin inhibits the activation of Mac-1 and the binding of E. coli on 
neutrophil cell wall. Isolated neutrophils treated with adiponectin for 1 hour and stimulated 
with unlabelled opsonized E. coli were immunostained for activated Mac-1. A. Adiponectin 
decreases Mac-1 expression (MFI) and (B) the percentage of neutrophils bearing active Mac-
1. Data are mean ± SEM (n = 7). C. After one hour treatment with adiponectin, the binding of 
bacteria to the neutrophil surface was measured by flow cytometry at 30, 60 and 90 minutes 
of incubation with opsonized FITC labeled E. coli at 4°C. FITC negative cells were 
considered unbound. Data are expressed as the percentage of cells with no E.coli bound and 
are mean ± SEM (n≥7). * indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001.  
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4.3.13 ADIPONECTIN DECREASES NEUTROPHIL PHAGOCYTOSIS VIA INHIBITION 
OF PKB AND ERK 1/2  
Neutrophil phagocytosis is sustained by activation of PI3K/PKB and MAPK signalling 
pathways, thus the effect of adiponectin on phosphorylation of PKB, ERK 1/2 and p38 
MAPK in E. coli-stimulated neutrophils was examined by Western blotting. Pre-treatment 
with adiponectin was associated with significantly lower phosphorylation of both PKB and 
ERK 1/2 compared to untreated stimulated neutrophils, though the effect on ERK 1/2 was 
more pronounced (Figure 4.18A and B), whereas phosphorylation of p38 was unaffected by 
the presence of adiponectin.  
The involvement of the two signalling pathways PI3K/PKB and ERK 1/2 signalling for 
complete neutrophil phagocytosis by using the pharmacological inhibitors LY294002 (PI3K 
inhibitor) and PD98059 (MEK1/ERK 1/2 inhibitor). These drugs were added 30 minutes 
before the addition of bacteria and beginning of the assay, and both of them decreased 
phagocytosis of E. coli in a dose-dependent manner (Fig. 4.19A and B). The efficacy of the 
two inhibitors was confirmed by Western blot (4.19C). 
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Figure 4.18 Adiponectin decreases the phosphorylation of PKB and ERK 1/2 but not p38 
in response to E. coli. Neutrophils pre-incubated with adiponectin were challenged with 
unlabelled opsonised E. coli for 10 minutes after which proteins were extracted and analysed 
by Western blotting. A. Representative Western blots showing the effect of adiponectin on 
phosphorylation of PKB, ERK 1/2 and p38 MAPK in response to E. coli stimulation. B. 
Densitometric analysis of three separate experiments for the effect of adiponectin on 
phosphorylation of PKB, ERK 1/2 and p38 MAPK, expressed as the ratio between the 
phosphorylated and unphosphorylated proteins. Data are expressed as mean ± SEM (n = 5). * 
indicates p<0.05, ** indicates p<0.01, *** indicates p<0.001 for treated versus control cells. 
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Figure 4.19 Inhibition of PI3K/PKB and MEK1/ERK1/2 pathways results in reduced 
neutrophil phagocytosis. The PI3K inhibitor LY294002 (A) and MEK-1/ERK 1/2 inhibitor 
PD98059 (B) were added to neutrophils at the two concentrations of 10 μM and 50 μM for 30 
minutes prior to addition of opsonised FITC labeled E. coli and the phagocytic index was 
measured by flow cytometry. Control samples were treated with the highest concentration of 
carrier (DMSO) used. Data are expressed as mean ± SEM (n≥7). * indicates p<0.05, ** 
indicates p<0.01, *** indicates p<0.001. C. Neutrophils were pre-incubated with LY294002 
and PD98059 (50 μM and 10 μM) for 30 minutes, stimulated with unlabelled opsonised E. 
coli for 10 minutes after which proteins were extracted and analysed by western blotting. 
Representative Western blots showing the efficacy of LY294002 and PD98059 in inhibiting 
the phosphorylation of PKB and ERK 1/2 in response to E. coli stimulation.  
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4.3.14 ADIPONECTIN EFFECT ON PHAGOCYTOSIS IS NOT MEDIATED BY AMPK 
As adiponectin induces activation of AMPK in phagocytes, it was next decided to determine 
whether this kinase could be involved in adiponectin-mediated reduction of neutrophil 
phagocytosis. Neutrophils were pre-treated with the AMPK activator AICAR (1 mM) for 30 
minutes prior to the addition of E. coli but AICAR did not significantly decrease phagocytosis 
(Figure 4.20). Thus, AMPK activation does not contribute to inhibition of phagocytosis in 
adiponectin-treated neutrophils. 
4.3.15 PI3K, BUT NOT ERK 1/2, REGULATE MAC-1 ACTIVATION  
The results show that adiponectin inhibited the activation of PI3K-PKB and ERK signalling 
and also Mac-1 activation in neutrophils challenged with E. coli. It was then asked whether 
these two signalling pathways could regulate activation of Mac-1. Using the specific 
inhibitors LY294002 and PD98059, it was possible to determine that PI3K, but not ERK 1/2, 
were partially involved in the conformational change of Mac-1 after neutrophils were 
stimulated with bacteria (Figure 4.21).  
4.3.16 ACTIN POLYMERIZATION IS INHIBITED BY ADIPONECTIN 
Actin polymerization is necessary to sustain neutrophil phagocytosis [668]. Activation of PI3K 
and generation of PtdIns(3,4,5)P3 is required for extension of pseudopods [237, 238] and 
cytoskeletal rearrangements also depend on ERK 1/2 activation [669]. As adiponectin 
decreased PKB and ERK 1/2 phosphorylation in bacteria stimulated neutrophils (Figure 
4.18A), it was hypothesized that the decrease in the activation of PI3K and ERK 1/2 could 
negatively influence F-actin generation in response to E. coli. FITC phalloidin staining 
confirmed the hypothesis, as adiponectin treatment reduced the amount of polymerized actin 
after 5 minutes of stimulation with unlabelled E. coli (Figure 4.22). This lack of F-actin 
formation could be responsible for a lack of pseudopod maturation and phagosome formation. 
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Figure 4.20 AMPK activation does not affect neutrophil phagocytosis. A. Neutrophils 
were incubated with AICAR (1 mM) for 30 minutes prior to addition of FITC labelled E. coli 
and measurement of phagocytic index. Data are expressed as mean ± SEM (n=6).  
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Figure 4.21 Inhibition of PI3K decreases Mac-1 activation. A. The PI3K inhibitor 
LY294002 and (B) the MEK1 inhibitor PD98059 (10 and 50 μM) were added to neutrophils 
for 30 minutes before stimulating the cells with unlabelled opsonised E. coli. After 90 minutes 
the activation of Mac-1 was measured by flow cytometry. Unstimulated and control E. coli 
stimulated samples were incubated with the highest concentration of carrier (DMSO) used. 
Data are expressed as mean ± SEM (n=6). * indicates p<0.05, ** indicates p<0.01, *** 
indicates p<0.001. 
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Figure 4.22 Adiponectin inhibits actin polymerization in response to E. coli stimulation. 
A. Neutrophils were pre-incubated with adiponectin and stimulated with unlabelled opsonized 
E. coli for 5 minutes, after which intracellular F-actin was stained with FITC phalloidin and 
measured by flow cytometry. Data are expressed as mean ± SEM (n=7). * indicates p<0.05. 
B. Representative images of F-actin in unstimulated and E. coli stimulated neutrophils with 
and without pre-treatment with adiponectin. 
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4.3.17 COMPLEMENT FACTOR C1Q DOES NOT RESCUE PHAGOCYTOSIS OF 
NEUTROPHILS TREATED WITH ADIPONECTIN 
The C-terminal domain of adiponectin shares structural homology with the complement 
protein C1q. Interestingly, the reduction of macrophage phagocytosis by adiponectin was 
completely rescued by the use of a C1qRp antibody [470]. Therefore whether addition of 
complement protein C1q protein to the phagocytosis assay would be able to inhibit the effect 
of adiponectin was determined.  Neutrophils were pre-incubated with human serum C1q (at 
the physiological serum concentration of 100 μg/ml [670] prior to the addition of adiponectin. 
However, C1q did not block the negative effect of adiponectin on neutrophil phagocytosis 
(Figure 4.23). 
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Figure 4.23 Inhibition of neutrophil phagocytosis by adiponectin is not prevented by 
addition of complement factor C1q. C1q (100 μg/ml) was added to neutrophils 15 minutes 
before the addition of adiponectin to saturate C1q receptors. Phagocytosis of opsonized FITC 
labelled E. coli was then measured by flow cytometry. Data are expressed as mean ± SEM 
(n=6). ** indicates p<0.01, *** indicates p<0.001. 
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4.4 DISCUSSION 
4.4.1 ADIPONECTIN REGULATION OF NEUTROPHIL APOPTOSIS  
Neutrophil lifespan is regulated by several factors which modulate pro- and anti-apoptotic 
signalling pathways, accelerating or inhibiting the process of spontaneous apoptosis [292]. 
Here, adiponectin was shown to inhibit neutrophil spontaneous apoptosis in vitro. 
Adiponectin prolonged neutrophil lifespan in a dose dependent manner at both 6 and 20 hours 
of treatment and the same effect was observed when neutrophils were incubated in serum free 
medium.   
This result was unexpected as this adipokine has been extensively studied with regard to its 
anti-inflammatory role [424] and you would predict that extending neutrophil lifespan would be 
pro-inflammatory. However, contradictory results have been reported with regard to its role 
on inflammation and also on apoptosis. For instance, whilst adiponectin enhances apoptosis in 
several tumor cell lines [470, 653-655], as well as activated T lymphocytes [450], it has been shown 
to protect post-mitotic cells, such as neurons [656] and endothelial cells [657] from apoptosis 
when these cells were stimulated with pro-apoptotic factors. In addition, low serum 
adiponectin was recently found to be associated with high levels of apoptotic markers in the 
blood in healthy obese subjects [473]. In light of the existing literature, the anti-apoptotic effect 
reported here for adiponectin on unstimulated neutrophils, which are short-lived, post-mitotic 
cells, is in agreement with previous findings. 
Adiponectin enhanced neutrophil survival by decreasing the cleavage of caspase-3 and 
reducing Mcl-1 degradation as demonstrated by addition of the protein synthesis inhibitor 
cycloheximide B [671]. Mcl-1 is the main anti-apoptotic protein belonging to the Bcl-2 family 
expressed by neutrophils [268] and its importance in the regulation of neutrophil apoptosis is 
well established [271-273], with most anti-apoptotic factors acting through the maintenance of 
expression of this protein. Adiponectin thus acts by similar mechanisms to other known 
neutrophil pro-survival factors.  
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The data reported here also showed that the main anti-apoptotic signalling pathways activated 
by adiponectin were AMPK, PI3K/PKB and the MAPK ERK 1/2 [671]. p38 phosphorylation 
was also increased by adiponectin, though pharmacological blockade of this kinase did not 
prevent the anti-apoptotic function of adiponectin. The exact role of p38 in the context of 
neutrophil apoptosis is controversial as it has been reported both to be anti-apoptotic [283, 284] 
and pro-apoptotic [281, 672] and may depend on the activation or priming status of the cell.  
The activation of AMPK and p38 by adiponectin has been reported by others [424] and PKB 
and ERK 1/2 phosphorylation in response to adiponectin has been shown in several cell types 
[457-460, 463, 464]. Both adiponectin receptors (AdipoR1 and AdipoR2) have been shown to 
contribute to adiponectin-mediated ERK 1/2 phosphorylation, specifically through Src-
mediated Ras activation, and partially through protein kinase A (PKA) activation, but 
independently of PKC activation [457]. Activation of Src and Ras by adiponectin could also 
explain the increased phosphorylation of AMPK, PKB and p38. In fact, c-Src has been shown 
to induce AMPK phosphorylation during hypoxia-reoxygenation in bovine aortic endothelial 
cells [673] and cancer cell lines [674], whilst Ras can bind and activate PI3K in fibroblastic cell 
lines [675] and the Src-Ras axis activates p38 in cardiac myocytes [676]. 
APPL1 is an adaptor protein that interacts with the intracellular tails of adiponectin receptors, 
and this event is enhanced by the binding of adiponectin to AdipoR1 and AdipoR2 [453].  
APPL1 is likely to participate in activating the downstream pathways cited above. Indeed it 
has already been shown to mediate adiponectin and insulin-induced phosphorylation of 
AMPK, PKB and p38 [467], whereas contrasting results exist concerning its involvement in the 
activation of ERK 1/2 [457, 467]. No data currently exist with regards to Src or Ras activation by 
APPL1. Future studies in neutrophils could determine if APPL1 is expressed and plays a role 
in regulation of apoptosis by adiponectin. 
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Although it has not been investigated in this thesis, NF-kB could be another anti-apoptotic 
factor activated by adiponectin, through PKB [677] and ERK 1/2 [678]. NF-kB activation can 
potently delay neutrophil apoptosis [286] and it was found to be activated by adiponectin by 
other groups, in unstimulated monocytic and endothelial cell lines [679, 680]. The PI3K/PKB 
pathway negatively regulates neutrophil apoptosis [276] and mediates the inhibition of 
apoptosis conferred by several pro-survival factors [277-279, 659]. Although ERK 1/2 activation 
does not appear to affect the lifespan of resting neutrophils, this MAPK contributes to 
inhibition of apoptosis in neutrophils stimulated with LPS [282, 285], GM-CSF [277, 659] and when 
neutrophils are cultured at high concentration [681]. Importantly, both PI3K/PKB [278, 659] and 
ERK 1/2 [659] increase Mcl-1 stabilization in stimulated neutrophils, therefore their activation 
could explain the increase in Mcl-1 levels mediated by adiponectin. 
To further investigate the role of AMPK activity in the context of neutrophil apoptosis the 
activating agent AICAR was used and it reduced neutrophil apoptosis without increasing Mcl-
1 stabilization, whereas the AMPK inhibitor compound C significantly increased neutrophil 
apoptosis as measured by caspase-3 cleavage. AMPK is physiologically activated by 
decreased levels of intracellular ATP [661] and by hypoxia [682]. Although AMPK 
phosphorylation has not been assessed in hypoxic neutrophils, it is known that neutrophils 
subjected to hypoxia have a longer lifespan [217], thus AMPK could potentially participate in 
delaying apoptosis in that context. Moreover, transient activation of AMPK enhances survival 
in other post mitotic cells, such as neurons [663].  How AMPK activation could inhibit 
neutrophil apoptosis was also investigated here. Both AICAR and compound C have been 
reported to affect the generation of ceramide [664, 665]and this was confirmed here in 
neutrophils as AMPK modulators altered ceramide accumulation measured within the cell 
membrane. The change in ceramide content represents a plausible mechanism by which 
AICAR and compound C could regulate neutrophil apoptosis as previous studies from our 
laboratory have shown that spontaneous neutrophil apoptosis is triggered by the accumulation 
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of ceramide in the cell membrane. The latter causes ligand-independent clustering of death 
receptors, activation of death receptor signalling and caspase dependent cell death [263]. 
Surprisingly, Mcl-1 protein levels were not affected by AICAR or compound C treatments. 
However in the literature there is no direct evidence for an increase in ceramide content being 
associated with a decline in Mcl-1 levels.  
Crucially, adiponectin also decreased the content of ceramide in the neutrophil membrane. 
This result was in agreement with previous reports showing that adiponectin exerted its anti-
apoptotic action on pancreatic beta cells and cardiomyocytes by decreasing the ratio between 
ceramide and its anti-apoptotic metabolite S1P [666]. However, in the latter study, the action of 
adiponectin on ceramide and S1P levels was independent of AMPK.  
In agreement with Chedid et al., it was found that adiponectin also reduced ROS production 
by isolated neutrophils stimulated with fMLP. This finding is consistent with the decrease 
observed in the level of ceramide, as ROS are responsible for enhancing the activation of 
sphingomyelinase, the enzyme responsible for the synthesis of ceramide [263]. Generation of 
ceramide-enriched membrane rafts can mediate the extracellular apoptotic pathway initiated 
by clustering of CD95 [263] and adiponectin could inhibit the extrinsic pathway of apoptosis by 
blocking the aggregation of FADD and caspase-8 following CD95 clustering. 
The activation of AMPK by adiponectin was transient and preceded the maximal 
phosphorylation of PKB, ERK 1/2 and p38. Experiments performed to elucidate the 
interconnection between these pathways indicated that AMPK activation was not directly 
responsible for the phosphorylation of PKB, ERK 1/2 and p38, as the pharmacological 
AMPK activator AICAR did not induce activation of these pathways [671]. This result is in 
agreement with a previous study showing that AICAR did not alter the phosphorylation of the 
MAPKs ERK 1/2 and p38 in neutrophils [683].  
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In contrast, the addition of compound C to neutrophils induced an increase in p38 
phosphorylation, indicating that compound C may have off target effects that activate this 
kinase. In fact, compound C has been found by others to exert certain actions independently 
of AMPK activation [684-686]. Intriguingly, compound C significantly reduced the effect of 
adiponectin on the phosphorylation of PKB, however activation of PKB, as well as ERK 1/2 
and p38 does not appear to occur downstream of AMPK activation as shown by treatment 
with AICAR. In addition, the decrease of PKB phosphorylation in neutrophils treated with 
both compound C and adiponectin could explain the decrease in adiponectin-mediated Mcl-1 
stabilization in the presence of compound C. 
4.4.2. ADIPONECTIN EFFECTS ON NEUTROPHIL FUNCTION 
Neutrophils are the first innate immune cell to be recruited to site of infection where upon 
arrival they assist in eliminating invading pathogens. Among the several defensive strategies 
employed by neutrophils, the processes of phagocytosis and superoxide generation are the 
best characterized. Adiponectin decreases the killing ability of neutrophils by impairing the 
generation of ROS through inhibition of p47phox phosphorylation [451]. This observation was 
confirmed here on isolated neutrophils. However, addition of adiponectin to whole blood did 
not decrease the oxidative burst produced in response to E. coli [687]. This could be due to the 
presence of factors in the serum combating the effects of adiponectin, other cell populations 
present in the whole blood, as well as the different stimulus used (E. coli was used to 
stimulate the oxidative burst in the blood whereas isolated neutrophils were stimulated with 
fMLP). In contrast, the reduction in neutrophil phagocytosis was observed both in the whole 
blood and on isolated neutrophils incubated with adiponectin. No substantial differences were 
observed between neutrophils obtained from young and elderly donors. 
The inhibitory function of adiponectin on isolated neutrophils was dose and time dependent 
and was much greater compared to the whole blood. This difference could be possibly due to 
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the presence of adiponectin in the blood, though we cannot exclude the possibility that in 
whole blood the effects of adiponectin are modified by other serum factors or immune cell 
populations. Another issue to consider is the time of incubation with E. coli. The Phagotest™ 
kit involves incubating whole blood with bacteria for 10 minutes, whereas the shortest 
incubation time used here with isolated neutrophils was 30 minutes. In the time course 
performed on isolated neutrophils an additive inhibitory effect of adiponectin over time was 
noted. Thus, the lower inhibitory effect of adiponectin observed in whole blood stimulations 
may be a consequence of the shorter incubation time.  
Adiponectin did not alter the expression of the phagocytic receptors CD11b, CD16 and TLR4 
on unstimulated neutrophils, but it decreased the activation of the complement receptor Mac-1 
in response to E. coli stimulation. Mac-1 is one of the main integrins expressed by 
neutrophils. Due to its large range of ligands, which include extracellular matrix proteins (i.e. 
fibronectin), blood proteins (i.e. fibrinogen), complement factors (i.e. iC3b) [688], adhesion 
molecules (i.e. intercellular adhesion molecule-1, ICAM-1) [667] and microbial components 
[689], it is involved in several processes, such as phagocytosis, adherence to the endothelium 
and chemotaxis [690, 691]. Mac-1 is expressed in a low-affinity conformational state on resting 
neutrophils. When cells are challenged with activatory stimuli the integrin undergoes 
clustering (to increase receptor avidity) and conformational changes in its extracellular 
portion to increase the receptor affinity for its ligands [667, 692]. The factors known to increase 
Mac-1 affinity and avidity are chemotactic molecules, cytokines, PMA, cations and 
physiological ligands [667, 690]. In this thesis, opsonized E. coli also resulted in increased 
activation of Mac-1 and adiponectin also reduced the binding of bacteria to the neutrophil 
surface.  
It is important to highlight that Mac-1 is not just involved in the binding of bacteria to the 
phagocyte surface but also in their ingestion [693]. In addition, Mac-1 can cooperate with 
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FcγRs enhancing FcγR-mediated phagocytosis, as blocking Mac-1 function downregulated 
the uptake of Ig-coated erythrocytes and yeast [694, 695]. Given the complexity and the 
importance of Mac-1 function in the different stages of phagocytosis, the reduced activation 
of Mac-1 caused by adiponectin could also have contributed to decrease the uptake of 
opsonised E. coli. 
In contrast to the findings in resting neutrophils, the PKB and ERK 1/2 signalling pathways 
were negatively affected by adiponectin when neutrophils were stimulated with bacteria. PKB 
phosphorylation results from activation of PI3K, which is involved in the process of 
phagocytosis [237, 238, 696]. ERK 1/2, whose activation can occur both downstream and 
independently of PI3K [238], also appears to be essential for optimal phagocytosis [240, 697]. The 
role of PKB and ERK 1/2 in neutrophil phagocytosis was confirmed here by the use of the 
specific inhibitors LY29004 and PD98059, which decreased neutrophil phagocytosis in a 
dose-dependent manner. With the use of these inhibitors, it was also possible to determine 
that the conformational change in Mac-1 following adiponectin treatment was dependent on 
PI3K but not ERK 1/2 activation. This was expected as previous studies have shown that 
Mac-1 activation is mediated by cytoskeletal rearrangements [698] and the PI3K product 
PtdIns-(3,4,5)P3 might activate integrins through regulation of the cytoplasmatic domain by 
adaptor proteins [692].  
The PI3K inhibitor LY29004 inhibited neutrophil phagocytosis to a greater extent compared 
to inhibition of Mac-1 activation, indicating that PI3K participates in multiple aspects of the 
phagocytic mechanism. In fact PI3K, its substrate PKB and its product PtdIns-(3,4,5)P3 are 
indispensable for cell polarization and elongation  [699], pseudopodia extension  [237, 238], F-
actin polarization [700, 701] and phagosome closure [702]. 
ERK 1/2 has been reported to be necessary for macrophage phagocytosis of Francisella 
tularensis, being activated by the tyrosine kinase Syk [697]. In addition, ERK 1/2 
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phosphorylates cortactin, a protein that promotes actin polymerization [669] and ERK 1/2 
inhibition in macrophages resulted in reduced cell elongation in response to mycobacteria 
[699]. Thus ERK 1/2 presumably regulates the ingestion of bacteria by facilitating the 
formation of pseudopods through cytoskeletal rearrangements, though to a lesser extent than 
PI3K. Therefore, the reduction in neutrophil content of F-actin observed in response to 
bacterial stimulation could the result of PKB and ERK 1/2 inhibition by adiponectin.   
Apart from the pathways explored here, the modulation of other protein kinases could lead to 
reduced phagocytic ability in response to adiponectin treatment. One of these kinases could be 
PKC ζ, whose activity has been found to be decreased by adiponectin [454]. PKC ζ activation 
is necessary for complete phagocytosis of bacteria Helicobacter pilori by monocytes [703], it is 
activated by PI3K and contributes to F-actin accumulation [701] and possibly to activation of 
Mac-1 [704]. Therefore, its activation in response to E. coli could have been dampened by pre-
incubation by adiponectin, though this would need further research to confirm this proposal. 
As AMPK is activated by adiponectin in phagocytes [451] its role in neutrophil phagocytosis 
was determined, but activation by AICAR did not decrease neutrophil phagocytosis, thus 
AMPK does not participate in the adiponectin inhibitory effect. A previous work has shown 
that AICAR increased neutrophil phagocytosis [705], though this was not seen in this thesis. 
Adiponectin could also have inhibited neutrophil phagocytosis through its C-terminal C1q-
homology domain, which has been found to exert an antagonistic action on macrophages [470], 
therefore impairing macrophage phagocytosis. The main receptor for C1q is C1qRp, but C1q 
is believed to bind to other phagocytic receptors expressed by neutrophils, particularly CR1 
[706]. To determine whether adiponectin impaired neutrophil phagocytosis through its C1q-
homologous domain, cells were pre-incubated with C1q at a physiological concentration 
before the addition of adiponectin, but neutrophil phagocytosis was not rescued by C1q 
treatment. Importantly, C1q has been reported to enhance the uptake of apoptotic bodies in 
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human macrophages [707] and monocytic cell lines [707, 708], suggesting that this complement 
factor regulates the phagocytic ability in a cell-specific manner. 
4.4.3 PRO- AND ANTI-INFLAMMATORY ACTION OF ADIPONECTIN ON 
NEUTROPHILS 
Full length adiponectin appears to have a marked effect on neutrophil biology. Previous work 
has reported that this adipokine inhibits superoxide generation [451], and in this thesis it was 
shown that it also delayed neutrophil apoptosis and inhibited phagocytosis. At first sight, 
these findings appear contradictory, as adiponectin exerted both a pro-inflammatory function, 
by increasing neutrophil lifespan, and an anti-inflammatory effect by dampening neutrophil 
phagocytic ability. The main difference between the two conditions is the activation status of 
cells. Adiponectin decreased apoptosis in resting neutrophils by increasing the 
phosphorylation of the pro-survival kinases AMPK, PKB and ERK 1/2 and decreased 
neutrophil phagocytosis when neutrophils were incubated with E. coli through a reduction in 
the phosphorylation of PKB and ERK 1/2. Intriguingly, phosphorylation of p38 was enhanced 
by adiponectin in resting neutrophils but it was not decreased in neutrophils exposed to E. 
coli. It is possible to argue that extending neutrophil lifespan but reducing the cells phagocytic 
ability, would overall be pro-inflammatory. 
This ambiguous effect of adiponectin is not entirely novel. As discussed in the introduction 
(section 1.3), a number of studies have reported pro-inflammatory effects of adiponectin 
through induction of PKB and ERK 1/2 phosphorylation in unstimulated cells, i.e.muscle, 
endothelial cells and hepatocytes [457-460], whilst others have reported the exact opposite effect 
on PKB and ERK 1/2 phosphorylation in cells stimulated with different factors [461, 462, 464-466]. 
Opposite effects of adiponectin were also found regarding the expression of pro-inflammatory 
cytokines (IL-6 and TNF-α) in human macrophages, depending on whether adiponectin was 
administered in resting cells [478] or cells subjected to further stimulations [474]. 
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Supporting these findings, two groups independently investigated the activity of NF-kB on 
resting and stimulated monocytic and endothelial cell lines in response to adiponectin and 
reported that adiponectin enhanced the transcriptional activity of NF-kB in unstimulated cells, 
whereas it decreased NF-kB activity when cells were pre-treated with adiponectin and then 
stimulated with pro-inflammatory stimuli (i.e. LPS, TNF-α), [679, 680]. Among the different 
isoforms of adiponectin, the only one able to influence NF-kB activity was the HMW [679].  
Apart from adiponectin, the pro-inflammatory cytokine IFN-γ also exerts differential effects 
according to the state of the cell: Frausto-Del-Rio et al. showed that despite IFN-γ enhancing 
F-actin polymerization through PI3K activation on resting monocyte-derived macrophages, it 
decreased F-actin content when cells were challenged with IgG-coated sheep red blood cells 
and CCL5 stimulation, thereby reducing the phagocytosis of IgG-SRBC and non-opsonized 
E. coli [709]. 
Despite adiponectin exerting opposite functions, common pathways may contribute to the 
reduction of both neutrophil apoptosis and phagocytosis. For instance, the decline in the 
content of ceramide in the neutrophil membrane not only represents an anti-apoptotic 
mechanism but it could also mediate the decrease in neutrophil phagocytosis caused by 
adiponectin, as ceramide-rich lipid rafts are required for receptor clustering [710] and ingestion 
of various bacteria [711]. Moreover, as mentioned before, the inhibitory effect that adiponectin 
exerts on ROS production is consistent with reduced apoptosis.  
It is evident that some molecules activated by adiponectin receptors are responsible for the 
differential modulation of the downstream signal pathways in resting and stimulated cells. 
The first factor to be recruited by adiponectin receptors is the adaptor molecule APPL1: this 
could represent the key protein modulating adiponectin signalling. Although APPL1 has been 
shown to participate in the activation of PI3K [469] and PKB [467, 712], as well as AMPK, ERK 
1/2 and p38 [467, 712, 713], Bohdanowicz et al. demonstrated that overexpression of APPL1 
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decreased phosphorylation of PKB in macrophages in response to IgG-coated beads. In 
particular, they showed that APPL1 moved to phagosomes recruiting two inositol-5 
phosphatases which are responsible for dephosphorylation of both PtdIns(3,4,5)P3 and 
PtdIns(3,4,5)P2, which serve as platforms for PKB activation, thereby inhibiting its 
phosphorylation [714]. In the case of neutrophils, APPL1 could have been recruited to the 
plasma membrane by adiponectin receptors, and it would have localized to forming 
phagosomes before their closure, thus recruiting these phosphatases and dampening PKB 
phosphorylation in response to stimulation. This hypothesis could partially explain also the 
inhibition of ERK 1/2 phosphorylation, as this is both dependent and independent on PI3K 
[238]
. Importantly, the same group found that APPL1 does not inhibit p38 phosphorylation in 
response to IgG-coated beads, which is coherent with results shown here as no change in p38 
phosphorylation was seen with adiponectin in E. coli stimulated neutrophils. 
4.4.4 CONCLUSION AND FUTURE PERSPECTIVES  
In summary, the work presented here demonstrated that adiponectin affects neutrophil biology 
by exerting an anti-apoptotic effect and by reducing the phagocytic ability of these cells 
(Figure 4.24). Supplemental work is necessary to further elucidate the reason underlying the 
apparent difference in effects on signalling pathways in resting and activated cells. As already 
discussed, APPL1 could be the main reason for this, and therefore its role should be 
investigated in more detail with regards to PI3K/ PKB and ERK 1/2 activation in different 
contexts. In addition, it would be useful to determine which signalling pathways are induced 
by the two adiponectin receptors in neutrophils, and consequently, it might be of interest to 
assess whether incubation with adiponectin and/or with pro-inflammatory stimuli alters the 
expression of the two receptors on neutrophil surface.   
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Figure 4.24 Proposed model for action of adiponectin on unstimulated (A) and E. coli 
stimulated neutrophils (B). Red question marks pathways induced by adiponectin that have 
still to be confirmed in neutrophils.  
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5.1 THE INFLUENCE OF SLEEP ON THE IMMUNE SYSTEM 
The world population has experienced a decline in sleep duration over the past century [1-3] 
and both short and long sleep duration have been associated with increased risk of mortality [5-
11]. Lack of sleep has also been linked to development of several morbidities, particularly 
metabolic [115-117, 139-141] and cardiovascular diseases [118, 119], and all of these are characterized 
by a high inflammatory status. Moreover, short sleep duration decreases the efficacy of 
vaccinations [129] and increases the risk of infections [127, 128]. Therefore, understanding how 
sleep acts upon the immune system has aroused increasing interest in the scientific 
community, though less so in respect to the elderly.  
Several lines of evidence have demonstrated the somnogenic effect exerted by pro-
inflammatory cytokines [371-373], however no study has extensively investigated how immune 
functions and inflammatory processes are governed by sleep. The majority of work conducted 
so far examined whether a few immunological parameters, especially the levels of cytokines 
and the number of circulating immune cells, could be altered following a session of acute or 
partial sleep deprivation. Moreover, sleep duration has often been the only parameter of sleep 
considered. Thus, the novelty of this project is in the large number of immune and sleep 
variables measured, allowing a comprehensive understanding of how both physiological sleep 
duration and continuity might impact on the immune system. Moreover the focus has been on 
this relationship in the context of ageing, which is not well researched.  
Healthy elderly individuals were recruited as the aged population has been suggested to suffer 
from physiological disturbances of sleep and these could negatively affect immune functions. 
In parallel, the effects of partial sleep deprivation on both young and elderly individuals were 
also investigated to assess whether this protocol could have differential outcomes on 
immunity in the two age groups.  
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The 93 elderly subjects recruited were characterised by homogeneous sleep duration, the 
majority of subjects displaying average sleep duration between 6.30 and 7.30 hours per night 
and very few subjects sleeping less than 5 hours or longer than 8.30 hours per night, despite 
their age range being quite broad. Surprisingly in the volunteers undergoing the partial sleep 
deprivation protocol no significant differences were detected in the baseline sleep parameters 
between young and elderly subjects. This lack of differences in sleep duration in our older 
volunteers may reflect the fact that they were all in very good health. In this thesis the initial 
hypothesis that sleep could affect the process of immunosenescence was not confirmed. 
Nevertheless, the results obtained showed that physiological sleep, both duration and 
qualitative parameters, can modulate the immune system in the elderly, particularly with 
regard to the number of circulating immune cell populations and T lymphocyte subsets. In 
general, short sleep duration as well as sleep disruption (low efficiency and average sleep 
bout, high WASO) were associated with a higher number of WBC, granulocytes, monocytes 
and a higher G:L ratio. Long sleepers were characterised by reduced number of lymphocytes 
and percentages of naïve T cells.  
To understand which factors could mediate or be modified by such changes, the serum 
concentration of pro- and anti-inflammatory cytokines, the adipokines leptin and adiponectin, 
and the adrenal stress hormones cortisol and DHEAS were measured. Serum adiponectin and 
lymphocyte numbers appear to be respectively increased and decreased in the tertile of long 
sleepers. In the literature adiponectin has been reported to indirectly inhibit B lymphopoiesis 
in bone marrow cultures [484], thus the reduction observed in the total population of 
lymphocytes could be caused specifically by decreased differentiation of B cells by this 
adipokine as B and T cell numbers are usually altered similarly as they have a common stem 
cell progenitor.  
Adiponectin also decreases myelopoiesis and granulopoiesis both in mice and humans [429, 470, 
471]. Although a tendency and not a significant association between adiponectin and sleep 
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duration (p=0.065) was seen, it is possible that this adipokine could contribute to the 
reduction in the number of circulating granulocytes and monocytes seen in long sleepers. 
However, its levels did not significantly correlate with sleep efficiency either, whereas the 
number of granulocytes and monocytes showed a significant reduction with this sleep 
parameter.  
Both the expression of adiponectin from the WAT [196-198] and hematopoiesis [322] are 
regulated by cytokines. The results shown here indicate that long sleep is associated with 
lower levels of IL-8 (analyses unadjusted for medications) and higher levels of IL-4. These 
two cytokines are known to be produced mainly by monocytes (IL-8) [715] and Th2 
lymphocytes (IL-4) [322] and, together with adiponectin concentration, the differences in their 
serum levels support the idea that sleep modestly influences the pro-inflammatory status of 
elderly individuals, with long sleep duration associated with decreased systemic 
inflammation. IL-8 is a potent chemotactic factor [716] and it can stimulate neutrophil 
mobilisation from the bone marrow [717, 718], hence this cytokine could contribute to increased 
number of circulating granulocytes in short sleepers, though the association of IL-8 with short 
sleep was not significant.  
In this study significant associations between the G:L ratio and the parameters of sleep 
fragmentation, WASO and average sleep bout were found. These two sleep variables were 
also correlated with cortisol levels, although the significant relationship between cortisol and 
WASO was lost when adjusted for use of anti-hypertensive drugs. Importantly, 
glucocorticoids delay apoptosis in neutrophils [344, 345] but they promote apoptosis in T 
lymphocytes [719]. Specifically, cortisol decreases the pool of naïve T cells in the circulation 
[326] and its levels have been shown to positively correlate with the neutrophil to lymphocyte 
ratio [720]. Although in our cohort cortisol was not significantly associated with the G:L ratio 
(R2=0.024, β=0.155, p=0.189), we cannot exclude its involvement in increasing G:L ratio in 
conditions of highly fragmented sleep. 
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In addition to these factors, it is possible that other circulating molecules, such as 
catecholamines, could also have determined those changes. In fact, Zhang et al. revealed that 
the 24-hour urinary norephinephrine and epinephrine were negatively associated with sleep 
duration and efficiency, and positively correlated with latency as measured by actigraphy in a 
cohort of middle-aged individuals [648]. Moreover, it has been shown that catecholamines can 
rise in response to acute stress, causing leucocytosis through mobilisation of both 
lymphocytes and granulocytes [348]. Finally, it is also possible that the altered number of 
peripheral immune cells is subsequent to modifications happening in the bone marrow 
environment, where hematopoiesis takes place. Fluctuations in the local levels of cytokines 
and adipokines, which might be not well be represented by the levels measured in the serum, 
could have determined these differences. 
As neutrophil and NK cell functions were not linked to sleep behaviour, it can be concluded 
that physiological sleep disruption does not contribute to accelerate innate 
immunosenescence.  When adaptive immunosenescence is considered, this appears to be even 
reduced with disrupted sleep, as the percentage of naïve T cells were negatively correlated 
with sleep duration, and CD4+ T cells as well as the CD4+:CD8+ T cell ratio were increased 
in association with higher sleep fragmentation. However, to confirm such relationships it 
would have been helpful to screen our volunteers for other factors thought to be influencing 
these parameters, notably CMV infection. CMV is thought to be mainly responsible for 
inversion of the CD4+:CD8+ T cell ratio in old age and for accumulation of terminally 
differentiated CD8+ memory T cells [584, 585]. Thus, if aged long sleepers have higher 
frequency of CMV infection, sleep would not be the primary cause driving these changes.  
Finally, as few markers of inflammation were significantly related to sleep duration, it is not 
possible to affirm that sleep may have an influence in accelerating the process of 
inflammaging in elderly individuals.  
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Despite the impact of physiological sleep shown on these aspects of immunity, the study of 
partial sleep deprivation did not corroborate these findings or confirm causality. In fact, the 
partial sleep deprivation protocol induced modest effects on the immune parameters 
considered, especially in young volunteers. Recruitment of a higher number of volunteers is 
necessary in order to detect significant changes prompted by forced lack of sleep and different 
responses displayed by young and elderly individuals.  
5.2 ADIPONECTIN AND NEUTROPHILS: IN VITRO STUDIES AND IN VIVO 
IMPLICATIONS 
Adiponectin is the adipokine mostly secreted by the WAT [424-426], it has elicited increasing 
interest as it protects from the development of insulin resistance, type II diabetes and 
cardiovascular diseases [184, 185]. Adiponectin appears to have a bidirectional communication 
with the immune system, as it acts as a potent modulator of immune functions and its 
expression by the WAT is regulated by cytokines [196-198]. With regard to neutrophils, before 
the publication of the results in this thesis [671, 687], adiponectin was only known to reduce the 
oxidative burst in response to fMLP and PMA stimulation [451, 472]. It was decided to further 
investigate the role of adiponectin on neutrophil apoptosis and phagocytosis, as these are 
other mechanisms essential to the resolution of systemic inflammation (apoptosis) and 
infection (phagocytosis). The in vitro findings show a dual pro- and anti-inflammatory role 
exerted by adiponectin in promoting neutrophil survival and inhibiting neutrophil phagocytic 
ability respectively. As discussed in chapter 4, these apparent contradictions in the actions 
exerted by adiponectin have already been observed in relation to NF-kB activity in endothelial 
and monocytic cells [679, 680] and in other studies exploring the modulation of pro-
inflammatory programs in macrophages [474, 478]. Such opposite effects were dependent on 
whether adiponectin was administered in unstimulated cells or cells subjected to further 
stimulations. 
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The main issue that could not be addressed in this thesis is whether these results achieved in 
an in vitro setting would be reproducible in vivo. To answer this question it would have been 
useful to carry out experiments on animal models, by evaluating neutrophil functions in a KO 
model for adiponectin and/or in wild type (wt) animals after systemic injection of this 
adipokine. From the sleep study performed with elderly volunteers it was observed that 
increased levels of adiponectin were associated with lower number of granulocytes in long 
sleepers, suggesting that adiponectin’s inhibitory effect on granulopoiesis could be greater 
than its anti-apoptotic action in vivo. Nevertheless, adiponectin levels are higher in certain 
inflammatory diseases, such as COPD [501], in which reduced levels of neutrophil apoptosis 
are well documented [721, 722]. In both cases, we cannot exclude the participation of other 
circulating factors which regulate both neutrophil lifespan and adiponectin expression; if this 
is the case, adiponectin would not directly modulate the number of circulating neutrophils in 
vivo. Whether adiponectin can delay neutrophil apoptosis also in a pro-inflammatory 
environment, i.e. when cells are activated, remains to be elucidated. As we [687] and others [451, 
470, 474] noted a distinct anti-inflammatory effect of adiponectin on activated cells, it is 
conceivable that, in a pro-inflammatory environment, adiponectin could promote neutrophil 
death. 
Although the exact role played by adiponectin on neutrophil apoptosis in vivo remains to be 
established, the inhibitory action exerted by adiponectin on neutrophil phagocytosis is more 
likely to persist in vivo, as pre-treatment of whole blood with adiponectin decreased the 
bacterial uptake by neutrophils. Moreover, several in vivo studies indicated an anti-
inflammatory role for this adipokine [488, 489, 723]. As confirmed in this thesis and shown by 
others [442, 611, 612], old age is characterised by higher levels of adiponectin, thus this finding 
could also help to explain the decreased phagocytic ability and the increased rate of infections 
typical of elderly individuals [505]. Therefore, although adiponectin exhibits many beneficial 
effects, raised levels of this adipokine could be harmful by increasing the risk of infection. 
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5.3 CONCLUSION AND PERSPECTIVES 
Although the results shown here demonstrate that physiological sleep disruption during 
ageing does not enhance immunosenescence, our data highlight that long sleep duration is 
associated with lower pro-inflammatory status and the number of myeloid cells, higher levels 
of adiponectin, decreased lymphocyte count and naïve T cell subsets.  Conversely, short sleep 
duration and poor sleep continuity associate with a higher number of several immune cell 
populations and increased level of cortisol. Therefore, it is proposed that a duration of sleep 
between 6.30-7.30 hours per night (as displayed by the middle tertile of sleep duration) and an 
improvement in sleep continuity, i.e. efficiency, latency and fragmentation, could induce a 
beneficial effect on the overall health status of the elderly population by controlling the 
immune and hormonal variables mentioned before. This, in turn, would also help to contrast 
the development of obesity, cardiovascular and metabolic diseases, for which inflammation is 
a crucial common factor [724-726]. 
The results in this thesis reinforce previous evidence pointing to the existence of a complex 
network of communications between the CNS and peripheral organs, particularly the immune 
system, the adrenal gland and the WAT. Physiological sleep duration and continuity were 
associated with changes in the number of circulating immune cells and serum concentration of 
cytokines, particularly IL-6 and IL-8, adipokines and cortisol in elderly subjects. All these 
factors have been shown to participate in the regulation of vital functions such as 
thermoregulation [727, 728], appetite, metabolism [729, 730] and sleep [98, 174, 371-373]. Therefore, the 
data in this thesis and the literature allow the proposal of a model for the interaction of sleep 
with the immune system, the adipose tissue and the HPA axis in old age (Figure 5.1).  
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Figure 5.1 Proposed model of bidirectional communications between the CNS and 
peripheral organs through soluble factors, as determined by findings from this thesis and 
previous studies. Circulating immune cells and soluble factors mediate the bi-directional 
communication lying between the CNS and the immune system: immune cell number is 
influenced by sleep duration and continuity as assessed in this thesis, while cytokines regulate 
sleep [371-373] and body temperature [727] and their serum levels are also influenced by sleep 
duration [640]. The adipose tissue communicates with the CNS through adipokines, mainly 
leptin, which regulates food intake [729], and adiponectin, which has been found to be 
upregulated in long sleepers in this thesis. Moreover, the adrenal gland secretes cortisol and 
catecholamines, whose levels fluctuate under psychological stress [65, 346] and whose role in 
regulating sleep [79, 347] and hunger [731] has also been proposed.  
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APPENDIX I: HEALTH SCREENING QUESTIONNAIRE 
 
This screening questionnaire should be completed honestly and accurately as it will determine 
if you are eligible for the research study. 
 
Name: ________________________________  Date: __________________ 
 
1. Do you consider yourself to be healthy?     Y/N 
 
2. Are you male or female?       M/F 
 
3. How old are you (in years)?      …….. 
 
4. Do you currently smoke or use elicit substances?    Y/N 
 
5. Have you been ill in the last 4 weeks?     Y/N 
 
If yes, provide further details: 
 
 
6. Do you suffer with any chronic illness?     Y/N 
 
If yes, provide further details: 
 
 
7. Do you take regular medication for any illness?    Y/N 
 
If yes, please provide further details and dosage: 
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8. Do you take sleep modifying medications (over the counter or prescribed?) Y/N 
 
9. Have you travelled to a different time zone in the past 4 weeks?   Y/N 
 
10. Have you worked shifts in the past year?      Y/N 
 
If yes, please provide details: 
 
 
11. Do you have a diagnosed sleep disorder?      Y/N 
 
12. Do you have a diagnosed mental illness?      Y/N 
 
13. Do you drink alcohol?        Y/N 
 
If the answer is yes, please indicate approximately how many units of alcohol you consumer 
per week. 
 
Units per week:  … 
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